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Abstract 
In animal development and tissue repair, gradients of extracellular signalling 
proteins, such as fibroblast growth factors (FGFs), are formed in the extracellular 
matrix (ECM) to conduct cell-cell communication. It has been argued that the 
heparan sulfate (HS) chains of proteoglycans are important in controlling the 
diffusion of these signalling proteins and the paracrine FGFs are classic HS binding 
proteins. There are over 883 proteins that bind to HS in the ECM, yet the extent to 
which protein binding is specific and selective is not clear. Moreover, the HS chains 
and the ECM in general are often considered to be a hydrated gel and have no 
structure, beyond the individual components. It is difficult to reconcile the regulation 
of critical and complex events in cell communication by HS and ECM with this 
view. 
In this thesis, the production of a number of recombinant FGFs is described.  This 
led to the discovery that HaloTag, a mutated chloroalkane dehalogenase 
conventionally used as a means to chemically label fusion proteins, is also an 
excellent solubilisation tag for FGFs. Thus, HaloTag fusions allowed the production 
and purification of members of the FGF family not generally available. These FGFs 
were used to characterise the interactions of FGFs with HS in vitro and in cells. 
The interactions of FGF10 and FGF20 with HS were characterised by differential 
scanning fluorimetry, using a library of model polysaccharides. The data show that in 
terms of their preferred binding structures, FGF10 is most like its closely related 
subfamily member, FGF7. Likewise, binding preferences of FGF20 are most similar 
to those of FGF9, which is in the same subfamily. These results support the idea that 
the specificity and selectivity of the interactions between FGFs and HS have been 
driven by the same selection pressures that led to the diversification of the FGF 
family and to their binding selectivity for isoforms of their receptor tyrosine kinase. 
To study the interaction with HS in cells, fixed Rama 27 fibroblasts were used, so 
that cell biochemistry would not confound the results. Fluorescent Halo-FGF-1, -2, -
6, -10 and -20 were produced by reacting the HaloTag with a chloroalkane-TMR 
ligand. The binding of the fluorescent FGFs to Rama 27 cell pericellular matrix was 
measured by confocal microscopy. This showed that the binding sites for these FGFs 
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were heterogeneously distributed and the number of the binding sites for each FGF 
was different. Diffusion of these FGFs was measured by fluorescence recovery after 
photobleaching (FRAP). This demonstrated that the diffusion speed and the relative 
proportion of mobile versus immobile FGF were different for each FGF. The data 
indicate that the HS in pericellular matrix is selective in its binding of FGFs and 
determining how they diffuse.  
In conclusion, the pericellular matrix exhibits high binding selectivity for different 
FGFs, which is consistent with the in vitro characterisation of their interactions with 
model polysaccharides. Moreover, cells spatially segregate the different binding 
structures in HS. This indicates that pericellular matrix is highly organised over 
length scales equivalent to hundreds or more HS chains, suggesting that it is formed 
by the self-organisation of its constituents though their extracellular interactions and, 
for transmembrane components, intracellular interactions as well. Such structure 
would then lie at the heart of how ECM performs its varied functions, including the 
selective binding and transport of FGFs.  
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Chapter 1 Introduction 
1.1 Cell-cell communication in development, homeostasis 
and disease  
A fertilised egg cell will develop into an organism, such as a monkey or a fly (Fig. 
1.1). Organisms are constructed of multiple cells, but they have very different 
structures, which arise through embryonic development. Cell-cell communication is 
one of the most important mechanisms contributing to embryogenesis, playing a 
critical role in coordinating cell functions and directing cell activities. By talking to 
each other, the cells are regulated to divide, to migrate to specific positions in the 
three dimensional space of the organism and to differentiate into another type of cell. 
For example, epithelial cells can differentiate into mesenchymal cells through cell-
cell and cell-extracellular matrix (ECM) contacts (Radisky, 2005, Lamouille et al., 
2014). Similarly, in tissue repair and homeostasis, cell division, differentiation and 
migration are also regulated by cell to cell communication (Chen et al., 2014).  
The language of cell communication is signalling molecules. These are mainly 
proteins, which are secreted into the extracellular space. When these signalling 
molecules are released by the source cells, they must diffuse to their target cells, 
where, through receptor systems, they elicit the appropriate biochemical response to 
transmit signals and the biological response ensues. Based on the distance of the 
target from the source cells, paracrine and endocrine mechanisms are two well-
established mechanisms of communication. Paracrine signalling molecules are 
restricted to the extracellular space surrounding the source cell and activate the 
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vicinal target cells, while the endocrine signalling molecules, hormones, are able to 
move systemically and so target distant cells. Autocrine is a special case of 
paracrine, by which the source cells signal to themselves. In development and tissue 
repair, the paracrine mechanism is critical to direct specific tissue and organ 
formation, such as limb development. 
 
Figure 1.1 Cell-cell communication in development. A single fertilised cell can 
divide and differentiate into different types of cells, which form tissues and organs in 
the organism through the action of signalling molecules. One important feature is 
morphogenesis, whereby morphogen signalling molecules form gradients distributed 
in the ECM from source cell to the target cells that can recognise the different 
concentrations and consequently follow different fates. Thereafter, gradients of 
signalling molecules regulate many aspects of homeostasis. 
1.2 Morphogen gradient formation and functions 
Morphogens are the signalling molecules, secreted into the extracellular space by the 
source cells to form a concentration gradient among the surrounding target cells, 
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which induces concentration-dependent biological outcomes. In developmental 
biology, morphogen gradients play a critical role, because they spatially and 
temporally regulate cell fate and cell division, migration and differentiation, and so 
specify the body’s structures are gradually developed (Sutherland et al., 1996, 
Gurdon and Bourillot, 2001). It is, therefore, important to know how morphogen 
gradients are formed, and how the cells create and maintain a particular morphogen 
gradient and concentration at specific positions (Fig 1.2 A) (Gurdon and Bourillot, 
2001). Free diffusion is unlikely to allow appropriate gradients to form, because the 
concentration of morphogen will decay exponentially from the source. Consequently, 
over distances of a few cell diameters, the gradient will be extremely shallow and 
unlikely to be decoded (Qu et al., 2012, Zhou et al., 2012). Thus, for a gradient to 
form, the diffusion of the morphogen needs to be slowed down, which can be 
achieved by reversible binding to molecules in the ECM that lies between cells. Such 
molecules include the glycosaminoglycans (Belenkaya et al., 2004, Yan and Lin, 
2009, Duchesne et al., 2012). Many classical morphogens, such as members of 
fibroblast growth factor (FGF), transforming growth factor-β (TGF-β), WNT and 
hedgehog families, have been identified in previous work and they share the property 
of binding to heparan sulfate (HS) (Gurdon and Bourillot, 2001).  
In Drosophila wing development, the two important signalling molecules, 
Decapentaplegic (Dpp) and Wingless (Wg), form different morphogen gradients in 
the same ECM by means of different transport mechanisms (Kicheva et al., 2007). A 
number of different models have been proposed to regulate the transport of 
morphogens (Yan and Lin, 2009, Muller et al., 2013, Akiyama and Gibson, 2015), 
which fall into four main types (Figs 1.2 B1-B4). The free diffusion model does not 
require the signalling molecules to bind to any components of ECM. However, under 
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these conditions the signalling molecules could be degraded, since they are not 
protected, and concentration gradients would be very steep and only exist next to the 
source (Fig. 1.2 B2) (Muller et al., 2013, Akiyama and Gibson, 2015). In contrast, in 
the restricted diffusion model, the interaction of signalling molecules with ECM 
components, of which HS proteoglycans are the most important in this respect, 
shapes the morphogen gradient, because binding slows diffusion (Fig. 1.2 B1) (Lin, 
2004, Kalinina et al., 2009, Yan and Lin, 2009, Makarenkova et al., 2009, Bokel and 
Brand, 2013, Akiyama and Gibson, 2015). The planar transcytosis model involves 
the transport from the source cells to the targets cells by repeated endocytosis and re-
secretion by the intermediary cells (Fig. 1.2 B3) (Kicheva et al., 2007, Muller et al., 
2013, Akiyama and Gibson, 2015). In this model, diffusion is slowed down by these 
cellular activities. Cytonemes have been proposed as another mechanism (Fig. 1.2 
B4) (Akiyama and Gibson, 2015, Yan and Lin, 2009), although the HS 
proteoglycans on the cytonemes might play the role in transport of signalling 
molecules. Other models have been proposed, such as lipoprotein transport 
(morphogens diffuse after packing into lipoprotein particles), but the diffusion 
restricted by HS proteoglycans is thought to be the most common mechanism 
contributing to the formation of the morphogen gradients (Yan and Lin, 2009).  
However, the mechanisms of morphogen gradient formation for many of these 
signalling molecules are still not very clear. Mutations of HS proteoglycans showed 
that the movement of Dpp-GFP in ECM was restricted by HS proteoglycans (Fig. 1.2 
B2) (Belenkaya et al., 2004), while a kinetic study using fluorescence recovery after 
photobleaching (FRAP) suggested that dynamin-mediated endocytosis was required 
for the movement of Dpp-GFP (Fig. 1.2 B3) (Kicheva et al.). Thus, the data from 
living systems appear contradictory. Moreover, it is difficult in living systems to 
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probe one mechanism in detail and in isolation of other potential mechanisms. A 
fixed, so dead system might be a better means to understand the transport of 
morphogen molecules in the ECM. Such an approach would potentially also provide 
insight into the organisation and structure of the ECM.  
 
Figure 1.2 Main mechanisms proposed for morphogen transport and gradient 
formation. Morphogens (signalling molecules) secreted by source cells can form 
gradients of different shapes. The transport of these molecules is thought to be 
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regulated by different mechanisms, some of which are described in this figure. (A): 
Short-fat and long-slim morphogen gradients. (B1-B4): Transport mechanisms. (B1): 
Restricted diffusion by binding to HS proteoglycans. (B2): Free diffusion in the 
ECM. (B3): Planar transcytosis model, where the morphogens are transported by 
endocytosis and re-secretion. (B4): Diffusion of morphogens along the cytonemes to 
other cells/target cells. 
1.3 ECM components and structure 
There is clear evidence for interactions with the ECM controlling the movement of 
signalling molecules (Migliorini et al., 2015, Akiyama and Gibson, 2015, Bokel and 
Brand, 2013, Muller et al., 2013, Duchesne et al., 2012, Belenkaya et al., 2004), so, 
two important questions are: what is in the ECM and is the ECM organised 
differently according to its functions? The answer to the first question is becoming 
relatively clear. The ECM consists of three regions. The pericellular matrix, which 
includes proteins anchored on the cell surface, proteoglycans and restricted proteins 
(Fig. 1.3 grey region), extends around 35 nm from the cell surface. The gap area 
(Fig. 1.3 the middle area) between cells is classic ECM and the pericellular matrix of 
epithelial cells is separated from that of mesenchyme by basement membrane, which 
is an ECM, but named for its aspect under the light microscopy. ECM and basement 
membrane contain secreted proteins, which include fibrous proteins, such as 
collagens, and a range of glycoproteins, e.g., fibronectin, laminin and proteoglycans 
(e.g., perlecan) (Mouw et al., 2014, Frantz et al., 2010, Lingwood and Simons, 2010, 
Davies, 2001). These ECM components give rise to physical cell-cell connections, 
adhesion, signalling and provide the tissue with particular mechanical characteristics 
(Harisi and Jeney, 2015, Fan et al., 2014, Olczyk et al., 2014). 
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A large number of studies of tissue ECM have found that the components and the 
number of the components are very varied (Mori et al., 2014, Bonnans et al., 2014). 
Tissue staining reveals that the expression levels of collagen, laminin and fibronectin 
in subcutaneous adipose tissue and visceral adipose tissue are very different (Mori et 
al., 2014). Even in the same tissue, the components of ECM vary at different ages 
and for the normal and abnormal (disease) states, since the ECM is remodelled in 
development, tissue repair and often in diseases, which reflects changes (desired or 
otherwise) underlying biological functions (Lu et al., 2012, Frantz et al., 2010, 
Bonnans et al., 2014, Mori et al., 2014). For example, studies with rat skin revealed 
that the expression levels of collagen 1, laminin b1 and c1, and fibronectin 1 are 
strongly related to age (Mori et al., 2014, Quaglino et al., 1993). The structural 
analysis of HS in mice indicates that HS content, disaccharide composition and 
overall degree of sulfation are different for each individual tissue (Guimond et al., 
2009, Ledin et al., 2004). The cancer cell microenvironment is also characterised by 
degradation and disorganisation of ECM (Lu et al., 2012). These types of 
observations indicate that it is likely that the ECM is an area with a highly dynamic 
structure rather than being a homogenous gel. 
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Figure 1.3 ECM components and structure, and diffusion of signalling proteins 
mediated by binding to HS chains. ECM includes the pericellular matrix (grey 
region) and the area between the cells (white region between cells). The pericellular 
matrix contains HS proteoglycans with core proteins inserted into the membrane, 
whereas the classic ECM contains secreted HS proteoglycans. Three different types 
of diffusion may be considered to arise from differential binding to HS chains. Weak 
binding to HS would lead to a fast diffusion (red dots), while strong binding might 
trap the HS binding proteins in the source cell matrix, which would then only release 
the HS binding proteins slowly (blue dots) or would require an external event, such 
as cleavage by heparanase to release the protein/protein-ligand complex (green dots). 
1.4 HS proteoglycans 
Proteoglycans are O-glycosylated proteins, such as perlecan, glypicans and 
syndecans (Taylor and Gallo, 2006, Yung and Chan, 2007). Some proteoglycans are 
inserted into the cell membrane and others are secreted into the ECM (Dreyfuss et al., 
2009, Bernfield et al., 1999). These proteoglycans are expressed in the rough 
endoplasmic reticulum and then transported to the Golgi apparatus where the 
I n t r o d u c t i o n  
 
 9 
glycosaminoglycan (GAG) chains are synthesised (Yanagishita and Hascall, 1992). 
The GAG chains are linear polysaccharides mainly consisting of repeating 
disaccharide units (Fig. 1.4 A) (Taylor and Gallo, 2006). The members of the GAG 
family are HS, chondroitin sulfate (CS), dermatan sulfate (DS), hyaluronan (HA) and 
keratan sulfate (KS) (Ori et al., 2008). 
HS is made of repeating disaccharide units of glucuronic acid (GlcA) linked to N-
acetylglucosamine (GlcNAc, Fig. 1.4 A). In the Golgi apparatus, the synthesis of HS 
GAG chains is started with the assembly of a tetrasaccharide linkage onto a serine 
residue of the core protein by four enzymes (Xyl transferase, Gal transferase I and II 
and GalA transferase); the repeat disaccharide units, [-GlcA-GlcNAc-]n (where n is 
~25 to 100) are then added by the copolymerases EXT1 and EXT2 (Lin, 2004, 
Tumova et al., 2000, Dreyfuss et al., 2009). After the synthesis of the GAG chain, 
clusters of N-acetyl glucosamine are deacetylated and N-sulfate groups are added by 
the dual activity N-deacetylase-N-sulfotransferases (NDSTs) (Lin, 2004, Tumova et 
al., 2000, Dreyfuss et al., 2009). The subsequent modifications on N-sulfated 
glucosamine containing disaccharides or their neighbours: an epimerase converts 
glucuronic acid to iduronic acid (IdoA), which may then be 2-O sulfated and the 
glucosamine may be 6-O and 3-O sulfated (Lin, 2004, Tumova et al., 2000, Dreyfuss 
et al., 2009). Therefore, HS contains two different disaccharide units: GlcA-GlcNAc 
(without N-sulfation and with low sulfation groups on 6-O, 3-O and 2-O positions) 
and IdoA-GlcNAc (with N-sulfation and with more sulfation groups on 6-O, 3-O and 
2-O positions). 
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Figure 1.4 Structures of disaccharide units of HS and heparin. (A): Structure of 
disaccharide unit of heparin/HS. Top: The N-acetylglucosamine containing 
disaccharide. This is generally not or only slightly modified by O-sulfation (in red) 
and the uronic acid will always be glucuronic acid. Bottom: An iduronic acid 
containing disaccharide, which always contains an N-sulfated glucosamine (N-
sulfate in red) and is often further modified by O-sulfation (red). (B): Structure of 
HS chains. The polysaccharide chain is covalently linked to a serine on the 
proteoglycan core protein. The sulfate groups are added by sulfotransferases after the 
GAG chain is polymerised. Owing to the hierachical dependence of the post 
polymerisation reactions and the mechanism of sulfation of discrete blocks of N-
acetylglucosamines by N-deacetylase-N-sulfotransferase (NDST), the HS chain has a 
domain structure of alternating NA (GlcNAc), NAS (~ one disaccharide in two is N-
sulfated) and NS (every glucosamine is N-sulfated) domains. Chain lengths vary 
from ~25 disaccharides to over 100. Heparin, a common experimental proxy for HS 
is ~30 disaccharides in length and can be considered to be a highly sulfated S domain. 
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Since NDST selectively acts on blocks of disaccharides, the modified HS chain has a 
domain structure of NA, NAS and NS domains (Fig. 1.4 B) (Dreyfuss et al., 2009, 
Ori et al., 2008, Connell and Lortat-Jacob, 2013). Differences in sulfation level of the 
NAS and NS domains provide the means for HS to bind with varying degrees of 
selectivity to over 883 proteins (Ori et al., 2008, Ori et al., 2011, Xu and Esko, 2014, 
Nunes, 2015); for example, FGF2 requires GlcNS-IdoA2S structures for binding, 
only found in S-domains, whereas antithrombin III binds a pentasaccharide 
containing both GlcNS and GlcNAc, which corresponds to a transition domain 
(Turnbull et al., 2001, Xu and Esko, 2014). Since the synthesis and modification 
reactions by the sulfotransferases do not go to completion, the length and level of 
sulfation of HS chains are also variable in different ECMs (Kirkpatrick and Selleck, 
2007, Dreyfuss et al., 2009). Thus, different tissues have been found to contain 
different amount of HS with varying relative levels of the different sulfated 
disaccharides  (Guimond et al., 2009, Ledin et al., 2004) 
1.5 FGFs 
1.5.1 Overview 
Members of the FGF family regulate embryonic development and homeostasis, 
including the repair of tissues and organs and certain aspects of metabolism. In the 
past decades, 22 human FGFs have been identified. They are grouped into 7 
subfamilies based on the analysis of their protein sequences (Fig. 1.5) (Ornitz and 
Itoh, 2001, Itoh and Ornitz, 2004). The FGF11 subfamily, known also as the 
fibroblast growth factor homology factors (FHF), exhibits high sequence and 
structural similarities with other FGFs, but the FHFs do not bind heparin or the FGF 
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receptor tyrosine kinase (FGFR) and are entirely intracellular (Beenken and 
Mohammadi, 2009). Consequently, FHFs are not always regarded as FGFs. The 
members of FGF 19 subfamily, which includes FGF19, FGF 21 and FGF 23, are 
endocrine factors, which act systemically and these three FGFs have very low or no 
heparin binding affinities (Itoh, 2007, Asada et al., 2009). The remaining five 
subfamilies (FGF1, FGF4, FGF7, FGF8 and FGF9) act locally. They are released 
into the ECM and their transport to their target cells is considered to be regulated by 
strong binding to HS in the ECM (Duchesne et al., 2012, Kirkpatrick and Selleck, 
2007, Makarenkova et al., 2009). These FGFs signal by binding to the FGFR, but 
this also requires simultaneous engagement of the HS co-receptor (Zhu et al., 2010, 
Ornitz, 2000). Thus, HS regulates both the transport and the effector functions of 
these FGFs. 
1.5.2 FGF evolution and functions 
Itoh and Ornitz pointed out that FGF genes have not been found in unicellular 
organisms, such as Escherichia coli (E. coli) (Itoh and Ornitz, 2004).  However, 
orthologous genes have been identified in all multicellular organisms, ranging from 
Caenorhabditis elegans (C. elegans) to Homo sapiens. Of the three FGFs in 
Drosophila, one called branchless induces branching of the trachea (Sutherland et 
al., 1996), while the pyramus and thisbe FGFs pattern the mesoderm of Drosophila 
embryos(Stathopoulos et al., 2004). Matus and coworkers isolated three FGF ligands 
(NvFGF8A, NvFGF8B, and NvFGF1A) from Nematostella vectensis and suggested 
their conserved roles in regulating gastrulation and development of neural tissue 
(Matus et al., 2007).  
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The evolution of FGFs is proposed to be divided into two major phases as the 
metazoan lineage extended to the chordate lineage (Itoh, 2007). In the first phase, the 
2 or 3 FGF genes in primitive metazoa were expanded to 6 homologous genes by 
gene duplication (Itoh and Ornitz, 2004). The most studied extant primitive 
metazoan containing FGF genes is C. elegans, in which elg-17 and let-756 were 
identified (Ornitz and Itoh, 2001). Five of the six fgfs found in the tunicate C. 
intestinalis appear to share a common ancestor with vertebrate fgfs, which suggests 
the FGF genes of C. intestinalis lie between the first and second phases of the 
evolution of this growth factor family. Furthermore, another FGF gene of C. 
intestinalis, Ci-fgf11/12/13/14, and vertebrate fgf11-fgf14 have identical intron-exon 
organization (Itoh and Ornitz, 2004). Therefore, the fgfs of the common ancestor of 
C. intestinalis and vertebrates are thought to have evolved into the FGF genes of 
vertebrates, such as Homo sapiens and Zebrafish, in the second phase (Itoh, 2007).  
Basic FGF and acidic FGF, now known as FGF2 and FGF1, respectively, are the two 
original members of the FGF family (Fig. 1.5), and they can stimulate the 
proliferation of a variety of cells (Zhu et al., 1991). A large number of functions has 
since been found for each FGF. The knockout mouse model of FGF3 caused 
deafness (Tekin et al., 2007).  FGF4 has the function of regulating the development 
of limb and cardiac valve leaflet formation, whereas FGF7 and FGF10, first known 
as keratinocyte growth factors (KGFs), are specifically expressed in mesenchyme 
where they signal to neighbouring epithelium (Beenken and Mohammadi, 2009). 
FGF6 was recognized as playing roles in myogenesis, which regulates muscle 
regeneration (Israeli et al., 2004). FGF8 has important roles in the development of 
brain, limb, eye and ear (Liu and Joyner, 2001, Lewandoski et al., 2000). Members 
of the FGF9 subfamily are involved in the stimulation of mesenchymal proliferation 
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(Beenken and Mohammadi, 2009). Many biological functions require several 
different FGF signaling pathways to work together. Taking the development of 
vertebrate limb as an example, mesenchymally expressed FGF10 elicits the 
development of the overlying apical ectodermal ridge, which subsequently secretes 
FGF8 to regulate the growth of the underlying mesoderm (Ornitz, 2000). Despite the 
substantial body of data on expression and spatial-temporal regulation of FGFs in 
development and homeostasis, there are still many questions about FGFs’ functions 
to be answered. 
 
Figure 1.5 Family tree of human FGFs. Based on protein sequence alignment with 
the phylogenetic tree displayed by TreeView, the 22 FGFs are grouped into seven 
subfamilies: five paracrine factor subfamilies (FGF1 subfamily, FGF4 subfamily, 
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FGF7 subfamily, FGF8 subfamily and FGF9 subfamily), one endocrine factor 
subfamily (FGF19 subfamily) and one intracellular FGF subfamily (FGF11 
subfamily). 
1.5.3 FGF structures  
Molecular weights of  human FGFs range from 17 kDa to 34 kDa and the alignment 
of their protein sequences indicates that the core region of FGFs shares many 
conserved residues responsible for binding FGFR and HS, as well as the position of 
β-strands (Ornitz, 2000, Itoh and Ornitz, 2004).  Thus, FGFs of Homo sapiens share 
more than 30 highly conserved amino acid residues (Fig. 1.6 A). Owing to the 
conservation of FGFs’ primary structures in Homo sapiens, they have a similar three 
dimensional structure of 12 antiparallel β strands that form a β-trefoil fold (Figs 1.6 
B-C). 
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Figure 1.6 Sequence alignment of FGFs. The protein sequences of human 
paracrine FGFs and endocrine FGFs without the signal peptide were extracted from 
UniProt. These sequences were aligned by ClustalX 2.0.10 and the alignment was 
viewed with Jalview 2.6.1. The aligned residue positions with the most identical 
amino acids were colored with deep blue and residue positions with fewer identical 
amino acids were colored with light blue. It is important to note that this analysis 
examines identity only and not similarity. The blue arrows indicate the positions of 
the 12 β-strands.  
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The FGFs contain binding sites for heparin/HS (heparin/HS binding sites or HBS) 
and for the FGFR (Fig. 1.7 A). Canonical heparin/HS interacting amino acids of 
FGF1 and FGF2 locate at the β1-β2 loop and the region between the β10 strand and 
the β12 strand, which are rich in basic amino acids (arginine and lysine) (Figs 1.7 A-
B) (Faham et al., 1996, Schlessinger et al., 2000, Pellegrini et al., 2000, Xu et al., 
2012). Interestingly, this heparin-binding site is flexible such that the β10 and β11 
strands are not well defined in the crystal structures (Fig. 1.7 & (Schlessinger et al., 
2000)) and β11 is absent in the NMR structure (Moy et al., 1996); this may be 
important for the interaction with HS. FGFR binding sites are physically distinct and 
generally contained in the regions that include part of the N-terminus (around 10 
amino acids before β1 (Olsen et al., 2006)), β1- β2 strands, β3 strand, β4-β5 strands, 
β6 strand, β7- β9 strand (Fig. 1.7 A and B) and the terminus of β12 strand. The 
primary sequences of these regions are very divergent among FGFs, which underlies 
the selectivity of different FGFRs for particular FGF ligands (Plotnikov et al., 2000, 
Mohammadi et al., 2005). 
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Figure 1.7 Structure of FGF2 and its interactions with FGFR and heparin/HS. 
(A): Structure of FGF2 (PDB: 1FQ9 (Schlessinger et al., 2000)). (B): Surface of 
FGF2 that interacts with FGFR1 (from PDB: 1FQ9 (Schlessinger et al., 2000)). (C): 
Heparin binding sites of FGF2 (PDB: 1FQ9 (Schlessinger et al., 2000)) identified by 
a selective labelling approach (Ori et al., 2009). Three binding sites were recognised: 
the canonical binding site (HBS1), and two secondary and relatively weaker binding 
sites (HBS2 and HBS3). (D): HS binding site of FGF9 (PDB: 1G82 (Hecht et al., 
2001)). Only the conserved HBS1 was identified by selective labelling (Xu et al., 
2012). Green is the N-terminus of the proteins. Grey is FGFR1. Magenta coloured 
proteins are FGFs (FGF2 in A, B and C, and FGF9 in D) with yellow coloured β 
strands. The residues in blue are the identified heparin binding sites of the FGFs.  
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1.5.4  Interaction of heparin/HS with FGFs  
A great deal of work has been done to analyse the binding specificity of FGFs with 
heparin, heparin derivatives and HS using a wide variety of assays, e.g., thermal 
stabilisation, heparin or FGF affinity chromatography (Turnbull et al., 1992, 
Maccarana et al., 1993, Jemth et al., 2002, Luo et al., 2006, Uniewicz et al., 2010, Xu 
et al., 2012). FGF1 and FGF2 are the two most studied FGFs in this respect. 
Originally, FGF2-affinity chromatography revealed that a tetradecasaccharide from 
HS (dp14, dp: degree of polymerisation) of 2-O-sulfated iduronate and N-sulfated 
glucosamine bound FGF2 with high affinity and the 6-O sulfate was not important 
(Turnbull et al., 1992). Maccarana et al. also found that the 2-O-sulfate of a smaller 
heparin dp5 was essential for FGF2 interaction, whereas 6-O sulfate groups were not 
required (Maccarana et al., 1993). In terms of FGF2 activity in mitogenesis assays, 
longer heparan sulfate oligosaccharides of at least 12 sugars (dp12) were required 
(Walker et al., 1994). Later, the crystal structure of heparin-FGF2 complexes 
demonstrated that both tetra- and hexasaccharides with 2-O-sulfate and N-sulfate 
groups can bind to FGF2 (Faham et al., 1996). A study with N-sulfated heparin 
oligosaccharide libraries suggested that FGF2 required either an octasaccharide with 
at least one 2-O-sulfate for binding. Alternatively, if the oligosaccharide lacked 2-O-
sulfate groups, three adjacent 6-O-sulfated disaccharides were necessary (Jemth et 
al., 2002). Recently, the protein-ligand interaction study by a thermal shift assay also 
indicated that N-sulfate and 2-O-sulfate are important for FGF2 binding, but not 6-
O-sulfate (Table 1.1) (Uniewicz et al., 2010). Studies using more heavily sulfated 
heparin-derived oligosaccharides have shown that heparin dp4 is the minimal length 
for FGF2 binding and activity and heparin dp8 can bind to both FGF2 and FGFR in 
the ternary crystal structure (Guglieri et al., 2008, Uniewicz et al., 2010, Schlessinger 
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et al., 2000). These differences may simply reflect the fact that heparin is highly 
sulfated and to obtain sulfates in the appropriate spatial orientation in HS requires 
longer structures than with heparin. 
Table 1.1 Summary of previous findings on the binding selectivity of FGFs to 
heparin, heparin derivatives and heparin oligosaccharides (Uniewicz et al., 
2010, Xu et al., 2012). Differential scanning fluorimentry (DSF) was used to 
measure the stabilisation effect of binding of FGFs to heparin and a library of model 
polysaccharides.  The stabilisation effect is reported as an increase in the melting 
temperature (Tm) of the FGF. dp is degree of polymerisation. 
Subfamily  Name Heparin effect 
on Tm 
Sulfation preference dp length 
FGF1 FGF1 > 22oC NS ≈ 2S ≈ 6S dp2 ~ dp10 
 FGF2 > 22oC NS, 2S > 6S dp4 ~ dp10 
FGF7 FGF7 ~ 7oC NS ≈ 2S ≈ 6S dp4 ~ dp8 
FGF8 FGF18 > 15oC NS ≈ 6S > 2S dp6 ~ dp10 
FGF9 FGF9 ~ 20oC NS ≈ 6S > 2S dp4 ~ dp10 
Both the N-sulfated oligosaccharide libraries and a library of chemically modified 
heparin derivative illustrate that FGF1 can bind to structures containing any two of 
6-O-sulfate, 2-O-sulfate and N-sulfate (Jemth et al., 2002, Uniewicz et al., 2010). 
The selective binding of heparin octasaccharides using immobilised FGF 
chromatography demonstrated that FGF1, FGF4 and FGF8 can bind to N-sulfated 
oligosaccharides with 2-O-sulfate or 6-O-sulfate groups, but that more than two of 
these sulfate groups were required for optimal binding (Kreuger et al., 2005). The 
thermal stability assay suggests that FGF7 has a preference for 6-O sulfate and N-
sulfate groups in heparin (Table 1.1) (Xu et al., 2012), and Luo et al. found 
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octasaccharides with 7 or 8 sulfate groups strongly bind to FGF7 (Luo et al., 2006). 
FGF9, which is a dimer (Hecht et al., 2001), prefers to bind more heavily charged 
heparin derivatives, which have only had one sulfate group (2-O-/6-O-/N- sulfate) 
removed (Xu et al., 2012).  
In terms of the minimal length of saccharide binding structures, FGF1, FGF2 and 
FGF7 can bind to heparin dp4, while FGF9 and FGF18 require dp6 to bind 
(Uniewicz et al., 2010, Xu et al., 2012). It was found that FGF1, FGF2, FGF7, FGF9 
and FGF18 can be efficiently stabilised by HS chains (Uniewicz et al., 2010, Asada 
et al., 2009). However, HS contains fewer sulfate groups and is more diverse in 
structure, thus a longer HS structure may be required to bind to these FGFs than with 
heparin (Walker et al., 1994, Turnbull et al., 1992). However, taken together these 
data suggest that FGFs bind to heparin and HS with a degree of selectivity. By 
binding to HS, FGFs can also be stabilised, protected from degradation by proteases 
and stored in the HS-rich pericellular matrix (Nur-E-Kamal et al., 2008, Uniewicz et 
al., 2010, Vlodavsky et al., 1987). Since HS from different cells and tissues 
possesses differences in sulfation patterns and domain structures (Ledin et al., 2004, 
Guimond et al., 2009), it seems reasonable to suggest that this may allow the 
regulation of the binding and the diffusion of FGFs in the ECM.  
Previous work identified secondary binding sites for the polysaccharide on some 
FGFs (Xu et al., 2012, Ori et al., 2009). FGF1, FGF2 have three distinct heparin 
binding sites, while FGF9 would appear to have only the canonical binding site (Figs 
1.7 B-C) (Xu et al., 2012, Ori et al., 2009). FGF7 also has an extended canonical 
binding site and a secondary binding site, which is on the side of canonical binding 
site, running orthogonal to this (Xu et al., 2012). An extended canonical heparin 
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binding site (HBS) was also found on the surface of FGF18, which also possesses 
one secondary binding site found on FGF1 and FGF2 (Xu et al., 2012). The 
canonical binding site is the most conserved binding site in the FGF family and is of 
highest affinity, so it is the primary driver of the interaction of the paracrine FGFs 
with HS (Ori et al., 2009, Makarenkova et al., 2009). 
 
Figure 1.8 The canonical heparin/HS binding site of paracrine and endocrine 
FGFs. The ten residues in the canonical HBS1 were extracted from the aligned 
sequences (Fig. 1.6 A). These sequences were aligned again to test the conservation 
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across subfamilies. (A): Sequence alignment of the 10 residues in HBS1 for FGFs. 
(B): The numbers of residues with side chains known to interact with the 
polysaccharide in HBS1: arginine (R), lysine (K), asparagine (N), glutamine (Q). 
(C): Structure alignment of HBS1 of FGF2 (PDB: 1FQ9 (Schlessinger et al., 2000), 
magenta string) and FGF7 (PDB: 1QQK (Ye et al., 2001), blue string). The eight 
labelled residues from FGF7 correspond to the heparin binding residues of FGF2.  
Ten amino acids in the core of the canonical HBS of FGF1 and FGF2 contribute to 
the interaction (Faham et al., 1996, Schlessinger et al., 2000, Pellegrini et al., 2000). 
Taking FGF2 as an example, the ten residues are K26, N27 (β1-β2 loop), K119, R120, 
T121, K125, L126, K129, Q134 and K135 (the region between the β10 strand and the β12 
strand), but the side chain of L126 is not a binding site (Fig. 1.8 A) (Faham et al., 
1996, Schlessinger et al., 2000). The amino acids at the same position with the ten 
selected amino acids from FGF1 and FGF2 were extracted from the aligned 
sequences of the 18 paracrine and endocrine FGFs (FGF1-FGF10 and FGF16-
FGF23). These sequences were then aligned by ClustalX 2.0.10 to compare the 
collinear part of the binding sequences. Arginine (R), lysine (K), glutamine (Q) and 
asparagine (N) were classed as heparin binding amino acids (Figs 1.8 A-B) (Faham 
et al., 1996, Schlessinger et al., 2000, Pellegrini et al., 2000), though this ignores 
contributions from the amide of the peptide backbone. The crystal structure of FGF7 
was aligned to that of FGF2 as an example, and the ten residues on FGF7 were 
identified, which illustrates that these are accessible to heparin/HS (Fig. 1.8 C). As 
described, the members in the FGF19 subfamily have the lowest heparin/HS binding 
affinity and most of the recognized amino acids do not bind to the charged groups in 
heparin (Figs 1.8 A-B) (Asada et al., 2009, Xu et al., 2012, Ornitz, 2000). The other 
FGFs have similar number of heparin binding amino acids in the canonical heparin 
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binding region and they possess good heparin binding affinities based on heparin-
affinity chromatography (Asada et al., 2009, Sun et al., 2015). However, in those 
cases where it has been measured, the FGFs prefer different structures in heparin 
polysaccharide, which suggests the binding of FGFs to HS is not simply primarily by 
protein surface charge (Figs 1.8 A-B) (Asada et al., 2009, Sun et al., 2015). 
1.6 FGFRs and FGFR binding specificity of FGFs  
FGFRs, anchored on the membrane, are the key to transferring induced signals into 
the cell, which direct the target cell activities, such as cell proliferation, 
differentiation and migration (Turner and Grose, 2010, Beenken and Mohammadi, 
2009, Ornitz, 2000). Five different FGFRs (FGFR1-4 and FGFRL1) and many of 
their alternative spliced isoforms have been found to bind with FGFs and induce 
different signalling pathways (Powers et al., 2000, Itoh and Ornitz, 2011, 
Wiedemann and Trueb, 2000). FGFR1-4 possess three extracellular 
immunoglobulin-like loops, I, II and III (often termed D1, D2 and D3), a 
transmembrane linker and a cytoplasmic kinase domain (Fig. 1.9) (Powers et al., 
2000, Beenken and Mohammadi, 2009, Goetz and Mohammadi, 2013). FGFRL1 
differs in that its intracellular domain lacks a tyrosine kinase (Wiedemann and Trueb, 
2000, Kim et al., 2001, Sleeman et al., 2001). The FGF ligand binds to surfaces in 
D2, the D2-D3 linker and D3 (Figs 1.9 A and B). In FGFR1, FGFR2 and FGFR3, 
half of D3 is encoded by alternative exons, denoted ‘a’, ‘b’ and ‘c’. The latter two 
give rise to the ‘b’ and ‘c’ isoforms of the transmembrane receptor, which impart 
additional ligand selectivity (Fig. 1.9 A and Table 3.2) (Ornitz et al., 1996, Zhang et 
al., 2006b).  
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Figure 1.9 Structure of FGFR and FGF-FGFR-HS complex. (A): Structure of 
FGFR. The extracellular part of FGFR1-4 contains 3 immunoglobulin-like domains 
(D1-D3), a transmembrane helix and the intracellular tyrosine kinase. The HS 
binding site of FGFR is located at the D2 domain and FGF ligands interact with D2 
and D3 domains and their linker. The splicing of D3 domain gives rise to ‘b’ and ‘c’ 
FGFR isoforms, which regulate the specificity of interaction of FGF and FGFR 
(Table 3.2). (B): FGF-FGFR-HS complex models. The two brief well-known models 
show the binding status of FGF-FGFR-HS and the stoichiometric ratio of FGF, 
FGFR and HS in the binding complex (Schlessinger et al., 2000, Pellegrini et al., 
2000). The FGF-FGFR complex always happens in couples to induce the 
dimerization of receptors. 
The FGFRs have varying degrees of selectivity for different FGFs, and the 
selectivity is most conserved between FGFs in the same subfamily (Zhang et al., 
2006b, Xu et al., 2013). FGF1 was recognised as a universal ligand for all the FGF 
receptors, while FGF2 and members of the FGF4 subfamily prefer to interact with 
FGFR 1c (Zhang et al.). For the ‘c’ isoform, the preference is FGFR1c > FGFR 2c 
and FGFR 3c, though the FGF4 subfamily is clearly distinguished from the FGF1 
subfamily in terms of their selectivity for FGFR 1b, which they do not bind, in 
contrast to FGF1 and FGF2 (Zhang et al., 2006b, Ornitz et al., 1996). Members of 
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FGF8 and FGF9 subfamilies preferentially bind to FGFR 3c (FGFR 3c > FGFR 2c 
and 1c), while members of the FGF7 subfamily mainly bind FGFR 2b and 1b (Zhang 
et al., 2006b). The alternative splicing of the D3 domain of the same receptor 
provides a means of imparting directionality and reciprocity to FGFs mediating cell 
communication, that is between two cells each acting as source/target for the other 
(Turner and Grose, 2010, Goetz and Mohammadi, 2013, Yu and Ornitz, 2001). For 
example, in limb development, FGFR2 IIIb is restrictively expressed by epithelial 
cells, while FGFR2 IIIc is mainly expressed by mesenchymal cells (Orrurtreger et 
al., 1993, Johnson et al., 1991). In contrast, the ligands binding to FGFR 2b, FGF7 
and FGF10, are expressed and secreted by mesenchymal cells and FGFR 2c ligands 
(FGF8 and FGF9) are secreted by epithelial cells (Yu and Ornitz, 2001, Ornitz and 
Marie, 2002, Goetz and Mohammadi, 2013). In addition, the tyrosine kinase FGFRs 
were also found to bind HS, which contributes to a stable ternary FGF-FGFR-HS 
structure (Fig. 1.9 B) (Schlessinger et al., 2000, Powell et al., 2002, McKeehan et al., 
1998). The most well-known models are 2:2:2 (symmetric) and 2:2:1 (asymmetric) 
FGF-FGFR-HS complex (Fig. 1.9 B). HS/heparin can facilitate the stability of FGF-
FGFR complex to bring about some special biological functions, such as mitogenic 
activity (Mohammadi et al., 2005). In the asymmetric model, only one HS/heparin 
chain binds to the two FGFs, and this engages two FGF receptors (Pellegrini et al., 
2000). The interaction of FGFs with their receptors induces the dimerization of 
receptors (Fig. 1.9 B), which regulates the phosphorylation of the intracellular kinase 
domain to induce intracellular signalling (Section 1.7). 
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1.7 FGF signalling pathways  
The binding of the FGF ligand to its receptor causes the FGFR to dimerise. This in 
turn enables phosphorylation of tyrosine residues in the kinase activation loop and 
then of tyrosines that are docking sites for signalling proteins (Goetz and 
Mohammadi, 2013). These phosphorylations cause the activation of many 
intracellular signalling pathways, e.g., RAS-RAF-MAPK, PI3K-AKT and 
phospholipase-IP3 (Fig. 1.10), which regulate cell fate and specific cell activities 
(Fig. 1.10) (Turner and Grose, 2010, Dorey and Amaya, 2010). Previous studies 
suggest HS/heparin is required for most, but not all signalling (Izvolsky et al., 2003, 
Delehedde et al., 2000, Delehedde et al., 2002b). FGF signalling can be negatively 
regulated by internalisation and degradation of the ligand-receptor complex, as well 
as by transmembrane regulators, such as FGFRL1 and intracellular ones, e.g., MAPK 
phosphatase 3, sprouty and spred proteins (Turner and Grose, 2010, Casci et al., 
1999, Eblaghie et al., 2003) . Since there is a great diversity of FGF ligands, FGFR 
isoforms, HS structure and feedback loops, the understanding of FGF signalling is 
still far from complete, though the link between the activation of the RAS-RAF-
MAPK pathway and the stimulation of cell division is well established, as least in 
cultured cells (Dorey and Amaya, 2010). 
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Figure 1.10 FGFR signalling. The interaction of FGF with the FGFR and HS co-
receptor leads to the dimerization of the FGFR and the subsequent 
transphosphorylation of tyrosine residues on the intracellular tyrosine kinase domain. 
PLC and GRB2 can dock to the phosphorylated tyrosines, while FRS2 docks to the 
juxta-membrane domain. The bound GRB2 activates the RAS-RAF-MAPK and the 
PI3K-AKT signalling pathways, while phosphorylation of PLC induces the 
phospholipase-IP3 pathway. The signalling pathways regulate many cell activities, 
e.g., cell fate, cell proliferation, migration and differentiation. FGF, fibroblast growth 
factor; FGFR, FGF receptor; D1-D3, FGFR immunoglobulin domains 1-3; ‘To core 
protein’, indicates that the HS chain (blue line) will be linked to a proteoglycan core 
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protein; FRS2, FGF receptor substrate 2; GRB2, growth factor receptor-bound 
protein 2; GAB1, GRB2-associated protein 1; PLC, phospholipase C; AKT, 
Protein kinase B; SOS, son of sevenless; RAF: raf-leukemia viral oncogene 
homologue 1; RAS, rat sarcoma; IP3, inositol trisphosphate; MEK, mitogen-
activated protein kinase kinase; MAPK, mitogen-activated protein kinase; PI3K, 
phosphoinositide 3-kinase; PIP2, phosphatidylinositol 4, 5-bisphosphate; red dots, 
phosphorylation of signaling proteins. 
1.8 Binding and transport of FGFs in ECM  
In development, one important feature of paracrine FGFs mediating cell-cell 
communication is that they will often have to diffuse from the source to the target 
cells. In addition, this diffusion can set up a gradient (morphogen gradient, Section 
1.2). These gradients are a key part of how the fate of cells is specified and how the 
cell activities are regulated. In the processes of homeostasis and tissue maintenance, 
FGFs also play important roles. Again, they signal between tissue compartments and 
so ensure, for example, repair. 
Abundant studies have already suggested that the ECMs in different tissues and 
tissues at different ages or different status are very diverse (Section 1.3) (Frantz et 
al., 2010, Davies, 2001, Olczyk et al., 2014, Mouw et al., 2014). These ECMs 
contain different components or same components with different structures, which 
regulates the binding and diffusion of FGFs. HS chains are the main FGF binding 
components and by binding to HS chains many spatial and temporal FGF morphogen 
gradients are formed in development (Duchesne et al., 2012, Dowd et al., 1999, 
Makarenkova et al., 2009, Shute et al., 2004). Binding to HS also regulates the 
biological activities stimulated by FGFs in many situations (Zhu et al., 2010, 
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Delehedde et al., 2000, Delehedde et al., 2002a, Izvolsky et al., 2003, Patel et al., 
2008).  
The expression of HS chains produces many different tissue-specific structures, 
which selectively bind to the secreted FGFs and control their diffusion (Izvolsky et 
al., 2003, Shute et al., 2004). Originally, it was found that FGF2 was stored in 
endothelial cell ECM and it could be transferred to its cellular receptors to induce 
cell signals (Vlodavsky et al., 1987). At the tissue level, specific distributions of 
many FGFs have been observed (Izvolsky et al., 2003, Harada et al., 1999, Gonzalez 
et al., 1996). A study with FGF2 revealed that FGF2 in many tissues (skin, heart, 
lung, kidney and intestine) is distributed to defined cells (Gonzalez et al., 1996). 
Similarly, FGF10 has been found to preferentially bind to urothelium rather than 
lamina propria in bladder and ureter (Zhang et al., 2006a). Even on one cell, the 
binding of FGF2 in the pericellular matrix is not homogeneous (Duchesne et al., 
2012, Nieves et al., 2015). These studies suggest FGFs selectively bind to HS 
structures in the ECM, which is consistent with the in vitro studies with heparin and 
its derivatives (Section 1.8) and that the distribution of these structures is spatially 
controlled (Xu et al., 2012, Ori et al., 2009). 
In embryonic development, it seems that FGFs usually diffuse through ECM, rather 
become trapped and stored there, as in the example of the development of vertebrate 
limb, in which FGF10 is expressed mesenchymally to regulate the development of 
the overlying apical ectodermal ridge (Zeller et al., 2009). So, how do the paracrine 
FGFs move to their target in the ECM, after they are secreted? HS in the ECM was 
found to control the diffusion of FGF2, which indicates that HS proteoglycans in the 
ECM might regulate morphogen gradient formation (Dowd et al., 1999). FGF10 
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bound to heparin acrylic beads could hardly disassociate from heparin and diffuse 
into either a collagen gel or Matrigel, because of its high affinity for heparin, 
whereas a mutant FGF10 (R178V), which bound more weakly, diffused out of the 
heparin bead (Makarenkova et al., 2009). FGF9 diffused more slowly in its targeting 
ECM than its mutant FGF9Eks which is unable to homodimerise to efficiently 
interact with HS (Kalinina et al., 2009). These data suggest that HS should 
selectively bind to FGFs if the FGF is to be allowed to diffuse, or if it is to be stored. 
The study of the movement of gold nanoparticle-FGF2 in the pericellular matrix of 
rat mammary (Rama) 27 fibroblasts (cells described in Section 2.6) suggests most 
FGF2 diffuses slowly by reversible binding to HS chains (Duchesne et al., 2012). 
Since the binding sites for FGF2 in the HS of pericellular matrix were not evenly 
distributed, this is likely to contribute to the regulation of the diffusion of FGF2 
(Duchesne et al., 2012). However, it is still unknown whether these properties of the 
binding and transport of FGF2 were a general phenomenon or only true for FGF2. 
Heparanase, a beta glucuronidase, which cleaves HS in NA and NAS domains, was 
also identified as an accelerator for the diffusion of FGFs by releasing the S domains 
to which FGFs will generally be bound (Shute et al., 2004).  
1.9 Aims of this project 
The aim of the thesis was to establish if HS may generally control the binding and 
diffusion of FGFs and whether the molecular basis of the interactions of FGFs with 
the polysaccharide affects FGF diffusion, since this would enable local control of the 
diffusion of different FGFs by HS. In cases where this has been measured, the 
paracrine FGFs recognise different, though often overlapping, structures in HS and it 
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seems that the selectivity of FGFs for HS may follow their phylogenetic relationships 
(Xu et al., 2012, Xu et al., 2013).  
Consequently, FGFs from different subfamilies were used in this thesis, to provide a 
group of proteins with defined HS binding characteristics, linked to their functional 
and evolutionary relationships. The first step was to produce FGFs suitable for 
measuring FGF diffusion. In some cases the specificity of the interactions of the 
chosen FGFs with HS had not been characterised, so this is determined. A heparin 
library (comprising different chain lengths and different sulfation modifications) was 
used as a simple in vitro tool to determine the specificity of the interactions of these 
FGFs with heparin/HS. Fixed Rama 27 fibroblasts were used as the cellular model to 
study the binding and diffusion of multiple FGFs in the pericellular matrix using 
imaging technology. Three sub-aims were established and the results are described in 
Chapters 3 to 5: 
i) Producing soluble and biologically active FGFs. 
ii) Measuring the heparin/HS binding specificity of FGFs. 
iii) Determining the binding and diffusion of FGFs in fixed Rama 27 fibroblast 
pericellular matrix by using imaging technology. 
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Chapter 2 Materials and methods 
2.1 DNA cloning 
2.11 Preparation of competent cells (DH5α, Top 10, SoluBL21 and BL21 plysS) 
The desired bacterial strain was grown in 8 mL LB broth (MERCK, Hertfordshire, 
UK) in a 37oC shaker overnight. Then, 1 mL bacterial culture was transferred into 
100 mL LB broth and the culture was incubated at 37oC in a shaker for 2~3 hours 
until OD600 was 0.4~0.6. The bacteria were harvested by centrifugation at 4000 g for 
10 minutes. The supernatant was discarded and the pellet was resuspended in 20 mL 
transformation buffer I (30 mM potassium acetate (KOAc), 100 mM RbCl, 10 mM 
CaCl2, 50 mM MnCl2 and 15% (v/v) glycerol, pH 5.8 adjusted with 0.2 M acetic 
acid) and incubated on ice for 5 minutes. The bacteria in transformation buffer I were 
collected by centrifugation and the supernatant was discarded. The cell pellet was 
gently resuspended with 2 mL transformation buffer II (10 mM MOPS, 75 mM 
CaCl2, 10 mM RbCl and 15% (v/v) glycerol, pH 6.5 adjusted with 1 M KOH). The 
cells in transformation buffer II were split into Eppendorf tubes and stored at -80oC. 
2.12 Transformation 
Competent cells (E. coli DH5α, Top10, SoluBL21, BL21 (DE3) plysS) and plasmids 
were thawed on ice for 10 minutes. Plasmids (1 µL, 50~300 ng/µL) and 70 µL 
competent cells were added to a sterile 1.5 mL Eppendorf tube, and the mixture was 
placed on ice for 30 minutes. Then the tube was heated at 42oC for 45 seconds, and 
immediately placed on ice for 2 minutes. LB broth (1mL) culture medium was then 
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added and the bacterial culture was incubated in a shaker (37oC, 250 rpm). After 60 
minutes incubation, the cells were centrifuged and the supernatant was discarded. 
The cell pellet was resuspended in 100 µL LB culture. Twenty µL cell culture was 
spread onto a solid LB agar (MERCK) medium plate containing an appropriate 
antibiotic (50 µg/mL ampicillin sodium salt or 100 µg/mL kanamycin sulfate), and 
bacteria were incubated in a 37oC overnight. Finally, the plate was usually stored at 
4°C until required. 
2.1.3 Plasmid amplification in DH5α cells and extraction from the cells  
The desired plasmid was transformed into DH5α cells, as described in Section 2.1.2. 
A single colony containing the plasmid was picked from the agar plate and 
inoculated into 6~8 mL LB broth medium and the culture was incubated in a 37oC 
shaker overnight. The bacteria were collected by centrifugation at 4000 g room 
temperature for 10 minutes and the supernatant was discarded. The plasmid was 
extracted from the bacteria pellet with QIAprep Spin Miniprep Kit (Qiagen, 
Manchester, UK) and stored at -20oC. 
2.1.4 DNA fragment amplification by Polymerase chain reaction (PCR) 
The PCR components, including polymerase (Merck), MgSO4, dNTP, primers, 
templates, buffer and water, were added to a PCR tube (STARLAB (UK), Ltd, 
Milton Keynes, UK) by following the protocol in Table 2.1 and mixed. Then, the 
samples were put into a PCR cycler (TC-PLUS, Bibby Scientific, Staffordshire, UK). 
The DNA fragment was amplified for 30 cycles with the conditions in Table 2.2. The 
PCR product was analysed by DNA agarose gel electrophoresis (Section 2.1.5) and 
stored at -20oC. 
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Table 2.1 PCR reaction (50 µL) components and volume: 
PCR Reaction Components  Volume/ µL 
10 X buffer for KOD Hot Start DNA polymerase      5  
25 mM MgSO4                                                                 3  
dNTP (2 mM each)                                                         5  
Sense Primer (30 mM)                                            2  
Anti-sense primer (30 mM)                                                     2  
Template DNA (200 ng/µL) 1  
KOD Hot Start DNA Polymerase (1 U/µL) 1  
PCR Grade water 31  
Total reaction volume 50  
 
Table 2.2 PCR cycling conditions: 
Cycling conditions Temp./ oC Time Circles  
Stage 1  Activation 98 5 min 1 
Stage 2.1  Denature 95 15 s  
 
30 
Stage 2.2  Annealing Tm - 5 15 s 
Stage 2.3  Extension 70 40 s 
Stage 3  Complete Extension 70 10 min 1 
Stage 4  Hold 4 +∞ 1 
 
2.1.5 DNA agarose gel 
TAE (Tris-acetate-EDTA) buffer (10 X, 1 L): 20 mL EDTA (0.5 M, pH 8.0), 48.4 g 
Tris-Cl, 11.42 mL acetic acid and H2O. 
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TAE buffer (1 X) was made by diluting 100 mL 10 X TAE buffer into 900 mL 
dH2O. Agarose gels (1.2% (w/v)) were made by dissolving 0.36 g agarose into 30 
mL 1 X TAE buffer and heating in a microwave oven. SYBR® Safe DNA Gel Stain 
(2 µL, Life technologies, Paisley, UK) was added to the gel liquid when its 
temperature was about 40oC to 50oC. Then the warm gel liquid was added into a gel 
making kit and allowed to set. 
DNA solutions were mixed with 6 X loading dye (Thermo Scientific, Leicestershire, 
UK) and loaded into the wells and 1 kb DNA ladder (Thermo Scientific) was used to 
identify the size of the DNA fragments. Agarose gels were run at 100 V in 1 X TAE 
buffer for 30 minutes. 
2.1.6 Restriction enzyme digestion 
The plasmid (vector) and PCR fragment (insert) were digested with two desired 
enzymes (NEB, Hitchin, UK) to open the plasmid and expose the restriction sites, 
such as NcoI and BamHI. The digestion reaction was set up, as described in Table 
2.3 and the buffer was chosen according to that recommended by the manufacturer of 
the enzymes. The reaction proceeded at 37oC for 2 hours. 
Table 2.3 Restriction enzyme digestion setup: 
Components Volume/ µL 
DNA (plasmid or PCR product) 5  
Enzyme 1 1  
Enzyme 2  1  
Buffer (10 X) 2  
H2O   11  
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2.1.7 DNA extraction from DNA gel 
The target DNA fragment was excised from the agarose gel with a scalpel, and the 
gel slice was weighed in a 1.5 mL Eppendorf tube. Then, the DNA fragment was 
extracted from the gel by using QIAquick Gel Extraction Kit (Qiagen). 
2.1.8 T4 Ligation 
The ligation components (Table 2.4) were mixed and the ligation reaction was 
carried out at room temperature overnight. The ligation product was transformed into 
Top 10 competent cells to amplify the ligated plasmid. 
Table 2.4 T4 ligation setup 
Ligation components Volume/ µL 
Insert   x  
Vector  y (50 ng) 
T4 ligase Buffer (10 X) 2  
T4 ligase 2  
H2O (20-x-y)  
 
Note: The volumes of insert (x μL) and vector (y μL) are based on different molar 
ratios (4:1 and 6:1). 
2.1.9 In-Fusion Ligation 
In-Fusion cloning is a ligation method, which is based on the overlap of base pairs at 
the ligation sites rather than the cleavage sites. The insert was prepared by PCR, and 
the vector was opened by enzyme digestion. The PCR product was designed to 
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possess around 15 bp complementary ends, which overlapped the respective ends of 
the opened vector. The in-fusion ligation (In-Fusion HD Cloning Kit, Clontech, 
Takara Bio Europe SAS, Saint-Germain-en-Laye, France) was prepared according to 
Table 2.5. The reaction was incubated for 15 minutes at 50°C, and then placed on ice 
for transformation. 
Table 2.5 In-Fusion Ligation setup: 
In-Fusion Ligation components Volume/ µL 
5X In-Fusion HD Enzyme Premix 2  
Linearized Vector x (50 ng) 
Purified PCR Fragment y (100 ng) 
H2O z (z=10-2-x-y) 
Total volume 10  
Note: The values of x and y are based on the concentration of the DNA fragment. 
2.1.10 Colony screening for ligation with PCR and DNA sequencing 
The colonies growing on the ligation plate were labelled and used as template in the 
PCR sample preparation. The PCR products of the predicted size were identified by 
DNA agarose gel electrophoresis and the corresponding colonies were transformed 
into 8 mL LB broth medium for plasmid extraction (Section 2.1.3). The extracted 
plasmid was sequenced across the insert in both directions by GATC Biotech (GATC 
Biotech Ltd., London, UK). 
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2.2 Protein expression and purification 
The proteins were expressed as described in ‘HaloTag is an effective expression and 
solubilisation fusion partner for a range of fibroblast growth factors’ in Chapter 3 
and the collected bacterial pellet was stored at -80oC before protein extraction 
(Sections 3.2 and 3.3). 
2.3 SDS-PAGE 
2.3.1 Sample preparation 
Samples were prepared by mixing 30 μL protein solution with 10 μL sample buffer 
(4 X: 4% (w/v) Sodium dodecyl sulfate (SDS), 40% (v/v) glycerol, 24% (v/v) 1 M 
Tris-Cl (pH 6.8), 5 % (v/v) β-mercaptoethanol, 0.04% (w/v) bromophenol blue and 
3.1 mL water). The mixture was heated at 98oC for 5 minutes, and centrifuged for 2 
minutes. 
2.3.2 Gel preparation 
The resolving gel for 12% (w/v) SDS-PAGE was prepared according to Table 2.6. 
The mixture was transferred into a 0.75 mm thickness glass plate assembly, and the 
resolving gel was covered with 0.5 mL water. When the gel had polymerized, the 
layer of water was discarded. The stacking gel (Table 2.7) was poured into the glass 
plate assembly and the sample well comb was inserted into the stacking gel. The gels 
were ready to use when they set.  
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Table 2.6 Resolving gel 12% (10 mL): 
Components  Volume 
Acrylamide/bis-acrylamide stock (30%, w/v) 4.0 mL 
Tris-Cl (3 M, pH 8.8)  2.5 mL 
Water  3.5 mL 
10% (w/v) SDS  100 μL 
TEMED 10 μL 
Ammonium persulfate (50 mg/ml, fresh)  100 μL 
 
Table 2.7 Stacking gel (10 mL): 
Components  Volume 
Acrylamide/bis-acrylamide stock (30%, w/v) 1.3 mL 
Tris-Cl (1.25 M, pH 6.8)  1.0 mL 
Water  7.7 mL 
10% (w/v) SDS 100 μL 
TEMED 20 μL 
Ammonium persulfate (50 mg/ml, fresh)  100 μL 
 
2.3.3 Loading samples and running gel 
After the comb was removed the gel assembly was placed in the electrophoresis 
apparatus. Running buffer (1 X: 14.4 g glycine, 6.04 g Tris-Cl and 1 g SDS for 1 L 
buffer) was added into the tank to cover the gel. Samples (Section 2.3.1) were added 
into the wells, and the gel was run at 30 mA per gel (maximum voltage: 200 V). 
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When the dye front reached the bottom of the gel, the gel was transferred into a 
staining box. 
2.3.4 Coomassie staining 
The gel was stained in staining buffer (300 mL methanol, 100 mL acetic acid, 550 
mL water, 50 mL glycerol and 1 g Coomassie blue) on a shaker (30 rpm) for 30 
minutes. Then, the staining buffer was discarded and the gel was destained with 
destaining buffer (300 mL methanol, 100 mL acetic acid and 600 mL water) on a 
shaker until the background was clear. The destained gel was imaged with a scanner. 
2.4 Cell disruption and protein purification 
The bacterial cells containing the expressed protein were disrupted and the soluble 
fraction was obtained and the expressed FGFs were purified as described, in 
‘HaloTag is an effective expression and solubilisation fusion partner for a range of 
fibroblast growth factors’, in Chapter 3. 
2.5 Differential Scanning Fluorimetry (DSF) 
The experimental procedure, data acquisition and data analysis are described in 
Chapter 4 (Section 4.2). 
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2.6 Tissue culture 
2.6.1 Routine culture 
Cell culture medium for Rama 27 fibroblasts (Rudland et al., 1984) and HaCaT 
keratinocytes (Boukamp et al., 1988) were prepared as described in ‘HaloTag is an 
effective expression and solubilisation fusion partner for a range of fibroblast growth 
factors’ in Chapter 3. The Rama 27 cells were isolated form the fast sticking fraction 
obtained from rat mammary gland and were triply single cell cloned. They were 
designated as fibroblasts based on their ability to be differentiated to a pre-adipocyte 
phenotype (Rudland et al., 1984). 
The cells were cultured in a 37oC incubator with 10% (v/v) CO2 until the 10 cm 
culture plate (Corning, Nottingham, UK) was ~90% confluent. The plate was washed 
with PBS (2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 and 0.15 M NaCl, pH 
7.4) twice and then incubated with 1 mL versene (Life technologies) containing 2.5% 
(v/v) trypsin stock (2.5% (w/v), Life technologies) in the incubator to release cells. 
The released cells were resuspended with 8 mL culture medium and split into 8 
dishes (Rama 27) or 4 dishes (HaCaT). Another 8 mL culture medium was added to 
each dish and the dishes were returned to the incubator. 
2.6.2 Counting cells 
Cells released by trypsinisation (Section 2.6.1) (0.5 mL) in cell culture medium (total 
volume: 10 mL) were added to a Coulter counting cup containing 19.5 mL Isoton II 
(Beckman Coulter, High Wycombe, UK). The cell number in 0.5 mL solution in the 
cup was determined in a Z1 coulter particle counter (Beckman Coulter). The total 
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number of cells in the dish was calculated by accounting for the dilutions, so by 
multiplying the number by 800. 
2.6.3 Freezing cells 
The cells were released from the cell dish by trypsin digestion (Section 2.6.1) and 9 
mL cell culture medium was added. The cells were counted, placed in a 20 mL 
universal tube and collected by centrifugation at 800 rpm for 5 minutes. The 
supernatant was discarded and the cell pellet was resuspended in freezing medium 
(14.5 mL Dulbecco’s modified Eagle’s medium (DMEM, Life technologies), 1.5 mL 
dimethyl sulfoxide and 4 mL fetal calf serum (FCS, Labtech International Ltd, East 
Sussex, UK)) to obtain the desired cell density (1~1.5 x 106 cells/mL). The cells (1 
mL) in freezing medium were split into 1.5 mL cryotubes and transferred into a -
80oC freezer. The frozen cells were stored in a -140oC freezer. 
2.6.4 Thawing cells 
The cells taken out from the freezer were thawed in a 37oC water bath. Then, the 
cells were transferred into a universal tube and 20 mL thawing medium (16 mL 
DMEM medium and 4 mL FCS) was slowly added. The cells in the thawing medium 
were collected by centrifugation at 800 rpm for 5 minutes and 10 mL cell culture 
medium was added to resuspend the cells, which were then placed into a 10 cm dish 
and transferred to the 37oC incubator. 
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2.6.5 Cell growth assay and p44/42MAPK signalling assay 
The cell growth assay and Western blotting for p44/42MAPK were performed as 
described, in ‘HaloTag is an effective expression and solubilisation fusion partner for 
a range of fibroblast growth factors’, in Chapter 3. 
2.7 Fluorescence imaging 
The sample preparation, imaging and data analysis were performed, as described in 
Sections 5.2, 5.3 and 5.4 in Chapter 5. 
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Chapter 3 Production of FGFs in E. coli 
3.1 Introduction 
An important aim of this thesis was to produce a range of FGFs from different 
subfamilies so that their interactions with GAGs could be investigated (Sections 
1.5.4 and 1.9). A number of FGFs had previously been expressed in E. coli and 
purified to explore their structures and interactions with their receptors (FGFR) and 
their co-receptors (Heparin/HS) (Zhang et al., 2006b, Xu et al., 2012, Xu et al., 
2013). However, the existing set of FGFs was limited and only one FGF was 
available from most subfamilies and none from the FGF4 subfamily was available 
(Xu et al., 2012). To test the hypothesis that the specificity of interactions of FGFs 
with GAGs was under the same natural selection pressure that drove the 
diversification of the FGFs, it would require a more comprehensive set of proteins. 
The functional implications of this hypothesis would also necessitate a larger set of 
FGFs. 
One reason for the previous expression of a limited set of FGFs was that many were 
insoluble. Consequently, a major focus was to develop the means of producing 
soluble proteins, which included testing a variety of bacterial hosts and the SUMO 
solubilisation tag. Alongside, a method to label FGFs with high structural specificity 
was required for fluorescence microscopy. HaloTag, a mutated dehalogenase (Los et 
al., 2008), was tested in this respect, since it potentially would provide great 
versatility in terms of labelling; the N-terminus of FGFs was deemed to be a suitable 
position for the fusion protein, since FGF2 had successfully been labelled at that 
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position with gold nanoparticles (Duchesne et al., 2012).  In this chapter the 
production of recombinant FGFs with and without an N-terminal HaloTag is 
described. The activity of these FGFs was also measured, since this depends on both 
binding to HS and FGFR and so would determine if the FGFs were properly folded. 
Much of this work is published in the following paper, with full author contributions 
included. 
3.2 Paper 
Sun, C., Li, Y., Taylor, S. E., Mao, X., Wilkinson, M. C., Fernig, D. G. (2015). 
HaloTag is an effective expression and solubilisation fusion partner for a range of 
fibroblast growth factors. PeerJ. 3, e1060. 
Contributions of the authors: 
Changye Sun: Cloning, design of cloning strategy, expression and purification of 
His-FGF1, His-FGF10, His-FGF6, His-FGF8, His-FGF20, His-FGF22, Halo-FGF6, 
Halo-FGF8, Halo-FGF20 and Halo-FGF22, measurement of protein yields, of 
stimulation of phosphorylation of p42/44MAPK and of cell growth by FGFs, planed 
and wrote the paper. With Sarah E. Taylor cloning, expression and purification of 
Halo-FGF2; With Xianqing Mao cloning, expression and purification of Halo-
FGF3, Halo-FGF7 and Halo-FGF10; With Yong Li cloning, expression and 
purification of Halo-FGF16 and Halo-FGF17; expression and purification of FGF2, 
His-FGF3, His-FGF7 (Plasmids from Ruoyan Xu, University of Liverpool); Mark 
C. Wilkinson: Provided guidance on protein purification and edited the paper; 
David G. Fernig: conceived the study and edited the paper.    
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3.3 Supplementary methods and results  
3.3.1 Cloning of His-FGF1, -FGF10, -FGF20, -FGF6, -FGF8 and -FGF22 
The cDNAs encoding FGF1, FGF10 and FGF20 were amplified by PCR with the 
corresponding primers (Table 3.1) from Life Technologies. The vector pET-M11 
containing an N-terminal hexahistidine tag was amplified in E. coli DH5α and 
extracted (Section 2.1.3). Then, the three FGF cDNAs and pET-M11 were double-
digested (Section 2.1.6) with NcoI (all three FGF cDNAs and pET-M11 vector) and 
EcoRI (FGF1 and pET-M11) / BamHI (FGF10 and pET-M11) / NotI (FGF20 and 
pET-M11) (Fig. 3.1). The FGF cDNAs and open pET-M11 vector were extracted 
from agarose gels (Section 2.1.7). The cDNAs encoding FGF1, FGF10 and FGF20 
were inserted into the corresponding pET-M11 vector by T4 ligase and subsequently 
transformed into Top 10 cells. The bacteria were grown on a karnamycin plate and 
the colonies were screened by PCR. The plasmids obtained from the colonies 
corresponding to the correct PCR product were sequenced by GATC Biotech. 
Table 3.1 Primers for PCR: 
FGF Primer sequence (5’---3’) Cleavage site 
FGF-1 Forward: TTAAACCATGGTTAATCTGCCTCCCG NcoI 
 Reverse: TGAATTCTTAATCAGAAGAGACTGGCAGG EcoRI 
FGF-10 Forward: TTCAGGGCGCCATGGCGCAAGCCCTTGGT 
CAAGA 
NcoI 
 Reverse: GCTGCTCGGATCCCTATGAGTGTACCACC 
ATTGG 
BamHI 
FGF-20 Forward: TTCAGGGCGCCATGGCGATGGCTCCCTTA 
GCCGAA 
NcoI 
 Reverse: TGGTGCTCGAGTGCGGCCGCTCAAGTGTA 
CATCAGTAGGT 
NotI 
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Figure 3.1 Cloning of His-FGF1, 10 and 20. pET M11 vector was prepared by 
digestion with NcoI and EcoRI/BamHI/NotI restriction enzymes. The same method 
was used to digest the PCR products of FGF1, 10 and 20. The opened pET M11 
vector and DNA fragments encoding FGF1, FGF10 and FGF20 were extracted from 
agarose gels. FGF cDNAs were inserted into the pET M11 vector using T4 ligase. 
The cDNA sequences corresponding to FGF4, 6, 8 and 22 were modified by 
GeneArt® Gene Synthesis software to enhance expression in E. coli and the DNA 
fragments were synthetized and cloned into the pMA-T vector (Life Technologies). 
One 5’ cleavage site (NcoI) and three 3’ cleavage sites (BamHI, NotI and KpnI) 
were designed into the DNA sequences. The FGF plasmids (pMA-T-FGF6, 8 and 
22) and vector (pET-M11) were amplified in E. coli DH5α, and were then double 
digested by NcoI and NotI (Fig. 3.2). The ligation, selection of successfully ligated 
plasmids and verification by sequencing were accomplished by following the 
approach used for cloning of His-FGF1, 10 and 20. 
P r o d u c t i o n  o f  F G F s  w i t h  E . c o l i  
 
 73 
 
Figure 3.2 Cloning of His-FGF6, 8 and 22. pET M11 vector was prepared by 
digestion with NcoI and NotI restriction enzymes. The same digestion method was 
used to extract sequences encoding FGF6, 8 and 22 DNA from the pMA-T vectors. 
The opened pET M11 vector and DNA fragments encoding FGF6, FGF8 and FGF22 
were extracted from DNA agarose gels. DNA encoding FGFs were inserted into pET 
M11 vector using T4 ligase. 
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Figure 3.3 Further purification of the heparin-affinity chromatography eluates 
of Halo-FGF2, Halo-FGF10, His-FGF1, FGF2 and His-FGF10. The soluble 
Halo-FGF10 eluted from heparin chromatography was purified using Q anion-
exchange chromatography, while Halo-FGF2 was purified by DEAE ion-exchange 
chromatography and Q anion-exchange chromatography. His-FGF1, FGF2 and His-
FGF10 eluted from heparin affinity chromatography were further purified by nickel 
affinity chromatography and/or CM cation-exchange chromatography. Lane M, 
markers; P, pellet following centrifugation of lysate; S, corresponding supernatant; 
Hep, eluate from heparin chromatography; T, unbound, flow-through fraction from 
heparin-affinity chromatography (D) or CM chromatography (B) or nickel 
chromatography (A); DEAE, eluate from DEAE chromatography, two identical 
samples; CM, eluate from CM chromatography; Q, peak fractions collected from Q 
HP chromatography; Red arrows: Halo-FGF, green arrows: His-FGF or FGF2. 
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3.3.2 Purification of His-FGFs and Halo-FGFs  
The His-FGFs and Halo-FGFs were purified by heparin affinity chromatography 
(Section 3.2). His-FGF1 and His-FGF10 collected from the eluate of the heparin 
column were further purified by nickel affinity chromatography and washed with 50 
mM Tris-Cl (containing 100 mM imidazole and 150 mM NaCl, pH 7.2). The bound 
His-FGFs were eluted with 50 mM Tris-Cl containing 300 mM imidazole and 150 
mM NaCl, pH 7.2 (Figs 3.3 A and C, Ni2+ lanes). His-FGF1 from the nickel affinity 
eluate and FGF2 from the heparin affinity eluate were efficiently purified by CM 
Sepharose Fast Flow chromatography (Figs 3.3 A and B, CM lanes), as described in 
Section 3.2. Halo-FGF2 from heparin affinity chromatography was purified by 
DEAE Sepharose Fast Flow chromatography, but the eluate still contained detectable 
impurities (Fig. 3.3 D, DEAE lanes). Since the eluate from DEAE chromatography 
was not sufficiently pure, it was further purified by HiTrap Q HP chromatography, as 
described in 3.2 (Fig. 3.3 D, Q lane). Halo-FGF10 was also purified by Q HP 
chromatography and the eluate was relatively pure (Fig. 3.3 E, Q lanes). 
3.3.3 Production of SUMO tagged FGF22 
Cloning of His-SUMO-FGF22: The cDNA encoding FGF22 was amplified by PCR, 
and KpnI and HindIII cleavage sites were designed into the PCR product with 
primers: 5’-CAGGTACCGAGAATCTTTATTTTCAGGGCACCCCGAGCGCAAG 
TC-3’ and 3’-CTACCAAGCTTTTAGCTAACCAGAACC-5’. The POPPINS-3C 
vector and FGF22 PCR product were double digested by KpnI and HindIII (Figure 
3.4). The ligation, selection of successfully ligated plasmids and verification by 
sequencing of the plasmid encoding His-SUMO-FGF22 were accomplished by 
following the approach used for cloning of His-FGF1, 10 and 20. 
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Figure: 3.4 Cloning of His-SUMO-FGF22. POPPIN-3C vector was prepared by 
digestion with KpnI and HindIII restriction enzymes. FGF22 DNA sequence with 5’ 
KpnI and 3’ HindIII cleavage sites was amplified using PCR and was digested with 
these two enzymes. FGF22 was inserted into POPPIN-3C vector using T4 ligase. 
Purification of His-SUMO-FGF22 from soluble fraction: The soluble fraction 
containing His-SUMO-FGF22 was loaded onto heparin- and nickel-affinity columns, 
and both the columns were washed with 0.2 M NaCl 50 mM Tris-Cl buffer (pH 7.4). 
The heparin column was eluted with 2 M NaCl 50 mM Tris-Cl buffer (pH 7.5), and 
then washed with 8 M urea containing 2 M NaCl. The nickel column was eluted with 
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300 mM and 600 mM imidazole. The cell lysate was also digested by TEV protease 
overnight at 4°C to determine the efficacy and effect of cleavage of the SUMO tag. 
The digestion product was centrifuged at 13000 rpm 4oC for 10 minutes to separate 
the soluble and insoluble proteins after digestion. The collected samples were 
analysed by SDS-PAGE. 
Purification result: The molecular weight of His-SUMO-FGF22 is 31.2 kDa. A 
protein corresponding to the expected size of His-SUMO-FGF22 on SDS-PAGE was 
produced in the transformed bacteria induced overnight at 16°C by IPTG. This 
protein was found in the soluble fraction, indicating that the SUMO tag had 
successful increased the solubility of the FGF22 (Fig. 3.5 A, S lane). However, upon 
heparin affinity chromatography, most of His-SUMO-FGF22 was found in the flow-
through fraction (Fig. 3.5 A, T lane). Similarly, most of His-SUMO-FGF22 failed to 
bind to the nickel affinity column (Fig. 3.5 A, T’ lane). Moreover, the small amount 
of protein that did bind to the affinity columns could not be eluted by normal elution 
buffers (Fig. 3.5 A, E-1 and Ni1 lanes), but required 8 M urea with 2 M NaCl 
(heparin column) or 600 mM imidazole (nickel column). The poor binding of the 
SUMO-FGF22 to the heparin-affinity column may indicate that the protein might not 
be correctly folded, since the canonical HBS is composed of residues that are 
spatially adjacent, but distant in sequence. An alternative explanation is that the 
protein is correctly folded, which would be consistent with its appearance in the 
soluble fraction, but was oligomerised such that the canonical HBS and the His tag 
were not exposed to solvent. That fraction that did bind to the affinity columns is 
likely to be oligomerised, since it did not all elute from heparin with 2 M NaCl and 
some required 600 mM imidazole for elution from the nickel affinity column. The 
digestion product of the fusion protein with TEV protease was not complete and both 
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the digested (FGF22) and non-digested (His-SUMO-FGF22) fragments were 
observed in the pellet following centrifugation (Fig. 3.5 B, D-p lane). These data 
suggest that FGF22 aggregated without the SUMO tag and the incomplete digestion 
with TEV is consistent with the presence of oligomers with buried N-terminal His 
tags.  
 
Figure 3.5 Expression and purification of His-SUMO-FGF22. (A): (M), marker 
(2-212 kDa protein marker, NEB, UK); (S), soluble fraction; (T), flow-through from 
heparin column; (E-1), eluate from heparin column with 2 M NaCl 50 mM Tris-Cl; 
(E-2), eluate from heparin column with 2 M NaCl and 8 M urea; (T’), flow-through; 
(Ni1), eluate with 300 mM imidazole; (Ni2), eluate from with 600 mM imidazole 
from nickel affinity chromatography; (B): (D-w), whole digestion product; (D-p), 
pellet of digestion product; (D-s), supernatant of digestion product. Red square: 
His-SUMO-FGF22; Orange arrow: non-digested His-SUMO-FGF22; Green 
arrow: FGF22. 
3.4 Conclusion 
Many different FGFs were produced by expression in E. coli and then successfully 
purified. FGF1 and FGF2, which had previously been successfully expressed (Ke et 
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al., 1990, Ke et al., 1992, Duchesne et al., 2008), were relatively simple to produce 
as the native or the tagged protein. FGF10, a well-studied member of the FGF7 
subfamily (Igarashi et al., 1998), was also straightforward to express and purify. 
However, the other FGFs were more challenging. Indeed many of these have proved 
difficult to produce by others (summarised in Section 3.2) and in our laboratory (Xu, 
2012).  
Table 3.2 Recommended constructs for producing FGFs. The yields of FGFs and 
Halo-FGFs, their receptor binding specificities (Zhang et al., 2006b) and biological 
activities are included in this table. 
Subfamily  Name Yield 
(mg/L) 
Receptor specificity Biological 
activity 
FGF1 FGF1 14 All FGFRs MAPK 
 FGF2 2.5 FGFR 1c, 3c >2c, 1b, 4Δ MAPK 
FGF4 Halo-FGF6 27 FGFR 1c, 2c >3c, 4Δ MAPK 
FGF7 Halo-FGF3 11  MAPK 
 Halo-FGF7 5.6 FGFR 2b >1b MAPK 
 FGF10 9.3  MAPK 
 Halo-FGF22 2.0  MAPK 
FGF8 Halo-FGF8 1.7 FGFR 3c > 4Δ >2c > 1c >> 
3b  
MAPK 
 Halo-FGF17 1.5  Cell growth 
FGF9 Halo-FGF16 1.0 FGFR 3c > 2c > 1c, 3b >> 
4Δ 
Cell growth 
 Halo-FGF20 10  MAPK 
FGF22 was not soluble (Section 3.2) and initially it was expressed with a SUMO tag 
to overcome this problem. However, the SUMO tagged FGF22 in the soluble 
fraction did not bind to heparin, which suggested the SUMO tag might not be able to 
fully solubilise FGF22. The HaloTag was initially used to provide a means of placing 
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a fluorescent probe in a structurally defined position on FGF2 (c.f. chemical 
modification of amino acid side chains), and was fortuitously observed to enhance 
protein expression (Section 3.2). HaloTag was, therefore, explored as a solubilisation 
tag. It was found to be suitable for the expression of soluble FGF3, FGF6, FGF7, 
FGF8, FGF17, FGF20 and FGF22, all of which could then be purified (Section 3.2). 
The recommended constructs for making each FGF are described in Table 3.2. All 
these proteins possess biological activity based on cell signalling and cell growth 
assays on cells possessing the appropriate receptors (HaCaT, FGFR2b, activated by 
FGF7 family members; Rama 27 FGFR1c, activated to different extents by all other 
FGFs) (Ornitz et al., 1996, Zhang et al., 2006b). In any event, since they bind 
heparin, they will be properly folded, because the canonical heparin-binding site has 
contributions from amino acids that are not adjacent in the sequence (Sections 1.5.3 
and 1.5.4). Why FGF16 and FGF17 did not elicit a stimulation of phosphorylation of 
p44/42MAPK, but nevertheless stimulated cell growth, is not known. However, the 
intracellular signalling pathways stimulated by these two FGFs have not been 
studied, so the present data suggest that their stimulation of cell growth may not 
involve to a great extent the p44/42MAPK pathway. The yields of some of these Halo-
FGFs (Halo-FGF8, 16, 17 and 22) are still low, which suggests HaloTag itself has 
not solved all the problems for production of soluble FGFs. However, the success of 
making many FGFs (FGF3, FGF6, FGF7, FGF17 and FGF20) provided enough tools 
for the analysis of the interaction of these FGFs with their polysaccharide co-
receptor, aspects of which are explored in the following chapters. 
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Chapter 4 Binding specificity of FGFs to heparin/HS 
4.1 Introduction 
The paracrine FGFs are morphogens involved in development, where they are 
thought to form different gradients by binding to HS chains in the ECM; 
subsequently in organism growth and homeostasis, such gradients are also likely to 
be important (Sections 1.2 and 1.8). Since the structure of HS chains shows some 
degree of tissue specificity (Section 1.3), then it follows that the ability of different 
tissues to bind and restrict the movement of different FGFs may also differ. The 
evolutionary development and natural selection that drove the expansion of these 
FGFs have been proposed to cause a divergence in their selectivity for binding 
structures in HS (Xu et al., 2012). Heparin, which can be viewed as a highly sulfated 
HS, is widely used to purify the paracrine FGFs, which demonstrates that all of the 
paracrine FGFs can strongly bind to heparin (Asada et al., 2009).  
To probe the binding selectivity of FGFs for the glycosaminoglycans, differential 
scanning fluorimetry (DSF) and a library of chemically modified heparins and model 
GAGs were used, as described (Uniewicz et al., 2010, Xu et al., 2012). DSF is a 
thermal shift assay, which follows protein denaturation due to increasing 
temperature. The melting temperature (Tm) of a protein is often very sensitive to the 
binding of ligands and buffer conditions. In the case of FGFs, the binding to 
polysaccharide increases Tm and this change is used as a proxy for affinity. DSF 
produces a large amount of data that requires analysis. Consequently, user-friendly 
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software has been developed to enable the efficient analysing and viewing DSF data. 
In this chapter the experimental procedure, data acquisition and analysis are 
introduced and the binding selectivity of two FGFs, FGF10 and FGF20 to the library 
of polysaccharides is measured by DSF and discussed. In previous work, the 
selectivity of the interactions with glycosaminoglycans of two members of the FGF1 
subfamily, along with one member of the FGF7 (FGF7), FGF8 (FGF18) and FGF9 
(FGF9) subfamilies was measured (Uniewicz et al., 2010, Xu et al., 2012). A 
hypothesis generated from these data was that the specificity of the FGF-
glycosaminoglycan interactions had been subjected to the same natural selection 
pressures that led to the diversification of the FGF family (Xu et al., 2012, Xu et al., 
2013). An aim of this chapter was to acquire data on FGFs from subfamilies that 
hitherto only had one member characterised, as this would enable the hypothesis to 
be tested. To this end, the interactions of FGF10, in the FGF7 subfamily, and FGF20, 
in the FGF9 subfamily (Section 1.5.1) with glycosaminoglycans were characterised. 
4.2 DSF experimental procedure, data acquisition and 
analysis (method paper) 
SimpleDSFviewer: a tool to analyse and view differential scanning fluorimetry 
data for characterising protein thermal stability and interactions 
Changye Sun, Yong Li, Edwin A. Yates, David G. Fernig 
Department of biochemistry, Institute of Integrative Biology, University of 
Liverpool, Liverpool L69 7ZB, UK 
PeerJ PrePrints 3:e1937 (DOI: 10.7287/peerj.preprints.1555v1) 
Contributions of the authors: 
B i n d i n g  s p e c i f i c i t y  o f  F G F s  t o  h e p a r i n / H S  
 
 83 
Changye Sun: Produced FGF10; wrote the program code; tested the program with 
example data; prepared the figures; Conceived study and wrote the paper. With 
Yong Li: Produced FGF7; tested the program with some experimental results; edited 
the paper. Ed A. Yates: Conceived study and edited the paper. David G. Fernig: 
Conceived study and edited the paper. 
Key words: differential scanning fluorimetry (DSF), protein melting curve, protein 
melting temperature, data analysis 
Abstract: Differential scanning fluorimetry (DSF) is used widely as a thermal shift 
assay to study protein stability and protein-ligand interactions. The benefit of DSF is 
that it is simple, cheap and can generate melting curves in 96 well plates providing 
good throughput. However, data analysis remains a challenge. In this article, the 
program, SimpleDSFviewer, is introduced as a user-friendly interface to help view 
and analyse DSF data.   
1 Introduction 
Differential scanning fluorimetry (DSF) is a thermal shift assay method used to 
measure the denaturation of proteins due to increasing temperature. Increased 
thermal energy will break the non-covalent bonds that underlie protein folding 
(Niesen et al., 2007, Semisotnov et al., 1991, Pantoliano et al., 2001). A high 
temperature is required to denature a stable protein, while an unstable protein will be 
denatured at lower temperature. The fluorescent dye, which gives high fluorescence 
in a non-polar environment, is used in the DSF assay to probe the hydrophobic sites 
on the unfolded proteins. So, as the temperature is increased, the protein unfolds to 
expose more and more hydrophobic residues until the protein is fully unfolded. This 
in turn produces more fluorescence by the interaction of fluorescent dye and the 
exposed hydrophobic residues. Since the DSF method has been  adopted by an ever 
wider community, an increasing number of applications have been developed to test 
protein stability and protein-ligand interactions (Vivoli et al., 2014). The equipment 
requirement is also so modest - a common RT-PCR instrument and 96 multi-well 
plates that the experiment can be done easily and a large volume of data can be 
acquired (Niesen et al., 2007, Vivoli et al., 2014). However, analysis of the data is 
more challenging. Consequently, a program for DSF data analysis has been written 
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to help users of DSF view and analyse efficiently their data. The program has a user-
friendly interface and a number of additional functions have been included, such as 
normalisation, smoothing and melting temperature extraction. Worked examples 
with two proteins, FGF7 and FGF10 are shown.  FGF7 serves as a reference, since 
its interactions with heparin have been previously characterised by DSF (Xu et al., 
2012). In contrast, FGF10, which is in the same FGF subfamily, has not had its 
interactions with heparin characterised previously. 
2 Data acquisition 
Proteins and ligands – In the given example, the reagents His-FGF10 (hexahistidine 
tagged Fibroblast Growth Factor 10) and His-FGF7 were produced, as described (Xu 
et al., 2013, Sun et al., 2015).  Heparin sodium powder (from porcine intestinal 
mucosa, Sigma-Aldrich, Dorset, UK) was dissolved in phosphate-buffered saline 
(PBS buffer: 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 and 137 mM NaCl, 
pH 7.4) to prepare a series of concentrations of ligands (supplementary: Example 
data) for FGF binding. 
Differential Scanning Fluorimetry (DSF) setup – The purified FGFs, heparin 
ligand and SYPRO Orange dye (Life technologies, Paisley, UK) were added into the 
corresponding buffer and mixed gently, as  listed in Table 1 (Uniewicz et al., 2010, 
Xu et al., 2013). Fast optical 96-well plates (Life technologies) were used to carry 
samples, which were read by a 7500 Fast Real-time PCR machine (Life 
technologies), and the prepared samples were split into three wells, 10 µL in each. 
The plate was then covered with Optical Adhesive Film to prevent evaporation. The 
running method was designed to raise the temperature from 32°C to 81°C in 0.5°C 
steps, and to measure the fluorescence every 0.5°C for 30 seconds. The protein 
concentration used for data acquisition was 5 µM. The raw data were exported from 
the running software (7500 Fast Real-time PCR system) to an Excel file, after the 
fluorescence reading. The details of the program for data analysis are described in 
the supplementary. 
Table 1 DSF reaction components for three wells: 
Components Protein Ligand 
(10X) 
SYPRO Orange 
(100X) 
Buffer Total 
volume 
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Volume / µL a1  3.5  3.5  (28-a)  35  
a1: volume of the protein for specified concentration. 
3 Data analysis and display with SimpleDSFviewer using Matlab 
3.1 Basic functions for data analysis and view – The SimpleDSFviewer 
automatically processes the raw data or the re-organised data (Fig. S2), as shown in 
the flow chart (Fig. 1). The melting curve data are normalised and smoothed with the 
given range and the first derivative of the melting curve is calculated as described in 
3.2. The melting temperature of each melting curve is extracted (3.3). The analysed 
data may be saved in an Excel file format for further analysis. 
The melting curve patterns of the tested proteins are also automatically screened and 
presented on an image, as is shown in 3.4 and 3.5, which gives a view of the 
proteins’ thermal stabilities across the 96 wells. The protein melting curves and the 
first derivative curves of selected wells can be plotted in the preview box or in a 
separate figure, which can be automatically or manually saved in different formats. 
The melting temperature point for each protein is also marked on the melting curve 
or first derivative curve.  
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Figure 1 Flow chart of DSF data analysis and display. The processing steps for 
the input data are described in this diagram. The red box and green boxes are the 
input (experimental data) and one output (melting temperature). The yellow boxes 
are the automatically analysed outputs. The purple boxes are to display data and to 
save data. The ‘Screen Data’ function directs the user to select the desired data for 
viewing. 
3.2 Normalise, smooth melting curve and first derivative curve – The background 
is removed by subtracting the minimum value of each curve from all points, and then 
the melting curve is normalised by dividing by the maximum value (Equation 1). The 
normalisation of melting curves enables these to be compared to each other (Figs 2 
A-B). The first derivative is calculated using Equation 2 and is normalised in the 
same way as the melting curves. The melting curves may be slightly noisy, e.g., due 
to low protein concentration (Figs 2 C-D), so each normalised curve is smoothed in 
three parts, the beginning to the minimum value, the minimum value to the 
maximum value and the maximum to the end, to avoid smoothing the part containing 
inflection point and ensure the original shape of the curve is maintained. Due to the 
Load data
Raw Melting 
curve (Mc)
Normalised Mc
Smoothed Mc
First derivative Tm
First derivative 
First derivative 
Save the analysed 
results in Excel
Display and save the 
analysed melting curves and 
first derivative curves
Screen the data in the 
96 wells
Give 2D and 3D Views 
about the data quality
Flow chart of DSF data analysis and display
Analysing 
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high quality smooth, the raw melting curve is strongly covered by the smooth curve. 
The smoothing method is based on Matlab - smooth function (MathWorks, 2015) 
and the smooth range can be defined by the user. Note that the ‘normalise’ and 
‘smooth’ functions are optional. 
 
Figure 2 Normalise and smooth the melting curves. Normalising the melting 
curves changes the display range of measured fluorescence intensity from 0 to 1, but 
the shape of the melting curve is unaltered. Smoothing the melting curves reduces 
the noise level, but also does not alter the shape of the curves. (A): Original melting 
curves of His-FGF10 (red) and His-FGF10 stabilised with 1.25 µM heparin (green). 
(B): Normalised melting curves of the same samples in (A). (C): Original melting 
curve (pink) and smoothed melting curve (black) of His-FGF7 stabilised with 50 µM 
heparin. (D): First derivative curves of melting curves in (C). 
Equation 1: 𝑀𝐶 =
𝑀𝐶−min⁡(𝑀𝐶)
max(𝑀𝐶)−min⁡(𝑀𝐶)
 
Equation 2: 𝐹𝐷 =
𝑀𝐶(𝑛+1)−𝑀𝐶(𝑛−1)
2∗𝛥𝑡
 
(A) (B)
(C) (D)
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MC: Melting curve values; min(MC): minimum value for the melting curve; 
max(MC): maximum value for the melting curve; MC(n+1) is the (n+1)th value in the 
melting curve; Δt is the difference in temperature of two neighbouring measurement 
points. 
3.3 Calculate melting temperature – (1) First derivative curve method: The melting 
temperature is generally defined as the temperature at the maximum of the first 
derivative curve (Fig. 3 A). (2) Melting curve method: The melting temperature can 
also be determined by calculating the half maximal denaturation temperature (DT50), 
which is temperature when the fluorescence intensity reaches 50% of highest 
fluorescence intensity (Fig. 3 B). The DT50 is a slightly higher melting temperature, 
because it calculates the first temperature after the ideal DT50. So, the difference of 
the ideal DT50 and acquired DT50 is less than the temperature increase for each 
measuring step.  
 
Figure 3 Extraction of melting temperatures. The stabilisation of His-FGF10 in 
the presence of a series of heparin ligands (concentrations are listed in 
Supplementary) was measured. The melting temperatures may be calculated by (A) 
the temperatures corresponding to half maximal fluorescence intensities and by (B) 
the temperatures corresponding to the maxima of the first derivative curves. The 
black points corresponding to melting temperatures are highlighted in the green 
dashed line boxes. 
3.4 Auto-screen a melting curve – The melting curves are screened by the default 
parameters when the data are input into the program. If the melting curve decreases 
(A) (B)
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from the maximal value to the minimal value as the temperature increases (Fig. 4 A, 
pink line), the protein corresponding to the melting curve is considered to be a 
denatured or unfolded protein. The findpeak function is used to find the peaks of the 
first derivative curves (Fig. 4 B). Only when the width and height of a peak are over 
10 % that of the highest peak in the assay, is the peak recognised as a second melting 
temperature (Fig. 4 B, orange line). However, if the number of recognised peaks is 
>=4, the corresponding protein is also thought to be a denatured protein (no example 
shown).  
 
Figure 4 Auto-screening the melting curves and preview of melting 
temperatures in 96 wells. Three different types of melting curves (A) can be 
screened and recognised by the program. The screened results and the melting 
temperature information are automatically presented in two figures (C and D). (A): 
Melting curves of His-FGF10 (red line), His-FGF10 stabilised with 0.625 µM 
heparin (yellow line) and His-FGF10 (pink line) denatured by 8 M urea. (B): First 
derivative curves calculated from melting curves in (A). (C): 2D map view of 
melting temperatures of the proteins in 96 wells. The dark blue wells contain 
unfolded proteins or unstable proteins (e.g., proteins in an inappropriate buffer). The 
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colours of the melting temperatures of folded proteins are distributed in the colour 
bar, which is from the lowest melting temperature to the highest temperature. (D): 
3D view of melting temperatures. The melting temperature of each well is plotted 
with a bar in the 3D graph with same colour for each column. 
3.5 Preview of the protein stabilities in the 96 wells – This function shows the 
wells containing unfolded proteins and to present the difference of their melting 
temperatures as an image map. The wells coloured with a low value colour (at about 
beginning of the colour bar, Fig. 4 C) are supposed to contain the unfolded proteins 
(Fig. 4 C). The melting temperatures are presented as different coloured squares from 
the lowest melting temperature the highest melting temperature (colour bar). A 3D 
bar plot containing the melting temperatures of the 96 wells is also prepared, to give 
a view of difference of proteins’ thermal stabilities (Fig. 4 D). 
 
Figure 5 Statistical analysis of different samples with ANOVA. The melting 
temperatures of different samples can be compared with ANOVA. The melting 
temperatures of His-FGF7 in PBS, His-FGF7 stabilised with 50 µM heparin in PBS, 
His-FGF7 in PBS containing 0.5% (v/v) Tween-20 (T-20) and His-FGF7 stabilised 
with 50 µM heparin in PBS containing 0.5% (v/v) Tween-20 (T-20). 
3.6 Comparison of melting temperatures of different samples – The melting 
temperatures of different samples can be compared by analysis of variance 
(ANOVA), as is described in Supplementary (User instruction). This will provide an 
appropriate statistical analysis (Fig. 5). The FGF7 example indicates that the addition 
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of 0.5% (v/v) Tween-20 did not change the melting temperature of FGF7 and 
heparin-stabilised FGF7, and the melting temperatures are the same as found 
previously (Xu et al., 2012). 
4 Discussion 
This program provides for analysis of large amounts of data, which can be easily 
transferred into analogous assays, such as spectral data acquired on 96-well plates. 
The program makes it more efficient to rapidly view and inspect the analysed data 
and produce a report graph. Further development can be introduced by the user or by 
contacting the authors.  
5 Supplementary (Program details) 
 
 
5.1 File Table: 
(1) Code files (Folder: SimpleDSFviewer MATLAB code): 
SimpleDSFviewer.m (SimpleDSFviewer.fig) is the main script, which displays the user 
interface and contains the buttons and parameter input. 
Normalisemc.m is connected to the user interface script to normalise the melting curves by 
using the parameters loaded into the user interface. 
Smomcurve.m is used to smooth the melting curves if it is required. 
Peaknumber.m is used to screen the melting curves, which automatically classifies the 
curves. The different curves shown in Fig. 4 A can be recognised automatically, and the 
parameters for classifying the curves can be changed manually. 
mapTm.m is to generate the preview map (Fig. 4 C) and 3 D bar plot graph (Fig. 4 D). 
(2) Runtime app files (Folders: SimpleDSFviewer Mac/Win32/Win64 runtime): 
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SimpleDSFviewer.exe is the software package for running the program. Choose the 
appropriate version, depending on the computer (Windows 32 or Windows 64 or Mac), and 
double click this file to run the program. 
readme.txt contains the details which introduce the requirement of installation of MATLAB 
runtime. 
Other files are icon pictures and supporting files. 
(3) Example data (‘example raw.xlsx’ and ‘example sorted.xlsx’). 
All the above files for the DSF data analysis program can be freely downloaded from 
GitHub: https://github.com/hscsun/SimpleDSFviewer.git. 
5.2 User instruction: 
5.2.1 Start the programme: Open SimpleDSFviewer.m in MATLAB R2015a 
(containing ‘Signal Processing Toolbox’, ‘Statistics and Machine Learning Toolbox’ 
and ‘Curve Fitting Toolbox’) and run the script. Alternatively, install the desired 
MATLAB Runtime 2015 (download from webpage: 
http://uk.mathworks.com/products/compiler/mcr/) and open the compiled app 
(SimpleDSFviewer), if MATLAB software is not installed. The interface (Fig. S1) 
will be loaded and ready to use. A Windows computer is preferred, since the 
analysed data cannot be written into an excel file for ‘Save Data’ function on a Mac 
computer. 
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Figure S1 User interface of SimpleDSFviewer. This figure shows the user interface 
of SimpleDSFviewer, in which the user can analyse and view the collected DSF data. 
The top-left three panels are used to load the parameters and collected DSF data. The 
96 well radio buttons and the data view buttons are distributed on the bottom left. 
The right side contains a graphical view box for displaying the selected data and the 
path of input data in a text box. 
5.2.2 Load parameters: The temperatures, including start temperature, temperature 
step and end temperature are required, if a raw data file (Fig. S2 A) is to be loaded.  
In the software, ‘1’ signifies Yes and 0 signifies No for ‘Smooth’, ‘Normalise’ and 
‘Legend’ parameters. The Smooth and Normalise parameters should be kept as ‘1’ as 
the data are loaded, but the range (Smooth Range) can be changed to be increased or 
decreased. The ‘Normalise’ and ‘Smooth’ functions can be turned off when the 
original melting curves are desired.   
The default values are loaded automatically and are generally ideal for analysis. 
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Figure S2 Templates of input data for SimpleDSFviewer. Two formats of input 
data can be loaded into the program. (A): Raw data contains all the fluorescence 
reading from wells 1 to 96 and from the lowest temperature to the highest 
temperature in one column. The number of desired column needs to be specified. 
(B): Sorted data contains the melting temperature in the first column and the 96 
wells’ fluorescence in 96 columns. 
5.2.3 Load experimental result: Two formats of data can be loaded, as shown in 
Fig. S2. The first format is the raw data, which contains all the data in a single 
column and the column that contains the desired data should be specified (Text box 
next to ‘Load RawData’ pushing button, Fig. S1). Column 3 was selected in the 
example (Figs. S1 and S2 A). The second format is sorted data (Fig. S2 B), which 
contains 96 columns corresponding to 96 wells and fluorescence intensities of each 
temperature in each row. The loading data should be stored in the first sheet of the 
Excel file. 
5.2.4 Functions: Multiple wells can be selected by clicking the corresponding radio 
buttons for data view. The melting curves and first derivative curves can be 
previewed in the graph box (Fig. S1) by pushing the buttons (containing MC or FD) 
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in the Select Wells panel or be viewed and saved by pushing the buttons in the Save 
Result panel. ‘+Tm’ means the melting temperature is marked on the melting curve. 
MC (Half-Value) shows the melting curves with half denaturation point (main paper 
3.3). The legend can be added by changing the legend parameter to ‘1’. 
Different samples can be compared by ANOVA: Repeating samples are selected by 
clicking the radio buttons and a name should be input the text box in the ‘Load 
Explanatory Values (X)’ panel. Then, the sample is added by pushing ‘Group 
(String)’ button. The selected wells should be deselected and more samples can be 
added in the same way. The ANOVA (string) button will give the statistical analysis 
and a box-plot graph for the samples under comparison. 
5.2.5 Save function: The sorted (Sheet1) and normalised melting curves (Sheet: 
nMC and nFD) and the first derivative curves and the melting temperatures (Sheet: 
Tm) calculated by the three different methods (Fig. 1) may be saved as an Excel file 
by pushing ‘Save Data’ button. 
5.2.6 Errors: When the data are input into the programme, a running status bar will 
be displayed on the screen and it will be turned off after the auto-analysis. However, 
if the running cannot be completed (bar status), the input data should be checked. For 
example, if the gradient numbers of temperature are longer than the fluorescence 
measuring numbers for each well, an error will be generated and running will not 
complete. Missing values in the loaded data also cause the same problem. 
5.2.7 Example data: Protein and the heparin (Hep) ligand concentrations are listed 
in the following table. Every three consecutive wells contain three same samples to 
ensure the experimental results.  
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FGF10 
PBS 
FGF10 
Hep 0.2 µM 
FGF10 
Hep 0.4 µM 
FGF10 
Hep 0.5 µM 
FGF10 
Hep 0.625 µM 
FGF10 
Hep 0.75 µM 
FGF10 
Hep 0.875 µM 
FGF10 
Hep 1 µM 
FGF10 
Hep 1.25 µM 
FGF10 
Hep 2.5 µM 
FGF10 
Hep 5 µM 
FGF10 
Hep 50 µM 
FGF10 
Hep 500 µM 
FGF10 
PBS 
FGF10 
Hep 0.2 µM 
FGF10 
Hep 0.4 µM 
FGF10 
Hep 0.5 µM 
FGF10 
Hep 0.625 µM 
FGF10 
Hep 0.75 µM 
FGF10 
Hep 0.875 µM 
FGF10 
Hep 1 µM 
FGF10 
Hep 1.25 µM 
FGF10 
Hep 2.5 µM 
FGF10 
Hep 5 µM 
FGF10 
Hep 50 µM 
FGF10 
Hep 500 µM 
FGF10 
6 M urea 
FGF10 
8 M urea 
FGF7  
PBS 
FGF7 
Hep 50 µM 
FGF7 
0.5% Tween-20 (v/v) 
PBS 
FGF7 
0.5% Tween-20 (v/v) 
Hep 50 µM 
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4.3 Binding selectivity of FGFs to heparin derivatives 
4.3.1 Proteins and ligands  
FGF10 and FGF20 (5 μM) were used to study their interactions with the following a 
library of chemically-modified heparins, oligosaccharides and GAGs. 
(a): Porcine intestinal mucosal heparin (Sigma-Aldrich, Dorset, UK, concentrations 
are listed in the figure legend of Fig. 4.1 A). As described in Section 1.4, heparin is a 
highly sulfated HS, which is nonetheless very polydisperse, both in terms of polymer 
length and sulfation. The average molecular weight of the heparin is 17.5 kDa, with a 
range that is generally between 5 kDa and 30 kDa, though some smaller and larger 
material is also present. 
(b): Heparin oligosaccharides: dp2, dp4, dp6, dp8, dp10 and dp12 (10 μM, Iduron, 
Manchester, UK).  
(c): Heparin derivatives shown in Table 4.2 (10 mΜ, gift from Dr. Ed Yates, 
University of Liverpool).  
(d): GAGs: HS (10 μM, Sigma-Aldrich), CS (10 μM, Iduron), DS (10 μM, Iduron) 
and HA (10 μM, Sigma-Aldrich). The structures of the constituent disaccharides of 
these GAG chains are described in Figure 4.1. 
4.3.2 Experimental setup and data analysis  
FGF10, FGF20 and the GAG ligands were mixed with SYPRO dye by following 
table 4.1. The measurement and data analysis were carried out by following Section 
4.2.  
Table 4.1 DSF reaction components for three wells: 
Components FGF GAG ligand 
(10X) 
SYPRO orange 
(100X) 
PBS Total 
volume 
Volume / µL a1  3.5  3.5  (28-a)  35  
a1: volume of the protein for specified concentration. 
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Figure 4.1 Structures of CS, DS, HA and HS (Goel and Gowda, 2011, Yung and 
Chan, 2007). Red saccharide: glucuronic acid; pink saccharide: iduronic acid; blue 
saccharide: N-acetyl-D-galactosamine (in CS and DS), N-acetyl-D-glucosamine (in 
HA and HS) or N-sulfated D-glucosamine (in HS). In CS and HA, a β(1–3) 
glycosidic bond links glucuronic acid to galactosamine or glucosamine, while in DS 
at least one glucuronic acid is epimerised to iduronic acid. In all these three GAGs, 
β(1–4) glycosidic bonds connect galactosamine (or glucosamine) to glucuronic acid 
(or iduronic acid). In contrast, the saccharide residues are linked by β(1–4) or α(1–4) 
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glycosidic bonds in HS. The possible sulfation positions are all labelled in the 
structures (green). 
Table 4.2 Chemically modified heparin structures (Xu et al., 2012): 
The letter I stands for iduronate (IdoA), and A stands for the amino sugar 
glucosamine (GlcN). Numbers refer to the carbon of the monosaccharide. 
Name 
 
Predominant 
repeat 
IdoA-2 GlcN-6 GlcN IdoA-3 GlcN-3 
Heparin I2SA6SNS -SO3
- -SO3
- -SO3
- -OH -OH 
D2 I2SA6SNAc -SO3
- -SO3
- -Ac -OH -OH 
D3 I2OHA6SNS -OH -SO3
- -SO3
- -OH -OH 
D4 I2SA6OHNS -SO3
- -OH -SO3
- -OH -OH 
D5 I2OHA6SNAc -OH -SO3
- -Ac -OH -OH 
D6 I2SA6OHNAc -SO3
- -OH -Ac -OH -OH 
D7 I2OHA6OHNS -OH -OH -SO3
- -OH -OH 
D8 I2OHA6OHNAc -OH -OH -Ac -OH -OH 
D9 I2S,3SA6S3S,NS -SO3
- -SO3
- -SO3
- -SO3
- -SO3
- 
 
The difference of melting temperatures of the FGF in PBS buffer and in the presence 
of ligand (heparin and heparin derivatives) was used to show the relative stabilising 
effect (Eq1) (Uniewicz et al., 2010). 
Eq1:⁡Relative⁡stabilising⁡effect =
Tm(FGF + ligand) − Tm(FGF + heparin)
Tm(FGF⁡in⁡PBS) − Tm(FGF + heparin)
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4.3.3 Results and discussion 
Thermal stability of FGF10 and FGF10-sugar complexes: The melting curve of 
FGF10 shows the fluorescence intensity was increased from ~40oC and reached a 
maximum at about 46oC (Fig. 4.2 A). As heparin was added, FGF10 was stabilised 
by binding to heparin, which shifted the melting curve of FGF10 to higher 
temperatures (Fig. 4.2 A). The first derivative curve reflects the melting temperature 
of each protein (Section 4.2). Interestingly, these first derivative curves show that 
only small amounts of FGF10 were stabilised (the second peak), when 0.4 and 0.5 
µM heparin was added. This suggests that FGF10 has a slow disassociation rate from 
heparin, so that there is no averaging of the bound and unbound FGF10 on the time 
scale (~5 min for the denaturation) of the measurement. Thus, at subsaturating 
concentrations of heparin, FGF10 is either bound or not bound to heparin, and the 
melting of both species is seen simultaneously. In contrast, in previous work with 
other FGFs (FGF1, FGF2, FGF7, FGF9 and FGF18), at these concentrations of 
heparin, just one intermediate melting temperature was observed (Uniewicz et al., 
2010, Xu et al., 2012), since the proteins would exchange on the polysaccharide over 
the time of the measurement.  
The melting temperature of FGF10 in PBS buffer is around 42°C, which is below 
that of many other reported FGFs (FGF1, FGF2, FGF7, FGF9 and FGF18) (Xu et al., 
2012, Uniewicz et al., 2010). The binding of FGF10 to heparin increases its thermal 
stability by ~15°C (Fig. 4.2: A-C), which is considerably more than seen with FGF7 
(~7°C), but less than the ≥20°C shift seen with FGF1 and FGF2 (Uniewicz et al., 
2010, Xu et al., 2012, Xu, 2012). Maximum stabilisation of FGF10 (~5 µM) was 
attained with 1 µM heparin, suggesting that more than one FGF10 could bind to a 
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single heparin chain. FGF10 did not interact with a dp2, with binding apparent from 
dp4 and a heparin-derived dp8 was as effective as full length heparin (Fig. 4.2 E). 
The melting curves of binding of FGF10 to heparin oligosaccharides show that 
FGF10 was more stabilised as increasing polymer length from dp4 to dp10 (Fig. 4.3). 
Since there was only one peak in each first derivative curve, all of the FGF10 in the 
reaction was stabilised by oligosaccharides (Fig. 4.3 B). Therefore, the gradual 
change of melting temperatures of FGF10-oligosaccharide was due to the partial 
stabilisation of FGF10 by short heparin and a dp8 or dp10 is preferred for binding.  
This is consistent with heparin having an average molecular weight of 17.5 kDa, 
which corresponds to around dp60 and the observed stoichiometry of five FGF10 per 
heparin (Fig.4.2C). 
The relative stabilising effect of FGF10 by heparin derivatives was measured to 
identify its preference for particular sulfation patterns. FGF10 did not discriminate 
between any of the doubly sulfated heparins (D2-D4) (Fig. 4.2 D). It bound less well 
to singly sulfated heparins and showed a modest preference for 6-O sulfated heparin 
over 2-O sulfated and perhaps N sulfated heparin, and failed to bind to completely 
desulfated heparin (Fig. 4.2 D). FGF10 bound persulfated heparin more strongly than 
heparin, and its interaction with HS was similar to that seen with singly 6-O sulfated 
heparin. Interestingly, FGF10 bound, though weakly, to CS and more strongly to DS, 
showing that there is a wider range of GAG species it can recognise (Fig. 4.2 D).  
In terms of cation coordinated heparins, FGF10 had a slight preference for divalent 
cation forms of the polysaccharide over the monovalent cation forms (Fig. 4.2 F). 
Compared to FGF7 (Table 4.3, Section 4.4), FGF10 is less sensitive to the position 
and number of sulfate groups in the polysaccharide, though it binds persulfated 
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heparin more strongly and exhibits a preference for divalent cation forms of heparin 
(Xu et al., 2012). The latter difference may be important for tuning responses in 
situations where both FGF7 and FGF10 are present, since previous studies have 
shown that cation coordination by heparin can alter FGF-heparin interactions and 
their biological activities (Rudd et al., 2007, Kan et al., 1996). Both FGF7 and 
FGF10 can bind to CS and DS, which makes them relatively unique amongst the 
FGFs. Taken together, the data indicate that FGF10 binds to sulfated structures in 
GAGs in a similar way to FGF7, but that FGF10 is more stabilised by heparin than 
FGF7.  
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Figure 4.2 Stabilisation of FGF10 (5 µM) by modified heparins and model 
GAGs. (A): Melting curves of FGF10 with different concentrations of heparin. (B): 
First derivative of the melting curves in (A). (C): Melting temperatures of FGF10 
with different concentrations of heparin. (D): Relative stabilising effect of FGF10 by 
different heparin derivatives, HS, HA, CS and DS (all 10 µM). (E): Relative 
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stabilising effect of FGF10 by heparin-derived oligosaccharides dp2 to dp12 (all 10 
µM). (F): Relative stabilising effect of FGF10 by heparin (10 µM)  coordinated by 
different cations (Na+, K+, Ca2+, Zn2+ and Cu2+). Relative stabilising effect was 
calculated by following Eq1 (Section 4.3.2). 
 
Figure 4.3 Binding of FGF10 (5 µM) to heparin oligosaccharides (10 µM). (A): 
Melting curve of FGF10 in PBS and in PBS containing 10 µM heparin and heparin-
derived oligosaccharides of different lengths (dp2-dp12 and full length heparin); (B): 
First derivative of the melting curves in (A). 
Thermal stability of FGF20 and FGF20-sugar complex: The melting curve of 
FGF20 was increased from about 45oC and the addition of heparin shifted the 
melting curve of FGF20 to higher temperatures (Fig 4.4 A). The first derivative 
curve indicates that the melting temperature of FGF20 in PBS buffer is about 52°C 
(Figs 4.4 B-C), which is consistent with previous studies (Fan et al., 2007, Maity et 
al., 2009). FGF20 was strongly stabilised by binding to heparin (Fig. 4.4: A-C), but 
in contrast to FGF10, FGF20 (~5 µM) did not appear to reach full stabilisation, and 
even at 10 µM heparin the stabilisation was not complete. The average length of a 
heparin chain (>25 nm for dp60) is much greater than that required for binding (two 
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aligned canonical HBSs in a FGF20 dimer would be around 7 nm). Because heparin 
is polydisperse, this suggests that the requirement for a high concentration of heparin 
may be due to FGF20 preferentially binding a rare structure in the polysaccharide; 
the effective concentration of heparin chains with such structures would then be 
lower than that of total heparin. Since FGF20 is a dimer, such structural requirements 
may reflect conformations available to the heparin chain, which are strongly affected 
by substitution by sulfate groups (Rudd et al., 2007). 
In terms of the length of heparin oligosaccharide that will bind to FGF20, the pattern 
is quite distinct. The melting curves of FGF20-oligosaccharide complexes indicate 
that the short modified heparin (dp2-dp8) did not stabilise FGF20 (Figs 4.4E and 
4.5). Only a small stabilisation was observed with heparin-derived dp10 and about 
40% of the relative stabilising effect of heparin was achieved by a dp12 
oligosaccharide (Fig. 4.4 E). These data indicate that FGF20 either requires longer 
structures to bind (around 7 nm to 8 nm, equivalent to dp16) or that the structures it 
binds are rare in heparin and/or tend to be destroyed when heparin is partially 
digested with heparinase I (cleaves at IdoA2S) to make the oligosaccharides. Since 
heparin itself, though sufficiently large, cannot fully stabilise FGF20, it is more 
likely that FGF20’s binding structures are rare in this polysaccharide.  
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Figure 4.4 Stabilisation of FGF20 (5 µM) by modified heparins and model 
GAGs. (A): Melting curves of FGF20 with different concentrations of heparin. (B): 
First derivative of the melting curves in (A). (C): Melting temperatures of FGF20 
with different concentrations of heparin. (D): Relative stabilising effect of FGF20 by 
different heparin derivatives, HS, HA, CS and DS (all 10 µM). (E): Relative 
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stabilising effect of FGF20 by heparin-derived oligosaccharides dp2 to dp12 (all 10 
µM). (F): Relative stabilising effect of FGF20 by heparin (10 µM) coordinated by 
different cations (Na+, K+, Ca2+, Zn2+ and Cu2+). Relative stabilising effect was 
calculated by following Eq1 (Section 4.3.2). 
FGF20 binding was reduced by around half when one sulfate was removed from 
heparin (D2-D4) and was marginal or undetectable with heparins possessing just one 
sulfate (D5-D7; Fig. 4.4 D). There was a slight preference of FGF20 for 2-O- and N-
sulfate groups over 6-O-sulfate group. Binding to HS was weak and similar to the 
interactions with the singly sulfated D5 and D6, and the two model GAGs, CS and 
DS (Fig. 4.4 D). FGF20 has a marked preference for divalent cation coordinated 
heparins, since these stabilised the protein more than twice as effectively as heparin 
(Fig. 4.4 F). Although the cation coordinated status of HS in vivo is unknown, it 
would seem that divalent cations might have some important roles in the regulation 
of the biological activities of FGF20.  
 
Figure 4.5 Binding of FGF20 (5 µM) to heparin oligosaccharides (10 µM). (A): 
Melting curve of FGF20 in PBS and in PBS containing 10 µM heparin and heparin-
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derived oligosaccharides of different lengths (dp2-dp12 and full length heparin); (B): 
First derivative of the melting curves in (A). 
4.4 Conclusion  
In this chapter, DSF was used to study protein stability and protein-ligand 
interactions, and a computer program ‘SimpleDSFviewer’ was developed to analyse 
DSF data. This provides far faster analysis than the conventional manual step-by-step 
analysis.  
FGF10 is a member of the FGF7 subfamily. The data on the interactions of FGF10 
with heparin and heparin derivatives indicate that it shares most of its preferences 
with FGF7, but, like FGF7, is distinct from FGFs in other subfamilies that have been 
analysed so far (Table 4.3) (Xu et al., 2012, Uniewicz et al., 2010). The main 
difference is heparin can better stabilise FGF10 (~15oC) than FGF7 (~7oC). FGF20 is 
in the FGF9 subfamily and there are strong similarities in its preferences for binding 
particular structures in the model GAGs used here (Table 4.3). The main differences 
between FGF9 and FGF20 are that FGF20 is more extreme in terms of its 
requirement for structures longer than dp10, the weakness (relative to heparin) of its 
interactions with singly sulfated heparins and its very strong preference for divalent 
cation coordinated polysaccharide. However, similarly, for FGF9 dp10 and dp12 can 
only stabilise the protein to 50% of the level observed with heparin and the 
stabilisation effect can be significantly decreased by removing any sulfation group in 
heparin (Xu et al., 2012). Therefore, FGF20 is more similar in its binding 
preferences to FGF9 than to FGFs in other subfamilies that have been characterised 
(Uniewicz et al., 2010, Xu et al., 2012). Previous work provides data on two 
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members of one other FGF subfamily, FGF2 and FGF1 (Table 4.3). While these 
FGFs have different sulfation preferences for binding, in that FGF1 is more 
promiscuous and binds to all singly desulfated heparins, whereas FGF2 requires N- 
and 2-O sulfate groups, they are both strongly stabilised by heparin and have similar 
relative stabilising effects by dp4-dp10. 
Table 4.3 Summary of binding preference of FGFs to heparin, heparin 
derivatives and heparin oligosaccharides (Uniewicz et al., 2010, Xu et al., 2012). 
Red coloured FGFs are from previous publications and green FGFs are from this 
PhD project. 
Subfamily  Name Heparin effect Sulfation preference dp length 
FGF1 FGF1 > 22oC NS ≈ 2S ≈ 6S dp2 ~ dp10 
 FGF2 > 22oC NS, 2S > 6S dp4 ~ dp10 
FGF7 FGF7 ~ 7oC NS ≈ 2S ≈ 6S dp4 ~ dp8 
 FGF10 ~ 15oC NS ≈ 2S ≈ 6S dp4 ~ dp8 
FGF8 FGF18 > 15oC NS ≈ 6S > 2S dp6 ~ dp10 
FGF9 FGF9 ~ 20oC NS ≈ 6S > 2S dp4 ~ dp10 
 FGF20 ~ 12oC 6S ≈ 2S > NS dp10 ~ dp12 
Taken together the present dataset on FGF10 and FGF20 and the previous findings 
supports the overall hypothesis that HS binding selectivity is more conserved in FGF 
subfamilies, and so is likely to have been subjected to the same natural selection 
pressures that led to the diversification of the FGF family and the more complex 
body plan of vertebrates.  
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Chapter 5 Binding and diffusion of Halo-FGFs in 
Rama 27 fibroblast pericellular matrix 
5.1 Introduction 
Gradients of signalling proteins are important in development, growth and 
homeostasis. For example, in embryonic development, morphogen gradients that 
form in the ECM are important to achieve functions, such as cell specification and 
differentiation. Morphogens are expressed and secreted into the ECM where many of 
them can bind to HS. Many other signalling proteins share this property and they are 
part of the heparin/HS-binding proteins, of which there are 883 have been identified 
in the human proteome (Ori et al., 2008, Ori et al., 2011, Nunes, 2015). HS chains 
anchored to the core proteins of the proteoglycans are proposed to be an important 
regulator of all HS-binding proteins and of the movement of morphogens and other 
signalling proteins (Sections 1.2 and 1.8).  
However, it is still unclear how and to what extent HS in the ECM can regulate the 
transport of these proteins. In particular, there is little evidence to indicate that HS 
has much specificity or selectivity in this function. The FGFs are a key model for 
addressing these questions, because they are the first recognised "heparin binding 
growth factors", so a considerable amount of work on the molecular specificity and 
the functional significance of their interactions with HS has been done. Together 
with the likelihood that the specificity of FGFs for binding structures in HS was 
subjected to the same natural selection pressures that led to the expansion of the FGF 
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family (Chapter 4), this means that FGFs are a powerful tool to determine the extent 
to which HS may be able to differently regulate FGF diffusion (Chapter 4). 
A limited number of studies have measured the movement of FGFs through ECM to 
shed light on the formation of gradients of FGFs (Section 1.9). A study with FGF7, 
FGF10 and FGF10 mutants (exchanging arginine (193) with lysine or arginine (187) 
with valine in the heparin binding site) suggests that FGF10 binds to heparin much 
more strongly than FGF7 and the FGF10 mutants, so that it does not diffuse far or 
fast from heparin beads (Makarenkova et al., 2009). This has been interpreted to 
explain why FGF10 causes elongation of lacrimal and salivary gland ductal 
epithelium, whereas the weak binding FGF7 gives rise to branching (Makarenkova et 
al., 2009), though other work also points out that heparanase, which will release S-
domains from HS, is critical to the ductal morphogenesis activity of FGF10 in 
salivary gland (Patel et al., 2007).  
Previous work in the pericellular matrix of Rama 27 fibroblasts had suggested that 
the distribution of FGF2 binding sites in HS was not homogenous, suggestive of a 
higher-order organisation of this matrix.  Moreover, measurement of the movement 
of the FGF2 in this pericellular matrix demonstrated that the FGF2 could undergo 
different types of movement, from confined motion to directed diffusion over many 
µm (Duchesne et al., 2012). What is not clear is whether these properties were 
specific to just one FGF (or indeed just one heparin/HS binding protein) or were 
more general. Thus, if ECM presented binding sites for different proteins on HS in a 
clustered and organised manner, this would allow the independent control of 
diffusion of different HS binding proteins. For this to occur, it is likely that the ECM 
would have to possess a supramolecular organisation. That is a structure due to 
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interactions of ECM components that extends beyond the length scale of its 
individual components.  
In this Chapter, two FGFs from one subfamily (FGF1 and FGF2, FGF1 subfamily) 
and three (FGF6, FGF10 and FGF20) from other subfamilies (FGF4, FGF7 and 
FGF9), all with well characterised polysaccharide binding properties, were used to 
determine how they bind to ECM and diffuse. To ensure that the data reflected 
properties of the ECM and were not confounded by cell biochemistry, fixed Rama 27 
fibroblasts were used. 
5.2 Binding and diffusion of FGFs in fibroblast pericellular 
matrix (Paper) 
Sun, C., Marcello, M., Li, Y., Mason, D., Lévy, R., Fernig, D. G. (2015). Selectivity 
in glycosaminoglycan-binding dictates the distribution and diffusion of fibroblast 
growth factors in the pericellular matrix. (Submitted to Open Biology on 23rd 
December 2015) 
Contributions of authors: 
Changye Sun: Produced Halo-FGFs and FGF1, prepared TMR labelled Halo-FGFs, 
acquired imaging data with confocal microscopy, analysed the imaging data, 
prepared figures and wrote the paper. Marco Marcello: Taught the confocal 
microscopy, supported ideas for imaging and edited the paper. Yong Li: Provided 
FGF2 and edited the paper. David Mason: Supported ideas for imaging data analysis 
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and edited the paper. Raphaël Lévy: Conceived study and edited the paper. David 
G. Fernig: Conceived study and edited the paper. 
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Selectivity in glycosaminoglycan-binding dictates the distribution 
and diffusion of fibroblast growth factors in the pericellular matrix 
Changye Sun1, Marco Marcello2, Yong Li1, David Mason2, Raphaël Lévy1 and 
David G. Fernig1 
Department of Biochemistry, Institute of Integrative Biology, University of 
Liverpool, Liverpool, UK L69 7ZB 
Centre for Cell Imaging, Institute of Integrative Biology, University of Liverpool, 
Liverpool, UK L69 7ZB 
 
Abstract:  
The range of biological outcomes generated by many signalling proteins in 
development and homeostasis is increased by their interactions with 
glycosaminoglycans, particularly heparan sulfate (HS). This interaction controls the 
localisation and movement of these signalling proteins, but whether such control 
depends on the specificity of the interactions is not known. We used five fibroblast 
growth factors with an N-terminal HaloTag for fluorescent labelling (Halo-FGFs), 
with well-characterised and distinct HS binding properties, and measured their 
binding and diffusion in pericellular matrix of fixed rat mammary 27 fibroblasts. 
Halo-FGF1, Halo-FGF2 and Halo-FGF6 bound to HS, whereas Halo-FGF10 also 
interacted with chondroitin sulfate/dermatan sulfate, and FGF20 did not bind 
detectably. The distribution of bound FGFs in pericellular matrix was not 
homogenous, and for FGF10 exhibited striking clusters. Fluorescence recovery after 
photobleaching showed that FGF2 and FGF6 diffused faster, whereas FGF1 diffused 
more slowly, and FGF10 was immobile. The results demonstrate that the specificity 
of the interactions of proteins with glycosaminoglycans controls their binding and 
diffusion. Moreover, extracellular matrix has long-range structures, since cells 
regulate independently the distribution of different protein sites in 
glycosaminoglycans. 
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Introduction: 
Extracellular matrix has a central role in mediating communication between animal 
cells through mechanisms mediated by mechanical forces and soluble effectors.  A 
large proportion of the soluble effectors, morphogens, growth factors, cytokines and 
chemokines that regulate animal development and homeostasis interact with 
glycosaminoglycans, particularly heparan sulfate, of the extracellular matrix (Ori et 
al., 2008, Xu and Esko, 2014). These interactions have been shown to exhibit 
varying degrees of specificity and selectivity at the tissue and at the molecular levels, 
and in a number of cases have been demonstrated to control the effectors’ transport 
and intracellular signalling. 
The glycosaminoglycans heparan sulfate, chondroitin sulfate and dermatan sulfate 
are linear, sulfated polysaccharides covalently attached to core proteins to form 
proteoglycans. These are either associated with the cell membrane and resident in 
pericellular matrix or secreted, so resident in extracellular matrix.  The long chains of 
heparan sulfate (~25 to 100 disaccharide units) consist of repeats of a disaccharide: 
D-glucosamine β 1-4 glucuronic acid or its epimer iduronic acid. The mature chains 
have a distinct domain structure of sequential blocks of unmodified disaccharides of 
N-acetyl glucosamine β 1-4 glucuronic acid, transition domains where N-acetyl 
glucosamine-containing disaccharides alternate with N-sulfated ones, and sulfated 
domains, where every glucosamine is N-sulfated and may also be O-sulfated on C3 
and C6, and the uronic acid is often epimerised to iduronate, which may be 2-O 
sulfated (Xu and Esko, 2014, Ori et al., 2008, Murphy et al., 2004).  
At least 883 extracellular regulatory proteins bind to transition and S-domains (Ori et 
al., 2008, Xu and Esko, 2014, Nunes, 2015). At the molecular level, analysis of the 
structural basis of the interaction of individual proteins with heparan sulfate and 
model polysaccharides (derivatives of the related heparin) show that there is a clear 
selectivity by proteins for particular patterns of sulfation (Maccarana et al., 1993, 
Faham et al., 1996, Jemth et al., 2002). At the tissue level, clear differences in the 
expression of sulfated sugar structures have been demonstrated, which impact on cell 
communication in development, homeostasis and disease (Theodoraki et al., 2015, 
Ford-Perriss et al., 2002, Thompson et al., 2011, Rudland et al., 1993, Chang et al., 
2000, Friedl et al., 1997).   
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One important functional consequence of proteins binding heparan sulfate is its 
potential to control the movement of effectors between cells.  Originally, endothelial 
cell extracellular matrix was demonstrated to be capable of storing fibroblast growth 
factor (FGF) 2, which could then transfer to its cellular receptors to stimulate the 
cells (Vlodavsky et al., 1987). Later, heparan sulfate in extracellular matrix was 
shown to control the diffusion of FGF2 (Dowd et al., 1999), which indicated that 
heparan sulfate had the potential to shape FGF2 gradients (FGF2 being both a 
growth factor and a morphogen (Serls et al., 2005)). Subsequently, the binding of a 
number of morphogens to heparan sulfate was shown to control their diffusion in 
contexts ranging from Drosophila to vertebrates (Makarenkova et al., 2009, Harada 
et al., 2009, Qu et al., 2012, Belenkaya et al., 2004, Izvolsky et al., 2003, 
Kleinschmit et al., 2010). However, this may not be universal (Zhou et al., 2012, 
Kicheva et al., 2007, Panakova et al., 2005).  Moreover, it is not clear whether it is 
the selectivity of an effector for particular structures in the polysaccharide or just 
non-selective ion-exchange protein-polysaccharide interactions (Kreuger et al., 2006) 
that are important in regulating the effector’s diffusion. A related issue is that 
heparan sulfate in extracellular matrix has been viewed as homogenous, that is there 
is no variation in the distribution of binding sites below the scale of tissue 
compartments. However, work with nanoparticle-labelled FGF2 demonstrated that 
the distribution of its binding sites in fibroblast pericellular matrix is heterogeneous 
and clustered from length scales of ~20 nm to 1 µm and above (Duchesne et al., 
2012). Recently, biophysical experiments have shown that some effectors that bind 
heparan sulfate can cross link the chains of heparan sulfate (Migliorini et al., 2015). 
This suggests that heparan sulfate chains in extracellular matrix may be organised 
into supramolecular structures, which could impose the selectivity on protein binding 
that is of higher spatial order than possible with individual chains. 
To test these ideas, we have used five FGFs, FGF1, 2, 6, 10 and 20, with well-
characterised heparan sulfate binding sites and binding selectivity for structures in 
the polysaccharide (Xu et al., 2012, Li et al., 2015).  These FGFs were expressed as 
N-terminal HaloTag fusions (Halo-FGFs) (Sun et al., 2015), which permitted 
specific fluorescent labelling. Measurement of the binding and diffusion of the Halo-
FGFs in the pericellular matrix of fibroblasts revealed that there were very 
substantial differences between these FGFs in their level of binding, their spatial 
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distribution, and their diffusion. These data indicate that heparan sulfate chains in 
pericellular matrix are organised over length scales far greater than that of a single 
chain and that this serves to present distinct numbers and spatial patterns of binding 
sites for effectors, which in turn modulates the diffusion of the proteins. 
Materials and methods: 
Protein production  
The FGFs and Halo-FGFs were produced exactly as described in detail previously 
(Xu et al., 2012, Sun et al., 2015). HaloTag protein was produced by digestion of 
Halo-FGF20 with TEV protease and purified by anion-exchange on DEAE 
Sepharose Fast Flow (GE Healthcare, Buckinghamshire, UK). Protein concentrations 
were determined by measuring their absorbance at 280 nm using a NanoDrop 1000 
spectrophotometer (Thermo Scientific, Leicestershire, UK). The biological activity 
of purified FGFs was detected by analysis of phosphorylation of p44/42MAPK, as 
described in Section 3.2. 
Protein labelling 
HaloTag and Halo-FGFs (0.5 µM) were incubated with 2.5 µM HaloTag TMR 
ligand (Promega UK Ltd, Hampshire, UK) in 100 µL phosphate-buffered saline 
(PBS: 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4 and 0.15 M NaCl, pH 7.4) 
at room temperature for 30 minutes, then kept on ice before use the same day. To 
determine the extent of labelling, TMR dye labelled Halo-FGFs were loaded onto a 
mini heparin agarose (BioRad, Hertfordshire, UK) column (20 µL) and washed with 
PBS containing 0.05% (v/v) Tween-20. The bound TMR labelled Halo-FGFs were 
eluted with 2 M NaCl buffered with phosphate (PB: 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4, pH 7.4). The quantum yields were measured in a fluorescence 
spectrophotometer (Varian, Walton-on-Thames, UK) by excitation at 561 nm and 
emission from 565 nm to 700 nm. 
Cell culture  
Rat mammary (Rama) 27 fibroblasts were cultured with Dulbecco’s modified 
Eagle’s medium (DMEM, Life Technologies, Paisley, UK) supplemented with 10% 
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(v/v) fetal calf serum (FCS, Labtech International Ltd, East Sussex, UK), 4 mM L-
glutamine (Life Technologies), 0.75 % sodium bicarbonate (Life Technologies), 50 
ng/mL insulin (Sigma-Aldrich, Dorset, UK) and 50 ng/mL hydrocortisone (Sigma-
Aldrich), as described (Rudland et al., 1984). 
Cell labelling  
Rama 27 cells were cultured on glass bottomed imaging dished (CELLview™ 
Culture dish: 35mm non-treated glass bottom, Greiner Bio-one, Stonehouse, UK) 
and fixed with 4% (w/v) paraformaldehyde (PFA) dissolved in PBS. The fixed cells 
were washed with PBS three times and then incubated with 2 mL PBS containing 10 
mg/ml BSA to block any remaining partially active fixative. The blocking medium 
was discarded after 15 minutes and the fixed cells were incubated with 1.5 mL 10 
nM TMR dye, 2 nM TMR labelled HaloTag or 2 nM TMR labelled Halo-FGFs for 
30 minutes at 37°C. The excess TMR dye and TMR dye labelled Halo-FGFs (TMR-
Halo-FGFs) were removed by three washes with PBS. In competition experiments, 
the competitor was added along with the labelled Halo-FGF at concentrations 
indicated in the figure legends. Degradation of heparan sulfate was achieved in fixed 
Rama 27 cells by incubation with 1 mL heparinase I, II and III (50 mU/mL each in 
100 mM sodium acetate and 0.1 mM calcium acetate, pH 7.0; gift from Prof. Jerry 
Turnbull, University of Liverpool). Chondroitin sulfate (including dermatan sulfate) 
was degraded by incubation with 1 mL chondroitinase ABC (Sigma-Aldrich; 400 
mU/mL in PBS). In both cases, cells were incubated with the enzymes overnight at 
37°C prior to incubation with Halo-FGFs.  
Microscopy and imaging  
A LSM780 confocal microscope with an environmental control chamber (Zeiss, 
Jena, Germany) was used to acquire cell imaging data with a 561 nm excitation filter 
and a 635 nm emission filter for detection. For all cell imaging, a 63X oil immersion 
lens (Plan-Apochromat 63x 1.4 oil DIC M27) was used. Cell images (67.3 µm x 67.3 
µm, 512 x 512 pixels, 16 bits) containing bright field and the red fluorescence 
channel were collected for the binding assays. The flat cells (not dividing cells) were 
selected for imaging. Images were collected using identical microscope settings. To 
test whether the Halo-FGFs in Rama 27 pericellular matrix might be released into the 
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bulk medium from pericellular matrix, 10 consecutive images at 30 s intervals were 
acquired for Halo-FGF1, Halo-FGF2 and Halo-FGF6. 
Fluorescence recovery after photobleaching (FRAP)  
The fixed cells labelled with TMR-Halo-FGF1 (2 nM and 1 nM), TMR-Halo-FGF2 
(2 nM), TMR-Halo-FGF6 (2 nM) and TMR-Halo-FGF10 (2 nM) were used for the 
FRAP experiments. The measurements were performed at 37oC. A square area 
(22.49 µm x 22.49 µm, 256 x 256 pixels, 8 bits) by the edge of the cell, very flat and 
no affect by the thick cell nucleus, was imaged 6 times with the 63X oil immersion 
lens and then the selected 2.5 µm (radius) disk area was bleached with the 561 nm 
laser at full power for 8 iterations (0.64 s in total). After that, another 195.6 s of 
images were acquired to measure the fluorescence recovery. An area free of cells and 
a non-bleached area on the same cell were selected to determine the background 
(subtracted in quantifications) and correct the photobleaching caused by the 
excitation laser during imaging, respectively. The fluorescence intensities of these 
three selected areas from 0 s to 197.2 s were extracted using ZEN 2012 software 
(Zeiss) for further analysis. 
Data analysis 
Fluorescence intensity of the labelled cells: the cell edges were automatically 
identified by using published Matlab codes (MathWorks, 2014) and the fluorescence 
intensities were averaged for each cell. The cell edges of low fluorescence labelled 
cells were detected in the bright field channel image (supplementary figures) and 
high fluorescence labelled cells were detected in the fluorescence channel image. 
The Matlab program for cell edge detection can be downloaded from GitHub 
(https://github.com/hscsun/DrawCellEdges.git) and the details of the program and 
instruction are included in Section 5.4. 
FRAP data analysis: The background fluorescence intensity (Ib) was subtracted from 
both the bleached area (I) and non-bleached reference area (Ir). The photobleaching 
was corrected by the reference area and Ic is the corrected fluorescence intensity of 
the bleaching area. The fluorescence curves were not analysed by fitting with the 
exponential models, because many curves did not fit to this simple model, which 
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may be related to the complicated diffusion (e.g., slow and fast) of FGFs in the fixed 
Rama 27 fibroblast pericellular matrix. A suitable model is being developed by 
colleagues from Mathematics department (University of Liverpool) to explain and 
understand the diffusion of FGFs in this matrix. Moreover, the fitting model is useful 
to extract the half recovery time and final recovery level of noisy fluorescence 
recovery curves, so it is not necessary for the collected smooth fluorescence recovery 
curves.  
Eq 1:  Ic = (I – Ib)*((Ir[1-6] – Ib) / (Ir – Ib)) 
Note: Ir[1-6] means the averaged fluorescence intensity of the reference area of the 
first six images, which are used to get a stable fluorescence intensity for before 
bleaching; the other fluorescence intensities (I, Ib, Ic, Icn and Idcn) are applied to any 
image in the frame, but they are corresponded to the same image number in both 
sides of the equation for each calculation (from frame 1 to 1000 in this FRAP 
experiment). 
The fluorescence intensity of bleaching area was normalised to the fluorescence 
intensity of the first image, where Icn is the corrected and normalised intensity of the 
image. 
Eq 2: Icn = Ic / Ic[1-6] 
Note: Ic[1-6] means the average of the first six corrected fluorescence intensities 
from Eq 1. 
To compare fluorescence recovery curves, the corrected and normalised fluorescence 
intensity of the first bleached image, Icn[7], was subtracted from the corrected 
fluorescence intensity of bleached area and the FRAP curve was normalised again, as 
in Eq 2.  
Eq 3: Idcn = (Icn – Icn[7]) / (1– Icn[7]) 
Note: [7] means the seventh image (or the first image after bleaching) for the 
normalised and corrected fluorescence intensity. 
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The final recovery level (If), the fluorescence intensity for the last measurement, and 
half recovery time (τ1/2) were extracted from the corrected and normalised curve 
acquired from Eq 3 by:  
Eq 4: If = Idcn (τ = ∞) 
Eq 5: τ1/2 = (τa + τb) / 2  
Note: ∞ means positive infinity and is equal to the time at which the last image was 
acquired in the actual experiments. τa is the time corresponding to the maximum 
value of the fluorescence intensities smaller than half of If; τb is the time 
corresponding to the minimum value of the fluorescence intensities larger than half 
of If. 
The radial profiles of the bleaching area were extracted using a published Matlab 
code (Chattrapiban, 2007) and the photobleaching was corrected for each analysed 
image as described in Eq 1. The Matlab program for FRAP data analysis can be 
downloaded from GitHub 
(https://github.com/hscsun/ImagingDataAnalyzerForFRAP.git) and the details of the 
program and instruction are included in Section 5.4. 
All calculations and image montages were done with Matlab R2014a. 
Boxplots of the half recovery time and final recovery level of different Halo-FGFs 
were prepared in OriginPro 9 and the statistical analysis was processed with Tukey 
test in OriginPro 9. The data plot with standard deviation area was prepared using a 
published Matlab code (Campbell, 2010). 
Results and Discussion: 
Labelling Halo-FGFs with TMR-Halo ligand dye 
The N-terminal HaloTag fusion does not affect the binding of FGFs to heparin or 
their biological activity and they are efficiently expressed (Chapter 3 and (Sun et al., 
2015)). Thus, they provide a convenient means to prepare genetically encoded 
fluorescently labelled FGFs, whose excitation and emission properties can be altered 
by changing the HaloTag ligand (Los et al., 2008). We first tested whether the 
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HaloTag TMR ligand dye interacted with heparin or grossly affected the interaction 
of the FGFs with heparin. A mixture of HaloTag and a 5-fold excess of Halo-TMR 
dye was incubated for 30 minutes and loaded onto a mini heparin column. After 
three 50 µl washes with PBS containing 0.05% (v/v) Tween-20 (PBST) to remove 
the unbound dye, there was no red fluorescence detectable on the heparin column 
(Fig. 1 A). This indicated that neither HaloTag nor the TMR-Halo ligand dye bound 
to heparin. In contrast, the heparin column loaded with TMR labelled Halo-FGF2 
gave strong red fluorescence (Fig. 1 A), which demonstrated that Halo-FGF2 was 
labelled with TMR-Halo ligand dye and retained its heparin-binding properties. 
Following purification of fluorescent dye labelled Halo-FGFs on mini heparin 
columns, the bound TMR-Halo-FGFs were eluted with 2 M NaCl. The fluorescence 
emission curves of the purified Halo-FGFs demonstrated that the emission peak of 
TMR dye remained at 580 nm and that the emission curves of these Halo-FGFs were 
quite similar (Fig. 1 B). Although there was a small difference of the fluorescence 
intensity for each TMR-Halo ligand labelled Halo-FGF, the results indicate that the 
labelling efficiency of the different Halo-FGFs was relatively consistent.  
 
Figure 1: Conjugation and quantification of TMR dye labelled Halo-FGFs. 
Halo-TMR dye was used to label HaloTag and Halo-FGFs at a ratio of 5:1 
(mole/mole). The labelled HaloTag and Halo-FGFs were loaded onto a mini heparin 
column, which was subsequently washed with PBST. (A): The HaloTag and Halo-
FGF2 loaded heparin columns were visualised under a red fluorescence filter 
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(ImageQuant LAS 4000 imager, GE Healthcare). (B): The five TMR-labelled Halo-
FGFs were loaded onto mini heparin-affinity chromatography columns, washed with 
PBS buffer and eluted with 2 M NaCl in the same buffer. The fluorescence 
intensities of the five purified Halo-FGFs were quantified in a fluorimeter by 
measuring the emission from 565 nm to 700 nm excited with 561 nm. 
Binding of different Halo-FGFs to Rama 27 fibroblast pericellular matrix heparan 
sulfate 
Rama 27 fibroblasts were fixed with paraformaldehyde prior to imaging, which 
stopped cellular biochemical processes. So, binding of FGFs to pericellular matrix 
will not be affected by internalisation. Since fixation is performed in an isosmotic 
buffer, such crosslinking will not alter the spatial relationship of the constituents, as 
might happen, for example, with a fixative that precipitates macromolecules, such as 
-20 oC methanol. 
Halo-FGF2 The fixed Rama 27 fibroblasts were incubated with 2 nM Halo-FGFs to 
determine if their binding capacities to heparan sulfate in the pericellular matrix of 
these cells differed. Halo-FGF2 strongly bound to Rama 27 fibroblasts (Fig. 2 A). 
There was evidence for the heterogeneities in the distribution of the Halo-FGF2, 
evidenced by bright spots (Fig. 2 A arrows).  
The BSA blocked cell dish was visualised by confocal microscopy. The cell edges 
were detected by the brightfield image (Fig. S1 B), and no autofluorescence from the 
cells was observed in the fluorescence channel image (Fig. 2 B). Using the same 
microscope settings, when TMR-Halo ligand alone and TMR-Halo ligand labelled 
HaloTag were incubated with the fixed Rama 27 cells, the fluorescence was the same 
as observed with a BSA blocked culture dish with cells; no red fluorescence was 
detectable (Figs 2 C-D). When the fixed cells were incubated with 2 nM TMR-
labelled Halo-FGF2 and with either of two unlabelled competitors, 8 µM unlabelled 
FGF2 or Halo-FGF2, the binding was reduced to undetectable levels (Figs 2 E-F). 
These data indicate that non-specific binding of TMR-Halo ligand and of TMR-Halo 
ligand labelled HaloTag protein was within the levels of background fluorescence 
and that the fluorescence observed with labelled Halo-FGF2 in Rama 27 pericellular 
matrix (Fig. 2 A) was entirely due to the FGF2 moiety of the Halo-FGF2. 
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Figure 2: Halo-FGF2 binding to Rama 27 fibroblasts. The binding specificity of 
Halo-FGF2 to Rama 27 cells was determined by competing with unlabelled FGFs 
and heparin, and by digestion with heparinases and chondroitinase ABC. TMR-Halo-
FGF2 (2 nM), Halo-TMR dye or TMR-HaloTag were used to label fixed Rama 27 
fibroblasts for 30 min. The excess Halo-FGF2, Halo-TMR dye or TMR-HaloTag 
was removed by washing with PBS three times. The cell edges are highlighted with 
white lines. (A): TMR-Halo-FGF2 (2 nM); (B): unlabelled cells imaged to show the 
auto-fluorescence; (C): Halo-TMR dyes (2 nM), to measure the non-specific binding 
of ligand dye to cells or glass dish; (D): TMR-HaloTag (2 nM) to determine the level 
of binding of HaloTag. (E and F): Cells incubated with 2 nM TMR-Halo-FGF2 and 
8 µM unlabelled Halo-FGF2 (E) or 8 µM FGF2 (F); (G): 2 nM TMR-Halo-FGF2 
and 4 µg/mL heparin; (H): Cells were incubated with heparinases I, II and III to 
remove heparan sulfate and then incubated with 2 nM TMR-Halo-FGF2; (I): Cells 
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were incubated with chondroitinase ABC to digest chondroitin sulfate and then 
incubated with 2 nM TMR-Halo-FGF2. The corresponding bright field images are 
presented in Fig. S1. Image size: 67.3 µm X 67.3 µm. 
To determine what Halo-FGF2 was binding to in the pericellular matrix of Rama 27 
fibroblasts, a series of competition and enzyme digestion experiments were 
performed, again using the same microscope settings. Competition with heparin (4 
µg/mL added with Halo-FGF2) abolished binding and fluorescence was reduced to 
background levels (Fig. 2 G).  This indicates that FGF2 is likely bound to 
glycosaminoglycans of the pericellular matrix. Moreover, while heparin will 
effectively compete for binding of FGF2 to glycosaminoglycans, it still enables 
FGF2 to bind to the FGFR on these cells (Rahmoune et al., 1998).  Therefore, Rama 
27 fibroblasts were subjected to heparinase and chondroitinase ABC digestion to 
ascertain its binding partner(s). Incubation of fixed Rama 27 fibroblasts with 
heparinases I, II and III prior to the addition of Halo-FGF2 reduced the level of 
fluorescence to background levels (Fig. 2 H).  In contrast, chondroitinase ABC 
digestion of the cells did not appreciably alter the binding of TMR-Halo-FGF2 to 
Rama 27 cell (Fig. 2 I). These data demonstrate that TMR-Halo-FGF2 is primarily 
bound to heparan sulfate in the pericellular matrix of Rama 27 fibroblasts. Moreover, 
these results are consistent with previous data, which indicate that more than 99% of 
binding sites for FGF2 on Rama 27 fibroblasts are heparan sulfate, and the FGFR 
less than 1% (Duchesne et al., 2012, Fernig et al., 1990). 
Halo-FGF1 The binding of TMR labelled Halo-FGF1 to Rama 27 cells was 
somewhat stronger than that observed for Halo-FGF2 (Figs 2 A and 3 A). Since the 
labelling efficiencies of the Halo-FGFs are similar, this indicates that FGF1 at this 
concentration possesses more binding sites on these cells than FGF2. As for Halo-
FGF2 the distribution of the fluorescence was not homogenous (Fig. 3 A). The lower 
fluorescence intensity in the centre of the cell was the result of the high focal plane 
of the plasma membrane in this region due to the underlying cell nucleus. The same 
competition and enzyme digestion experiments performed with Halo-FGF2 were 
done with Halo-FGF1, to identify its binding partner(s) in Rama 27 pericellular 
matrix. Both unlabelled 8 µM Halo-FGF1 and FGF1 effectively competed with 2 nM 
TMR-Halo-FGF1 (Figs 3 B and C).  Addition of 4 µg/mL heparin with TMR-Halo-
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FGF1 also abolished detectable binding of the latter to Rama 27 fibroblasts (Fig. 3 
D). Treatment of fixed Rama 27 cells with heparinases was similarly effective in 
reducing the binding of TMR-Halo-FGF1 below the limit of detection (Fig. 3 E). 
However, digestion with chondroitinase ABC increased the level of fluorescence 
(Fig. 3 F). The increase in binding of Halo-FGF1 observed after chondroitinase ABC 
treatment may indicate that removal of chondroitin sulfate changed the structure of 
ECM and somehow increased the number of available heparan sulfate binding sites 
for FGF1 (Fig. 3 F). Collectively, these data demonstrate that the detectable 
fluorescent Halo-FGF1, like the Halo-FGF2, is bound to the heparan sulfate of the 
pericellular matrix of Rama 27 fibroblasts.  Though FGF1 binds heparan sulfate 
preferentially, it also binds dermatan sulfate more weakly (Xu et al., 2012), but 
dermatan sulfate binding sites are either not available or too weak in Rama 27 
pericellular matrix, since chondroitinase ABC treatment increased, rather than 
decreased binding.  Interactions with the FGFR are below the level of detection, 
which is consistent with the relative numbers of binding sites corresponding to 
heparan sulfate and the FGFR established previously for FGF2 in these cells (Fernig 
et al., 1990, Duchesne et al., 2012).  
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Figure 3: Halo-FGF1 binding to Rama 27 fibroblasts. The binding specificity of 
Halo-FGF1 to fixed Rama 27 fibroblasts was tested by competing with unlabelled 
FGF1 and heparin and by digestion with heparinase and chondroitinase ABC. (A): 
Cells were incubated with 2 nM TMR-Halo-FGF1 at 37oC for 30 min; (B and C): 2 
nM TMR-Halo-FGF1 was added with 8 µM unlabelled Halo-FGF1 (B) or 8 µM 
unlabelled FGF1 (C); (D): TMR-Halo-FGF1 (2 nM) in the presence of 4 µg/mL 
heparin; (E and F): TMR-Halo-FGF1 binding to Rama 27 fibroblasts previously 
subjected to digestion with heparinase I, II and III, and chondroitinase ABC, 
respectively. The corresponding bright field images are presented in Fig. S2. Image 
size: 67.3 µm X 67.3 µm. 
Halo-FGF6 Halo-FGF6 bound only slightly less than FGF2 to fixed Rama 27 
fibroblasts and again the fluorescence was not homogenous (Fig. 4 A). No binding of 
Halo-FGF6 was observed on the fixed Rama 27 fibroblasts when TMR-Halo-FGF6 
was added with 4 µg/mL heparin (Fig. 4 B). Similar to FGF1 and FGF2, digestion of 
heparan sulfate by heparinase decreased the binding of TMR-Halo-FGF6 to 
undetectable levels (Fig. 4 C), whereas digestion of chondroitin sulfate and dermatan 
sulfate led to an increase in Halo-FGF6 binding to the cells, as seen with FGF1 (Fig. 
4 D). These results indicated that the detectable Halo-FGF6 was bound to heparan 
sulfate in the pericellular matrix of Rama 27 fibroblasts. The number of these sites is 
similar to those recognised by FGF2, but chondroitin sulfate (or dermatan sulfate) 
would appear to prevent directly or indirectly some Halo-FGF6 binding to the 
heparan sulfate in the pericellular matrix.  
Halo-FGF10 Halo-FGF10 clearly only bound to some areas of the pericellular 
matrix, whereas in other areas, virtually no binding was detected (Fig. 4 E).  Thus, 
the binding of Halo-FGF10 to Rama 27 fibroblasts was characterised by very 
substantial heterogeneities. The binding sites on Rama 27 fibroblasts for FGF10 were 
also blocked by addition of 4 µg/mL heparin, which effectively prevented FGF10 
binding to fixed Rama 27 fibroblasts (Fig. 4 F). Digestion of heparan sulfate with 
heparinase I, II and III reduced the level of binding of Halo-FGF10 (Fig. 4 G), but 
unlike Halo-FGF1, Halo-FGF2 and Halo-FGF6, did not abolish it (Figs 2 H, 3 E and 
4 C). Moreover, digestion of chondroitin sulfate / dermatan sulfate with 
chondroitinase ABC also reduced the amount of bound Halo-FGF10 (Fig. 4 H). 
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These results indicated that Halo-FGF10 may bind to both heparan sulfate and 
chondroitin sulfate in Rama 27 fibroblasts pericellular matrix. Therefore, a double 
digestion (heparinase and chondroitinase) was performed. When both sets of 
glycosaminoglycans were digested, the level of bound Halo-FGF10 was nearly 
undetectable (Fig. 4 I), demonstrating that FGF10 does indeed bind to both 
chondroitin (dermatan) and heparan sulfate. 
 
Figure 4: Binding specificity of Halo-FGF6 and Halo-FGF10 to Rama 27 
fibroblasts. Halo-FGF6 and Halo-FGF10 were used to label fixed Rama 27 
fibroblasts and heparin and the enzyme digested fibroblast pericellular matrix was 
used to determine their binding specificity. (A): Rama 27 fibroblasts were incubated 
with 2 nM TMR-Halo-FGF6; (B): 2 nM TMR-Halo-FGF6 in the presence of 4 
µg/mL heparin; (C and D): 2 nM TMR-Halo-FGF6 binding to Rama 27 fibroblast 
B i n d i n g  a n d  d i f f u s i o n  o f  H a l o - F G F s  i n  R a m a  2 7  
f i b r o b l a s t  p e r i c e l l u l a r  m a t r i x  ( p a p e r )  
 
 129 
pericellular matrix digested with heparinase I, II and III, and chondroitinase ABC, 
respectively; (E): Rama 27 fibroblasts were incubated with 2 nM TMR-Halo-FGF10; 
(F): TMR-Halo-FGF10 (2 nM) in the presence of 4 µg/mL heparin; (G and H): 
TMR-Halo-FGF10 (2 nM) binding to Rama 27 fibroblasts pericellular matrix 
digested with heparinase I, II and III, and chondroitinase ABC, respectively; (I): 2 
nM Halo-FGF10 binding to the pericellular matrix digested by both heparinase I, II 
and III, and chondroitinase ABC. The corresponding bright field images are 
presented in Fig. S3. Image size: 67.3 µm X 67.3 µm. 
Comparison of binding of Halo-FGFs to Rama 27 cell pericellular matrix heparan 
sulfate 
Quantification of the level of binding of the Halo-FGFs to Rama 27 cell pericellular 
matrix revealed some marked differences. The fluorescence intensity of the Halo-
FGFs was determined by calculating the averaged fluorescence intensity of the 
highlighted cell area to compare their binding capacities to the pericellular matrix. 
There were more binding sites for Halo-FGF1 than the other Halo-FGFs (Fig. 5 A). 
Based on Tukey t-test, the binding capacities of Rama 27 pericellular matrix for 
Halo-FGF2 and for Halo-FGF6 were also significantly different (p=0.005, Tukey 
test) with Halo-FGF2 possessing more binding sites. In terms of binding intensity, 
Halo-FGF6 and Halo-FGF10 did not have significant difference (p=0.08), but the 
distributions of Halo-FGF10 and the other three Halo-FGFs were clearly not the 
same (Fig. 5 A). For example, Halo-FGF6 was more evenly distributed in 
pericellular matrix, with a level of inhomogeneity similar to that seen with Halo-
FGF2, whereas Halo-FGF10 only bound to specific areas of the pericellular matrix. 
In contrast, Halo-FGF20 bound extremely weakly, if at all, which was not detectable 
(Figs S4 A and B).  
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Figure 5: Quantification of binding of different Halo-FGFs to Rama 27 
fibroblast pericellular matrix. (A): TMR labelled Halo-FGF1, Halo-FGF2, Halo-
FGF6, Halo-FGF10, Halo-FGF20 and HaloTag (all 2 nM) were incubated with fixed 
Rama 27 fibroblasts, as described in Figs 2 A, 3 A, 4 A, 4 E, S4 A and S4 B. The 
fluorescence in the highlighted cell area was averaged to quantify the level of 
binding of the FGF to Rama 27 pericellular matrix. Fluorescence intensities on 
different cells in the same set of dish and different sets of dishes were acquired and 
are shown as a box plot. Each symbol corresponds to independent dishes of cells 
measured on different days; (B): The binding intensities of Halo-FGF1, Halo-FGF2, 
Halo-FGF6 and Halo-FGF10 to Rama 27 fibroblasts pericellular matrix digested 
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with heparinase I, II and III, and with chondroitinase ABC were quantified and 
normalised to the values obtained with untreated matrix. 
These results differ from those obtained upon affinity chromatography of these FGFs 
to heparin (Sun et al., 2015). The previous work indicated that Halo-FGF2, Halo-
FGF1 and Halo-FGF10 could bind to heparin in 0.6 M NaCl, and 1 M or higher 
NaCl was required to efficiently elute them from heparin-affinity chromatography 
matrices. Both Halo-FGF6 and Halo-FGF20 could stably bind to heparin in 0.4 M 
NaCl, though less Halo-FGF20 was bound than Halo-FGF6. These data highlight 
that binding to heparin, which is far more sulfated than heparan sulfate, does not 
reflect the binding capacity of heparan sulfate, which is both less sulfated and more 
structurally diverse (Ori et al., 2008, Xu and Esko, 2014), which allows a far more 
selective interaction with individual proteins (Jemth et al., 2002, Xu, 2012).  
The binding and competition data demonstrate that the detectable binding of the four 
Halo-FGFs is to glycosaminoglycans in the pericellular matrix.  In the presence of 
heparin these FGFs will interact with their receptor tyrosine kinase (Zhang et al., 
2006b). Thus, the absence of binding of Halo-FGF2 detected with heparin is in 
agreement with previous work, which showed that the number of heparan sulfate 
binding sites for FGF2 is several orders of magnitude greater than the number of 
receptors (Duchesne et al., 2012). A similar difference is, therefore, likely to exist for 
FGF1, FGF6 and FGF10, since binding was not detected in the presence of heparin 
(Figs 2 H, 3 E, 4 C and 4 I). Whereas Halo-FGF1, Halo-FGF2 and Halo-FGF6 
interacted only with heparan sulfate, Halo-FGF10 had a significant interaction with 
chondroitin sulfate (and/or dermatan sulfate) species on Rama 27 fibroblasts (Fig. 5 
B). FGF1 has previously been shown to interact with dermatan sulfate, but not 
chondroitin sulfate, whereas FGF7, which is in the same subfamily as FGF10, 
interacts weakly with both chondroitin sulfate and dermatan sulfate (Xu et al., 2012). 
Consistent with the latter result, FGF10 has been shown to bind to chondroitin 
sulfate and dermatan sulfate (Li et al., 2015). In the case of Halo-FGF1, either the 
interaction with dermatan sulfate is too weak to be detectable or there is little 
dermatan sulfate with appropriate binding structures in Rama 27 cell pericellular 
matrix. In contrast, the interaction of Halo-FGF10 with chondroitin sulfate and/or 
dermatan sulfate on these cells is sufficiently strong to be detected (Fig. 5 B). 
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The increase in binding observed with Halo-FGF1 and Halo-FGF6 upon 
chondroitinase ABC treatment of cells suggests that chondroitin sulfate may 
somehow mask heparan sulfate binding sites for these Halo-FGFs. Whether such 
masking occurs directly or due to bridging by endogenous proteins that bind both 
chondroitin sulfate and heparan sulfate is not known. It is intriguing that the effect is 
not seen with Halo-FGF2, since this is in the same subfamily as FGF1 and the major 
difference in binding selectivity between these FGFs is that FGF1 readily binds tracts 
of sulfated saccharides containing 6-O sulfated glucosamine with one of N-sulfated 
glucosamine or 2-O sulfated iduronic acid, whereas FGF2 binds these very poorly 
(Uniewicz et al., 2010, Jemth et al., 2002, Maccarana et al., 1993). Thus, the masking 
effect of chondroitin sulfate on Halo-FGF1 binding to heparan sulfate may be related 
to its interactions with such structures in heparan sulfate. 
The binding of all the Halo-FGFs was observed to be heterogeneous. The differences 
in binding between FGF10 and FGF1, FGF2 and FGF6 together with the complete 
absence of binding of FGF20 demonstrate that the observed heterogeneity of binding 
is not simply due to differences in the distribution of HS. Instead, these data indicate 
that it is the distribution of binding sites of polysaccharide chains for Halo-FGF1, 
Halo-FGF2 and Halo-FGF6 in heparan sulfate and for Halo-FGF10 in heparan 
sulfate and chondroitin sulfate that are not evenly distributed across the pericellular 
matrix. This is consistent with similar observation made with gold nanoparticle 
labelled FGF2 by photothermal microscopy (optical resolution) and by transmission 
electron microscopy (molecular resolution) (Duchesne et al., 2012, Nieves et al., 
2015). Taken together, these data suggest that the previously observed clustering of 
FGF2 binding sites in heparan sulfate of Rama 27 cell pericellular matrix may be a 
more general phenomenon, since it is seen here with four FGFs from three different 
subfamilies that possess different binding selectivity for heparan sulfate (Li et al., 
2015, Xu et al., 2012). This suggests that the binding sites for these FGFs are 
spatially organised in Rama 27 pericellular matrix and this is likely to extend to 
supramolecular length scales (distance equivalent to several/many heparan sulfate 
chains). Such organisation would arise from the interaction of heparan sulfate and 
(for FGF10) chondroitin sulfate / dermatan sulfate chains with their endogenous 
binding proteins, which for heparan sulfate have been catalogued to at least 883 (Ori 
et al., 2011, Nunes, 2015). 
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Detection of FGF diffusion by FRAP 
The differences in the binding of Halo-FGF1, 2, 6, 10 and 20 to Rama 27 pericellular 
matrix, relate, at least in part, to differences in the structures these FGFs bind in 
heparan sulfate (and chondroitin sulfate/dermatan sulfate for FGF10). It is 
established in some cases that the interaction of proteins with heparan sulfate can 
control their movement in the extracellular space (Duchesne et al., 2012, Akiyama 
and Gibson, 2015, Muller et al., 2013, Dowd et al., 1999, Yan and Lin, 2009). 
Therefore, to determine if the differences in heparan sulfate binding may result in 
differences in movement in extracellular matrix, we measured the diffusion of Halo-
FGF1, 2, 6 and 10 in Rama 27 pericellular matrix by FRAP. 
 
Figure 6: FRAP of Halo-FGF1, Halo-FGF2 and Halo-FGF6 in Rama 27 
fibroblast pericellular matrix. Fixed Rama 27 fibroblasts were used to provide a 
pericellular matrix that could be probed with Halo-FGF1, Halo-FGF2 and Halo-
FGF6. A 5 µm radius disk area on the cell was bleached by full power laser to 
measure the recovery of the fluorescence in the bleached area. (A, E and I): TMR-
Halo-FGF1, -FGF2 and -FGF6 labelled cells before bleaching; (B, F and I): Same 
areas as (A, E and I), but following the bleaching of a 5 µm radius disk; (C, G and 
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K): The partial recovery of fluorescence in the bleached area 64 s after bleaching; 
(D, H and L): Images acquired when the bleached area had recovered to a stable 
level (196 s). Size of the scale bar: 5 µm. 
 
Figure 7: Fluorescence recovery curves and recovery radial profiles of Halo-
FGF1, Halo-FGF2 and Halo-FGF6 in Rama 27 fibroblast pericellular matrix. 
The fluorescence intensity of the bleaching area was analysed, as described in 
materials and methods, to identify the different recovery patterns. The radial profile 
of the bleached area was extracted from the imaging data to reflect how the FGFs 
exchanged between the bleached area and the surrounding non-bleached pericellular 
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matrix. (A, B and C): The normalised fluorescence intensities of Halo-FGF1 (A), 
Halo-FGF2 (B) and Halo-FGF6 (C) in the bleached area were plotted against time 
(Average of 10 measurements for Halo-FGF1, 17 measurements for Halo-FGF2 and 
28 measurements for Halo-FGF6); (D, E and F): The radial profiles of the bleached 
area before bleaching, immediately after bleaching, when fluorescence had reached 
half the final recovery value and at final recovery were extracted from the imaging 
data. Multiple repeats were applied to acquire the standard deviation. The mean of 
radial profiles for each FGF was plotted with standard deviation area against the 
distance to the centre of the bleached disk area (18 measurements for Halo-FGF1, 23 
for Halo-FGF2 and 17 for Halo-FGF6). µ is the mean value of multiple fluorescence 
intensity curves for each FGF; ơ is the standard difference; ‘Before’ is before 
bleaching; ‘After’ is the image immediately after bleaching; ‘Half’ is the time when 
the fluorescence was recovered to half of the final recovery level; ‘Final’ is the time 
for the last measurement. 
The FRAP experiments employed the same labelling protocol as the imaging ones.  
Fixed cells were again used, because this allowed the measurement of the diffusion 
of each Halo-FGF in pericellular matrix to be made without any confounding effects 
that might have arisen due to the movement of cells or of membrane. The amine 
reactive fixative  (paraformaldehyde) will not affect the binding of the Halo-FGFs in 
heparan sulfate, since these proteins recognise oligosaccharide structures where the 
amino group of the glucosamine residues is sulfated (Ori et al., 2008, Xu and Esko, 
2014). However, the fixative may cross link endogenous multivalent heparan sulfate 
binding proteins and the core proteins of heparan sulfate proteoglycans. This may 
then restrict movement of heparan sulfate chains and diffusion in the membrane of 
the heparan sulfate proteoglycan core proteins both of which will restrict the freedom 
of the heparan sulfate chains (Duchesne et al., 2012), though this effect may be less 
pronounced on glycosyl-phosphatidylinositol anchored glypicans than 
transmembrane core proteins such as syndecans (Tanaka et al., 2010).  
Another important feature of these experiments is that following the binding of Halo-
FGFs to heparan sulfate in the pericellular matrix, the cells were washed to remove 
unbound Halo-FGF. Trapping of FGF2 on heparan sulfate in the extracellular matrix 
has been well documented (Duchesne et al., 2012, Zehe et al., 2006, Dowd et al., 
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1999, Mundhenke et al., 2002, Taverna et al., 2003, Shute et al., 2004, Vlodavsky et 
al., 1987) and, given a suitable density of heparan sulfate binding sites, is a general 
property of extracellular matrix (Dowd et al., 1999, Lin, 2004, Yan and Lin, 2009, 
Belenkaya et al., 2004). As for FGF2 (Duchesne et al., 2012), Halo-FGF1, Halo-
FGF2 and Halo-FGF6 bound to the pericellular matrix did not dissociate appreciably 
into the bulk culture medium over 270 s (Fig. S5). Thus, since FRAP measurement 
were made in 197 s, dissociation into the bulk culture medium followed by re-
association with heparan sulfate in the pericellular matrix cannot contribute to the 
recovery of fluorescence. Instead, the recovery of fluorescence will be due to 
diffusion of these Halo-FGFs within the pericellular matrix. 
After the bleaching iterations, the selected area became dark (Figs 6 A, B, E, F, I and 
J). Recovery of fluorescence then occurred (Figs 6 C, D, G, H, K and L). These data 
demonstrate that the Halo-FGFs were able to diffuse between the bleached and 
surrounding areas of pericellular matrix in fixed Rama 27 cells. Thus, while these 
Halo-FGFs were clearly trapped within the pericellular matrix (Fig. S5), they were 
able to diffuse within it.  Movement of nanoparticle labelled FGF2 has similarly been 
evidenced before by photothermal imaging, tracking and raster image correlation 
spectroscopy (Nieves et al., 2015, Duchesne et al., 2012). Earlier work using 
diffusion chamber also demonstrated that FGF2 trapped on heparan sulfate in 
extracellular matrix was mobile (Dowd et al., 1999).  Thus, the present data 
demonstrate that the movement of proteins bound to heparan sulfate and trapped in 
extracellular matrix is likely to be a more general phenomenon.  
Quantification of diffusion of Halo-FGF1, Halo-FGF2, Halo-FGF6 and Halo-
FGF10 
The fluorescence intensity of the bleached area during recovery was quantified as the 
normalised fluorescence (Materials and Methods). In the case of Halo-FGF1, 
recovery was partial after 64 s and still not complete by 196 s (Figs 6 C-D and videos 
S7 and S8). The fluorescence recovery curve shows that Halo-FGF1 fluorescence in 
the bleached area recovered relatively slowly and by 196 s only half the fluorescence 
was recovered (Fig. 7 A). The decrease of fluorescence intensity of the reference 
area was due to the photobleaching by the imaging laser (Figs S6 A-B), since Halo-
FGF1, Halo-FGF2 and Halo-FGF6 could be trapped in the pericellular matrix for 
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more than 4.5 min (Fig. S5), as discussed above. The recovery of fluorescence was 
greater for Halo-FGF2, although the bleached area is still perceptible after 196 s 
(Figs 6 G- H and video S9). Quantification of the recovery of Halo-FGF2 
fluorescence demonstrates that this is substantially faster than that of Halo-FGF1 and 
the final level of fluorescence, 80%, was higher (Fig. 7 B). The fluorescence of Halo-
FGF6 recovered similar to that of Halo-FGF2 (Figs 6 K-L and video S10). The rate 
of fluorescence recovery of Halo-FGF6 was somewhat faster than Halo-FGF2, 
though the level of recovery attained after 196 s was similar (Figs 7 B-C). The weak 
photobleaching for Halo-FGF2 might suggest that the bleached Halo-FGF2 and 
Halo-FGF6 during imaging could be quickly exchanged into the surrounding areas 
(Figs S6 C-D). 
The fluorescence recovery curves (Figs 7 A-C) allowed the calculation of the half 
recovery time, which is directly related to the movement of molecules in the FRAP 
experiments and the relative proportions of mobile and immobile Halo-FGF. The 
half recovery times demonstrated that Halo-FGF1 diffused more slowly in the 
pericellular matrix of Rama 27 fibroblasts than Halo-FGF2 or Halo-FGF6 (Fig. 8 A). 
Moreover, Halo-FGF6 had the shortest half recovery time (16 s), which was 
significantly (p=0.0008, Tukey test) faster than that of Halo-FGF2 (22 s) and clearly 
of Halo-FGF1 (49 s). Fluorescence recovery is due to the diffusion of the Halo-
FGFs.  Thus, the difference of final level of recovered fluorescence and the initial 
fluorescence is indicative of the fraction of immobile Halo-FGFs. Only 52% of Halo-
FGF1 was mobile, whereas 81% of Halo-FGF2 and 82% of Halo-FGF6 were mobile 
(Fig. 8 B). Previous work demonstrates that FGF2 that appears immobile at the 
resolution of a confocal microscope will in fact be undergoing confined motion, 
diameter ~100 nm (Duchesne et al., 2012). Like Halo-FGF2, Halo-FGF1 and Halo-
FGF6 are also bound to heparan sulfate in the pericellular matrix. Though there are 
clear differences in the distribution and number of their available binding sites on 
heparan sulfate chains, it seems reasonable to suggest that the immobile fraction of 
Halo-FGF1 and Halo-FGF-6 are also undergoing similar confined motion.   
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Figure 8: Quantification of moving speed and mobile/immobile fractions of 
Halo-FGF1, Halo-FGF2 and Halo-FGF6 on Rama 27 fibroblasts. The half 
recovery time and final recovery level were extracted from each fluorescence 
recovery curve, as described in materials and methods. (A): The half recovery times 
for Halo-FGF1, Halo-FGF2 and Halo-FGF6 were plotted to compare their diffusion 
speeds in the pericellular matrix. Each half recovery was extracted from one FRAP 
experiment, which shows the time it took to recover to half of the final fluorescence 
intensity in each fluorescence recovery curve; (B): Normalised final recovery levels 
of the three FGFs were used to determine the ratio of mobile and immobile FGF in 
the pericellular matrix. The final recovery level shows the mobile fraction and the 
immobile fraction is its difference from 100%. 
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Analysis of the movement of FGF2 at the single molecule level revealed that it 
undergoes different types of diffusive motion over different length scales. To see if 
some insight could be gained from the present average measurements of Halo-FGF 
diffusion into the types of movements the FGFs underwent, the fluorescence of the 
bleached area and surrounding unbleached area were determined as a series of radial 
profiles, diameter 14 µm.  These analyses are presented as the radial profile at 
selected times:  before bleaching, after bleaching, at the time corresponding to half 
recovery of the final fluorescence, and at final recovery. The results show that the 
radial profile after bleaching (Figs 7 D-F, blue lines) is “U” shaped, but, as the 
bleached area recovered, the profile (Figs 7 D-F, pink lines) it became more “V” 
shaped.  Moreover, for Halo-FGF1, as the recovery profile of the bleached area (2.5 
µm radius) increased, there was a small decrease in fluorescence in the surrounding 
unbleached area (Fig. 7 D, pink line and green line). Together, this suggests that the 
majority of the movement of the Halo-FGFs at these time scales is over 1 µm or less, 
corresponding to the confined and simple diffusive motion observed previously with 
FGF2 and that FGF1 may undergo comparatively little fast and directed diffusion 
(Duchesne et al., 2012). In contrast, the half recovery profiles of Halo-FGF2 and 
Halo-FGF6 (Figs 7 E-F, pink lines) were more “U” shaped and the fluorescence of 
the surrounding unbleached areas was not much affected during recovery (Fig. 7 D, 
pink line). Moreover, the final recovery profiles of Halo-FGF2 and Halo-FGF6 were 
close to that seen before bleaching (Figs 7 E-F, green lines). These data are 
consistent with the previous demonstration that FGF2 can undergo fast and directed 
diffusion in addition to confined and simple diffusive motion and it would appear 
that Halo-FGF6 may undergo similar types of movement.  
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Figure 9: Diffusion of Halo-FGF10 in Rama 27 fibroblast pericellular matrix. 
Fixed Rama 27 fibroblasts were used to provide a pericellular matrix for Halo-
FGF10 binding. A 5 µm radius disk area on the cell was bleached by full power laser 
to measure the recovery of the fluorescence in the bleached area. The fluorescence 
intensity of the bleached area was extracted to detect the diffusion of TMR-Halo-
FGF10 in the pericellular matrix. (A and D): TMR-Halo-FGF10 labelled cells (two 
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areas with different binding intensities) before bleaching; (B and E): Same areas as 
(A and D), but following the bleaching of a 5 µm radius disk; (C and F): The partial 
recovery of fluorescence in the bleached area 196 s after bleaching; (G): The 
normalised fluorescence intensities of Halo-FGF10 in the bleached area were plotted 
against time (average of 10 measurements). Size of the scale bar: 5 µm. 
Since the distribution of Halo-FGF10 in Rama 27 fibroblast pericellular matrix was 
very heterogeneous, FRAP experiments were conducted to determine the diffusion of 
Halo-FGF10 in both areas of high (Figs 9 A-C) and lower binding (Figs 9 D-F). As 
for Halo-FGF1, Halo-FGF2 and Halo-FGF6, a small area of the cells was bleached 
and the fluorescence recovery was measured over the following 196 s (Figs 9 A-C 
and D-F). Compared to the image acquired immediately after bleaching, there was no 
obvious recovery of fluorescence after 196s (Figs 9 B-C and E-F). The averaged 
fluorescence recovery curve demonstrates that the TMR-Halo-FGF10 in the 
bleaching area did not exchange appreciably with the TMR-Halo-FGF10 outside the 
bleached area (Fig. 9 G). These data suggest that FGF10 does not dissociate readily 
from the heparan sulfate, chondroitin sulfate and dermatan sulfate chains it is bound 
to. Interestingly, the thermal shift assay used to identify its selectivity for sulfation 
patterns with a library of chemically modified heparins shows that rather than 
equilibrating between bound and unbound forms, FGF10 appears to partition into 
two populations (FGF10 and FGF10 bound to heparin) (Li et al., 2015). This is 
consistent with a very slow dissociation of FGF10 from heparin, since faster 
dissociation would enable exchange of FGF10 molecules on the heparin and so an 
averaging of the measured thermal stability of bound and unbound species. Work in 
two development models where FGF10 has a role in epithelial morphogenesis, in 
lung and salivary gland morphogenesis, also indicates that FGF10 bound to 
glycosaminoglycans does not readily dissociate and that FGF10 diffusion requires 
either suboptimal binding structures or the action of heparanase (Izvolsky et al., 
2003, Patel et al., 2007). 
The substantial differences in diffusion observed between Halo-FGF1, Halo-FGF2 
and Halo-FGF6 may be a consequence of differences in the number and spatial 
organisation of their respective binding sites on heparan sulfate chains. Alternatively, 
the much greater level of binding of Halo-FGF1 may reduce its mobility, due to a 
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lower availability of free binding sites for Halo-FGF1 to move to in the pericellular 
matrix.  To distinguish between these possibilities a lower concentration of Halo-
FGF1 was used to measure its diffusion. 
Effect of changing the concentration of Halo-FGF1 
The level of bound TMR-Halo-FGF1 was changed by halving the concentration of 
Halo-FGF1 added to fixed Rama 27, which reduced the fluorescence intensity to 
levels similar to that observed with 2 nM TMR-Halo-FGF2 (Fig 10 A). However, at 
the lower level of binding of Halo-FGF1, the recovery of fluorescence following 
bleaching was similar to that observed with 2 nM Halo-FGF1. Thus, the half 
recovery time for 1 nM Halo-FGF1 was 45 s and only 50% of the fluorescence was 
recovered. Consequently, reducing the amount of Halo-FGF1 bound to the heparan 
sulfate in pericellular matrix by a factor of 2 had no strong effect on the diffusion 
speed of the Halo-FGF1 or on the relative proportions that were mobile and 
immobile (Figs 10 B and C). These results indicate that the slower diffusion 
observed with 2 nM Halo-FGF1 is unlikely to be due to the larger amount Halo-
FGF1 bound to heparan sulfate in the pericellular matrix. Instead the slower 
diffusion of Halo-FGF1 is more likely to be due to differences in the number and 
spatial organisation of these binding sites, and the rate of association and 
disassociation of the FGF1 from them.  
Thus, the diffusion measurements suggest Halo-FGF1 is less mobile in pericellular 
matrix than FGF2 or FGF6, but still moves though only smaller steps are accessible 
to it. If there was a focal source of FGFs, then FGF1 would form shorter and steeper 
gradients than FGF2 and FGF6 in Rama 27 fibroblast pericellular matrix.  
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Figure 10: Effect of concentration of Halo-FGF1 and of Halo-FGF2 on their 
binding and diffusion in Rama 27 fibroblast pericellular matrix. TMR-Halo-
FGF1 (1 nM) was used to label fixed Rama 27 fibroblasts to identify any dependence 
of their level of binding and their diffusion on concentration. The FRAP experiments 
with TMR-Halo-FGF1 (2 nM) and TMR-Halo-FGF2 (2 nM) were carried out at the 
same time and are those shown in Figs 7 and 8. Six FRAP experiments are included 
for each sample. (A): Binding intensities of Halo-FGF1 (1 nM and 2 nM) and Halo-
FGF2 (2 nM) at the areas for FRAP measurements; (B): the moving speed (half 
recovery time) of different concentration of Halo-FGF1 and Halo-FGF2 in the 
matrix; (C): the mobile/immobile fraction (Final recovery level) of different 
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concentration of Halo-FGF1 and Halo-FGF2 in fixed Rama 27 fibroblasts 
pericellular matrix. 
Binding and Movement of FGFs in extracellular matrix 
The expansion of the FGF family is associated with an increase in the complexity of 
multicellular organisms, highlighting its importance in mediating cell 
communication in development and homeostasis (Itoh and Ornitz, 2004, Itoh, 2007, 
Itoh and Ornitz, 2011).  FGFs in a subfamily are more closely related in amino acid 
sequence and in function than FGFs in different subfamilies. The functional relations 
are evidenced, for example, by the selectivity of FGFs in different subfamilies for 
isoforms of the FGFR (Zhang et al., 2006b, Ornitz et al., 1996), for the patterns of 
sulfated sugars they bind in heparan sulfate and for the number and location of 
heparan sulfate binding sites on the FGF (Xu et al., 2012, Li et al., 2015, Ori et al., 
2009).  Previous work with FGF2 demonstrated that its diffusion in pericellular 
matrix of Rama 27 fibroblasts was controlled by the spatial organisation of its 
heparan sulfate binding sites (Duchesne et al., 2012). This raises an important 
question, whether the diffusion of other heparan sulfate-binding effectors, with 
different selectivity for patterns of sulfated sugars, also possess heterogeneous 
networks of binding sites that control their diffusion. To tackle this question, we 
have used five FGFs from four different subfamilies, with well-characterised heparan 
sulfate binding properties (Section 4.3 and (Xu et al., 2012, Uniewicz et al., 2010)). 
This allows the effects of subtle differences between members of the same subfamily 
(FGF1 subfamily: FGF1 and FGF2) and more substantial differences between 
members of different subfamilies (FGF6 is in the FGF4 subfamily, FGF10 in the 
FGF7 subfamily and FGF20 in the FGF9 subfamily) to be measured.  
There are differences between the diffusion of FGFs occurring in the experiments 
described here and in vivo. First, the Halo-FGF is bound to pericellular matrix and 
any unbound ligand is removed by washing.  Thus, unlike in vivo, there is no source 
of diffusing ligand.  Second, since the cells are fixed, receptor-mediated endocytosis 
cannot occur, so there is no sink to remove ligand. Therefore, the binding 
experiments (Figs 2-4) provide a snapshot of the distribution of binding sites on 
glycosaminoglycans in pericellular matrix. The FRAP experiments measure the 
movement of the FGF due to its dissociation and reassociation to sites on 
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glycosaminoglycans, without any effects of concentration gradients or cell 
biochemistry (membrane protein movement, membrane flow and cell movement).  
There are a large number of binding sites for FGFs and other heparan sulfate binding 
proteins on the polysaccharide in pericellular matrix; for FGF2 in Rama 27 
fibroblasts these amount to 3x106 sites per cell (Duchesne et al., 2012).  The five 
FGFs used here preferentially bind different structures in heparan sulfate (Chapter 6, 
Table 6.1) and, perhaps unsurprisingly, their level of binding differed considerably; 
FGF1 bound to the greatest extent, whereas the binding of FGF20 was undetectable, 
since it was within the threshold of background fluorescence (Figs 2-4 and Fig. S4). 
In all cases the distribution of the FGFs was heterogeneous (Figs 2-4), indicating that 
their binding sites are not evenly distributed in pericellular matrix. This has been 
shown previously for FGF2 over length scales ranging from 10 nm to several µm in 
the same cells (Duchesne et al., 2012, Nieves et al., 2015).  The clustering of heparan 
sulfate proteoglycans in lipid rafts would be one mechanism that could contribute to 
the heterogeneous distribution of heparan sulfate binding sites (Pike, 2004, 
Lingwood and Simons, 2010). Other mechanisms may operate in parallel. For 
example, interactions of transmembrane proteoglycans, e.g., syndecans (Couchman, 
2003), with the cytoskeleton through their cytoplasmic domains may lead to their 
localisation to particular membrane microdomains.   
The present data demonstrate that the heterogeneous distribution of binding sites 
observed previously with nanoparticle labelled FGF2 (Duchesne et al., 2012, Nieves 
et al., 2015) and in experiments with radiolabelled FGF2 (Chu et al., 2004) is likely 
to be a more general phenomenon, since it was observed here also with FGF1, FGF6 
and FGF10. One interpretation is that the heparan sulfate chains possessing binding 
sites for a particular protein (FGFs in the present case) are at least in part differently 
localised in pericellular matrix, through, for example, the various clustering 
mechanisms discussed above. However, this interpretation is likely to be too 
simplistic. For heparan sulfate there are 883 extracellular proteins that bind it in the 
human proteome (Ori et al., 2011, Nunes, 2015).  Thus, the subset of the heparan 
sulfate-binding proteins expressed by Rama 27 fibroblasts will have a substantial 
portion of their binding sites engaged with heparan sulfate. Consequently, the 
heparan sulfate binding sites available to a particular FGF (3x106 for FGF2 in Rama 
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27 cells) are likely to be less than the total possible binding sites (Duchesne et al., 
2012). Moreover, these heparan sulfate-binding proteins also have very extensive 
networks of protein-protein interactions (Ori et al., 2011), which will influence their 
protein-polysaccharide interactions. One consequence of this multiplicity of 
interactions is that there are many free binding sites for exogenously-added proteins 
on heparan sulfate (e.g., Figs 2-4) and there are many free binding sites on 
endogenous heparan sulfate-binding proteins for exogenously added polysaccharide 
(Castellot et al., 1985). Thus, pericellular matrix is not at equilibrium and the ingress 
of a heparan sulfate binding protein may perturb a wide range of interactions. Such 
perturbations may involve substantial changes in the 3-dimensional structure of 
heparan sulfate chains. For example, a number of heparan sulfate binding proteins 
are multivalent, that is they have more than one binding site for the polysaccharide 
(Haas and Culp, 1984, Battaglia et al., 1992, Sweeney et al., 1998, Migliorini et al., 
2015, Xu et al., 2012, Lortat-Jacob et al., 2002, Li et al., 2015, Ori et al., 2009). A 
recent biophysical analysis of brushes of heparan sulfate chains demonstrated that 
some heparan sulfate binding cytokines and growth factors with multiple binding 
sites are able to cross link the chains (Migliorini et al., 2015). Since heparan sulfate -
binding matrix proteins such as collagens and fibronectin have multiple binding sites 
for the polysaccharide, it seems reasonable that they too will in some instances cross-
link heparan sulfate chains. Thus, the heparan sulfate chains in pericellular matrix are 
likely to be engaged in large-scale supramolecular networks, which would ultimately 
be responsible for the heterogeneous distribution of binding sites and through which 
the Halo-FGFs diffuse. 
The FRAP data for the four FGFs with detectable binding show that they move 
differently in Rama 27 fibroblast pericellular matrix (Figs 7-10). In the case of FGF1 
and FGF2, the slower movement of the former may be explained by its larger 
number of binding sites. Within the FGF1 subfamily, FGF1 binds to any desulfated 
saccharide structure of degree of polymerisation (dp) 4 or longer, whereas FGF2 
requires N-sulfate and 2-O sulfate groups (Turnbull et al., 1992, Maccarana et al., 
1993, Jemth et al., 2002, Uniewicz et al., 2010). Thus, even taking into account 
occupation of some sites by endogenous proteins, the greater promiscuity of FGF1 is 
likely to explain why Halo-FGF1 binds Rama 27 pericellular matrix to a greater 
extent than Halo-FGF2.  The larger number of sites in heparan sulfate that FGF1 can 
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bind may also underlie its more restricted mobility; a greater density of binding sites 
would reduce the distance the protein can travel in a given time, since the likelihood 
of rebinding will be greater. Indeed, binding site density and clustering have been 
shown to prevent effective dissociation of heparan sulfate binding proteins such as 
FGF2 from pericellular matrix and is likely to alter the distance a protein can travel 
within pericellular matrix before re-binding (Dowd et al., 1999). The differences in 
movement of the other FGFs would then similarly reflect their selectivity for binding 
structures in heparan sulfate and how the available binding structures are presented. 
In the extreme, as seen with FGF10, the FGF does not diffuse appreciably over the 
time of the FRAP measurement. In such instances, the movement of the heparan 
sulfate-binding protein would require additional mechanisms. This could be provided 
by heparanase, an extracellular  glucuronidase, which cleaves heparan sulfate 
chains in their unmodified and transition domains. This would release cargoes of S-
domains and bound protein, as shown for FGF2 in a skin wound healing model (Kato 
et al., 1998). Indeed heparanase has been shown to be important for the stimulation 
of ductal morphogenesis by FGF10 in salivary gland (Patel et al., 2007). 
Conclusion: 
The selectivity of FGFs for different binding structures in glycosaminoglycans 
provides a means to probe the distribution of these binding sites in Rama 27 cell 
pericellular matrix and to determine the effect this has on the diffusion of the FGFs. 
The results show that protein binding sites in heparan sulfate (and chondroitin 
sulfate/dermatan sulfate for FGF10) of pericellular matrix are not randomly 
distributed. A number of different mechanisms are likely to regulate the distribution 
of these binding sites, including the biosynthesis of the heparan sulfate chains, the 
localisation of core proteins in membrane microdomains and the interactions of the 
polysaccharide chains with endogenous heparan sulfate binding proteins. The high 
multiplicity of interactions, between both proteins and polysaccharide and between 
the polysaccharide-binding proteins themselves (Ori et al., 2008, Ori et al., 2011, Xu 
and Esko, 2014) are likely to produce a dynamic network of interlinked molecules. 
This would then be responsible for the long-range (supramolecular) structure of the 
pericellular matrix, which determines its spatial binding capabilities for individual 
proteins. Such a structure would be sensitive to perturbations, such as the ingress of a 
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heparan sulfate binding protein from a neighbouring cell (in the same or different 
tissue compartment) and clearly can control the diffusion of such effector proteins. 
Supramolecular structure in extracellular matrix has been clearly shown in cartilage 
(Heinegard and Saxne, 2011), where there are also definitive structural and 
functional differences between the pericellular matrix of chondrocytes, and the 
territorial and inter-territorial matrices that are more distant from the cells. Thus, 
although extracellular matrix in cartilage is specialised, in other tissues an analogous 
situation may exist, where pericellular, extracellular and basement membrane 
matrices may exhibit different types of supramolecular structure and consequently 
has different functions.  
5.3 Supplementary results 
5.3.1 Supplementary results for the manuscript in Section 5.2 
The bright channel images in Figs S1, S2, S3 and S4 were acquired to show the 
locations and profiles of the cell. The edges of the cells with low fluorescence 
intensity were highlighted as described in the methods. Fluorescence and brightfield 
channels of Halo-FGF20 (Figs. S4 A and C) and HaloTag (Figs. S4 B and D) show 
the binding of Halo-FGF20 to the Rama 27 fibroblast pericellular matrix. Since 
Halo-FGF20 exhibited weak non-specific binding to the culture dish (Fig. S4 A), any 
binding of Halo-FGF20 was within this background signal. 
The fluorescence intensities in a same area were quantified for Halo-FGF1, Halo-
FGF2 and Halo-FGF6 over 4.5 min (Fig. S5). No change of the fluorescence 
intensities for these three Halo-FGFs was detected, indicating that the FGFs are 
effectively trapped in pericellular matrix over this time and do not dissociated 
appreciably into the bulk culture medium. The fluorescence intensities of reference 
areas during the FRAP experiments were also quantified. The FGF trapping results 
(Fig. S5) indicate that the changes of fluorescence intensities of reference areas 
during FRAP experiments (Fig. S6) were caused by photobleaching and exchange of 
the bleached TMR-Halo-FGFs from the bleaching area, rather than dissociation of 
B i n d i n g  a n d  d i f f u s i o n  o f  H a l o - F G F s  i n  R a m a  2 7  
f i b r o b l a s t  p e r i c e l l u l a r  m a t r i x  ( p a p e r )  
 
 149 
Halo-FGF into the bulk culture medium. The imaging videos are examples of FRAP 
experiments for Halo-FGF1, Halo-FGF2 and Halo-FGF6. 
 
Figure S1: The brightfield images corresponding to the images in Fig 2. The 
images A, B, C, D, E, F, G, H and I are corresponding to images A, B, C, D, E, F, G, 
H and I in figure 2. 
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Figure S2: The brightfield images corresponding to the images in Fig 3. The 
images A, B, C, D, E and F are corresponding to images A, B, C, D, E and F in 
figure 3. 
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Figure S3: The brightfield images corresponding to the images in Fig 4. The 
images A, B, C, D, E, F, G, H and I are corresponding to images A, B, C, D, E, F, G, 
H and I in figure 4. 
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Figure S4: Binding of Halo-FGF20 and HaloTag to Rama 27 fibroblasts: (A): 
Rama 27 fibroblasts were incubated with 2 nM TMR-Halo-FGF20; (B): Rama 27 
fibroblasts were incubated with 2 nM TMR-HaloTag; (C-D): The brightfield images 
channel for (A) and (B). Image size: 67.3 µm X 67.3 µm. 
 
 
 
 
 
(A) (B)
(C) (D)
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Figure S5: Dissociation of Halo-FGF1, Halo-FGF2 and Halo-FGF6 from Rama 
27 pericellular matrix into the bulk culture medium. Rama 27 fibroblasts were 
incubated with 2 nM TMR-Halo-FGF1, TMR-Halo-FGF2 and TMR-Halo-FGF6. 
Ten images at 30 s interval were acquired for each area (six different areas for each 
Halo-FGF) to measure the dissociation of Halo-FGFs from the pericellular matrix 
into the bulk culture medium. The averaged fluorescence intensity was quantified as 
described in materials and methods. The fluorescence intensity lines above the dash 
line are the fluorescence intensities of Halo-FGF1. Halo-FGF2 is between the dash 
line and dotted line and Halo-FGF6 is below the dotted line. 
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Figure S6: Photobleaching of TMR-Halo-FGFs during FRAP experiments. The 
fluorescence intensity of the reference area was extracted to determine the 
photobleaching of TMR-Halo-FGFs during the FRAP experiments. (A): Averaged 
fluorescence intensity of the reference area labelled with 2 nM Halo-FGF1; (B): 
Averaged fluorescence intensity of the reference area labelled with 1 nM Halo-
FGF1; (C): Averaged fluorescence intensity of the reference area labelled with 2 nM 
Halo-FGF2; (D): Averaged fluorescence intensity of the reference area labelled with 
2 nM Halo-FGF6. 
 
 
 
Video S7-S10: FRAP movies for 2 nM Halo-FGF1 (S7), 1 nM Halo-FGF1 (S8), 2 
nM Halo-FGF2 (S9) and 2 nM Halo-FGF6 (S10). Each video consists of 1000 
images acquired over 197 s. 
(A) (B)
(C) (D)
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5.3.2 Nonspecific binding of Halo-FGFs to the glass dish 
A confounding issue in imaging is the non-specific binding of proteins and probes to 
the glass dish or cells. This is often blocked by incubating with BSA. However, some 
FGFs were found to bind to the glass or BSA blocked dish, even when BSA in the 
binding buffer was used to compete for the nonspecific binding. When Halo-FGF7 
was used to label Rama 27 cells, as described for Halo-FGF2, more fluorescence was 
found on the cell free area than on the cell membrane. This indicates that the non-
specific binding signal was stronger than the potential specific one.  
 
Figure 5.1 Using TMR-Halo-FGF7 to label fixed Rama 27 fibroblasts. (A): 
Rama 27 fibroblasts were incubated with 2 nM TMR-Halo-FGF7; (B): The bright 
field channel for (A). Image size: 67.3 µm X 67.3 µm. 
5.3.3 Cross-binding competition of FGFs to Rama 27 fibroblast pericellular matrix 
TMR-Halo-FGF1 and TMR-Halo-FGF2 (both 2 nM) were competed with seven 
different concentrations of FGF1 and FGF2. Thus, TMR-Halo-FGF1 (2 nM) was 
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used to label fixed Rama 27 fibroblasts in the presence of competing FGF1 (8 M, 2 
M and 0.4 M) or of FGF2 (8 M, 2 M, 0.4 M and 0.1 M) in a 37oC incubator 
for 30 min.  A similar experiment was conducted with TMR-FGF2. The excess FGF 
was removed by three washes with PBS. The images were collected as before 
(Section 5.2), to determine the changes of binding intensities of TMR-Halo-FGF1 
and TMR-Halo-FGF2. 
 
Figure 5.2 Competition of Halo-FGF1 and Halo-FGF2 binding to Rama 27 
fibroblasts by FGF1 and by FGF2. The labelling of 2 nM Halo-FGF1 and 2 nM 
Halo-FGF1 was competed with different concentrations of FGF1 and FGF2, as 
indicated in the figure. (A): Binding intensity of 2 nM Halo-FGF1 in the presence of 
competing unlabelled FGF1 and FGF2. (B): Binding intensity of 2 nM Halo-FGF2 in 
the presence of competing unlabelled FGF1 and FGF2. 
When 0.4 M FGF1 was used to compete for the binding of Halo-FGF1, the binding 
of TMR-Halo-FGF1 decreased to half that of the control sample (no competitor) and 
it required 8 µM FGF1 to reduce binding by over 90% (Fig. 5.2). In contrast, 0.1 M 
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FGF2 could prevent most of the binding of TMR-Halo-FGF1. At first sight this is 
somewhat puzzling. FGF1 has more binding sites in Rama 27 pericellular matrix 
(Figs 2 A and 3 A, Section 5.2), which is consistent with FGF1 possessing binding 
structures in HS than FGF2, since it binds heparin structures containing two of N-
sulfate, 6-O-sulfate or 2-O-sulfate, whereas FGF2 only binds desulfated structures 
containing both N-sulfate and 2-O-sulfate (Turnbull et al., 1992, Maccarana et al., 
1993, Jemth et al., 2002, Uniewicz et al., 2010). Therefore, it is expected that there 
are binding sites occupied by FGF1, which FGF2 cannot compete for. When the 
experiment was reversed, so the FGF2 was labelled, the inclusion of unlabelled 
FGF1 could be interpreted as a simple competitor. With 0.4 µM unlabelled FGF1, 
the fluorescence of Halo-FGF2 was decreased by around half and with 8 µM FGF1, 
it was decreased by about 90%. In contrast, 0.1 M FGF2 could reduce the binding 
of Halo-FGF2 by 80% and 2 M FGF2 reduced the binding by about 90%. These 
competition results indicated that FGF2 is a better competitor than FGF1 for FGF1 
and FGF2 binding sites. 
These data show that competition by FGF1 for FGF2 binding sites (and vice-versa) 
in Rama 27 pericellular HS does occur. The stronger competition by FGF2 for FGF1 
and FGF2 binding sites could be explained by the absence of FGF1 binding sites 
containing desulfated saccharide sequences with 6-O sulfate. However, this would 
contradict the much higher level of binding of FGF1 than of FGF2 to this pericellular 
matrix. An alternative explanation is that the experiment is probing mechanisms 
rather than simple mass action-driven displacement. It is established that FGF2 is 
able to crosslink HS chains, at least in vitro (Migliorini et al., 2015), though whether 
FGF1 can do this is not known. In any event, if FGF2 were crosslinking HS chains, 
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this would cause substantial conformational change in the polysaccharide and may as 
a consequence reduce the affinity of FGF1 for binding sites unoccupied by the 
competing FGF2.  In this scenario, FGF2 exerts a competitive effect directly by 
displacement of bound FGF1 and indirectly, by changing the conformation of HS 
chains. 
5.4 Matlab programs for imaging data analysis 
Using DrawCellEdges (a Matlab user interface) to highlight the cell edges and to 
quantify fluorescence intensity of individual cells  
 
Program introduction 
The DrawCellEdges program (Fig. 5.3) was developed to draw the cell edges using 
either the fluorescence channel or the bright field channel. The cell edges are also 
drawn on another channel to highlight the cell areas. The average fluorescence 
intensity of the cell areas is automatically quantified and saved to an excel file for 
further analysis.  
The program was developed by following a published Matlab code (MathWorks, 
2014), and some important parameters in the ‘Draw Cell Edges’ panel can be 
modified to adapt to the user’s input image. Multiple separate images (single or 
multiple channels for each image) or an image stack containing many images can be 
analysed by running the program once. The details for using the program are 
introduced below. 
 
File table: 
DrawCellEdges.m contains the main code for analysing the imaging data.  
DrawCellEdges.fig is a figure window, which contains the user interface, and all the 
functions in the interface are connected to the main code to do the mathematical 
analysis. 
User instruction: 
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1. Run the program. Open DrawCellEdges.m in MATLAB R2014a installed on a 
windows computer and run this program. The user interface (Fig. 1) will be 
displayed on the screen.  
2. Load the first image (Fig. 5.3 ‘Load First Image’ panel). If multiple separate 
images are to be analysed, the image files should be named as filename0n.lsm (n 
is a number from 1 (the first image) to n (number of the last image)). There is no 
special name requirement for an image stack. The fluorescence channel, bright 
field channel and the image bit-depth should be specified in the text box. Then, 
the first image or the image stack can be loaded by pushing ‘Load’ button and 
selecting the image file in the desired directory. 
 
 
 
Figure 5.3 User interface of DrawCellEdges program. The user interface 
contains the parameters panels on the left side and image display box on the right 
side. The save functions are under the image display box. 
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3. Select the image stack or multiple images (Fig. 5.3 ‘Stacks || Images’ panel). 
If multiple images are to be analysed, the text box for ‘Is stack’ should be 0, 
which means no. The total number of images with same filename (‘Image 
Numbers’ text box) should be specified to analyse multiple images in a single 
run. If an image stack is to be analysed, the text box should be 1, which means 
yes. The total number of images in the stack (‘Image Numbers’ text box) should 
also be specified if the images in the stack are to be run once as a single batch. 
The number of total channels is required as well to logically analyse the desired 
image. 
4. Load parameters and analyse the cell edge (Fig. 5.3 ‘Draw Cell Edges’ 
panel). The loaded image/images can be analysed with the default parameters. If 
the acquired results are not fit for purpose, the following parameters 
(MathWorks, 2014) can be modified to re-analyse the images.  
The ‘SNr’ is a threshold parameter (0~1) used to separate the cell from background. 
The recommended range for this parameter is 0.35~0.65. The ‘Size of Mask’ 
(generally around 3) is used to dilate the image. Since the detected cell areas 
generally contain some gaps, the image should be dilated to fill the gaps. The ‘Size 
of Mask’ is based on the size of gaps. ‘Smooths’ is used to remove the small noisy 
areas, which are detected outside of cell areas. This positive integer number is the 
number of cycles for smoothing the image. The recommended number is 2~6 cycles. 
5. Saves. The analysed images (fluorescence channel and bright filed channel) with 
highlighted cell edges are automatically saved in ‘analysed’ folder in the same 
directory with the loaded images. The parameters for image analysis and the 
averaged fluorescence intensities of the cell areas are saved in the same folder as 
well. The save function can be turned off by changing the corresponding 
parameters to 0. 
The analysed images will be displayed on the screen and all of the figures can be 
closed by pushing ‘Close All Figures’ button. 
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Using ImagingDataAnalyzerForFRAP (a Matlab user interface) to analyse 
fluorescence recovery after photobleaching data 
 
Program introduction 
The ImagingDataAnalyzerForFRAP program was developed to efficiently analyse 
fluorescence recovery after photobleaching (FRAP) data. Three main functions are 
included in the program: fluorescence recovery curve analysis, imaging data viewing 
and radial profile analysis (Fig. 5.4).  
The fluorescence intensity of the bleached area is analysed in box 1 (Fig. 5.4: 
fluorescence recovery curve analysis) with the method described in materials and 
methods (manuscript). The half recovery time and final recovery level are also 
extracted (Fig. 5.5). The raw FRAP imaging data can be loaded and viewed in box 2 
(Fig. 5.4: loading and viewing imaging data). The radial profile of the bleached area 
and surround is analysed in box 3 (Fig. 5.4: radial profile analysis) to spatially 
investigate the fluorescence recovery. By default, the frame numbers (or image 
numbers) corresponding to before bleaching, immediately after bleaching and from 
10% to 100% final recovery level in steps of 10% were extracted from the analysed 
fluorescence recovery curve (Fig. 5.5). The radial profiles of these twelve frames are 
extracted. More details of the files included in this programs and a user instruction 
are described below.  
 
File table: 
ImagingDataAnalyzerForFRAP.m (ImagingDataAnalyzerForFRAP.fig) is the 
main script, which contains the program interface (Fig. 5.4) and the code for 
fluorescence recovery curve analysis. The view function of raw imaging data (.lsm 
format) is included in this script as well. 
rscan.m is a published Matlab code for radial profile extraction (Chattrapiban, 
2007). A profile example is presented in figure 2. The profile of one image was 
extracted from the bleaching centre to the circle (Fig. 5.6). 
B i n d i n g  a n d  d i f f u s i o n  o f  H a l o - F G F s  i n  R a m a  2 7  
f i b r o b l a s t  p e r i c e l l u l a r  m a t r i x  ( p a p e r )  
 
 162 
MoRscan.m is a linker between the user interface and rscan.m. It passes the 
parameters to rscan.m and returns the collected radial profile data back to the main 
script. 
shadedErrorBar.m is a published Matlab code (Campbell, 2010), which is used to 
add a shaded error bar to the plotted curve. 
 
 
Figure 5.4 User interface of ImagingDataAnalyzerForFRAP. Three main 
functions are shown in the interface. Box 1 is the fluorescence recovery curve 
analysis panel. Box 2 is used to view the images from the FRAP experiments. Box 3 
combines the desired image numbers from box 1 and the images from box 2 to 
extract the radial profiles. The default parameters are the parameter used for the 
Halo-FGFs study. 
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Figure 5.5: Flow chart of ImagingDataAnalyzerForFRAP. The diagram shows 
how the program works and how the different functions communicate with each 
other. 
 
User instruction: 
1 Run the program. Download shadedErrorBar.m (Campbell, 2010) and rscan.m 
(Chattrapiban, 2007) from the webpage link in the reference list and add these two 
files to the folder containing the program. Open ImagingDataAnalyzerForFRAP.m in 
MATLAB R2014a installed on a windows computer and run this program. The user 
interface (Fig. 5.4) will be displayed on the screen and be ready to use.  
2 Fluorescence recovery curve analysis 
The fluorescence recovery curve is not fitted, but the FRAP curve fitting was 
described in another FRAP software paper (Rapsomaniki et al., 2012). As the half 
recovery time and final recovery level are extracted, a simulation curve is generated 
to test whether the fluorescence recovery curve can be fitted to the model: 
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Model: I = If – If * e(-ln(2) * t/t1/2) 
I: Fluorescence intensity at time t; If: Final fluorescence intensity; t: time value; t1/2: 
Half recovery time.  
The parameters in box 1 (Fig. 5.4) are based on the fluorescence recovery input data. 
In general, the fluorescence intensities of three regions are included in the input data: 
fluorescence intensity of bleached area (ROI), fluorescence intensity of non-bleached 
reference area (REFA) and fluorescence intensity of background (BG). The number 
of regions and column position of the three regions in the file are required to be 
specified. The time values are always in first column of the input data, but it is not 
counted for the column position of the three regions. The number of images collected 
before bleaching should be input into the ‘PreBleach FramNo’ text box. ‘Given 
Name’ will give a name to the analysed half recovery time and final recovery level, 
but it is not required if the half recovery time and final recovery level will not be 
saved in an excel file by ‘Save T-half & RL’ button (‘Zero T-half & RL’ function is 
used to remove from memory the half recovery time and final recovery level). 
The ‘Load’ button allows a file to be chosen (excel or txt) for analysis. A file 
containing both a single fluorescence recovery curve and multiple fluorescence 
recovery curves can be analysed. The analysed fluorescence recovery curve and the 
fluorescence intensity of the reference area will be presented in separate figures.  
3 Load imaging data 
The parameters for the image channel should be checked before loading the imaging 
data. The whole channel number (All Channel) and the channel of interest (ChanOI) 
are required to be specified. Image files (.lsm or .tif) can be loaded by ‘Load Image’ 
button. The desired frame specified by a frame number (‘Frame No’ button) can be 
viewed by ‘View’ button.  
4 Analysis of radial profiles  
The position of the bleaching centre (X: column and Y: row) is required to locate a 
position for analysis. Radius controls the size of the analysed area. The pixel size is 
used to scale the x axis for the radial profile plot. Then, the radial profile can be 
analysed by clicking on the ‘Radial profile Plot’ button. Smooth range is used to 
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smooth the extracted raw radial profile, while the raw profile can also be presented 
by clicking on the ‘Raw Profile’ button. 
5 Saved files 
After the analysis, the FRAP curve data will be automatically saved to the anaFRAP 
folder, which is in the same folder as the input data. The four radial profiles of before 
bleaching, immediately after bleaching, after half of final recovery and final recovery 
will be saved to the same folder as the analysed FRAP curve data. The other figures 
in separate windows can be saved manually by using the ‘save as’ function. 
 
 
Figure 5.6 Radial profile analysis of an image. The radial profile of the image 
from the circle centre to the circle edge was extracted. (A): An image from the FRAP 
experiment; (B): The extracted radial profile of the fluorescence intensity. 
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5.5 Conclusion  
In this chapter, the binding and the diffusion of five Halo-FGFs were studied by 
confocal microscopy. The methods for acquisition and processing of imaging data 
and their analysis with Matlab programs were developed, which will be useful to 
other researchers. There are five main findings revealed by this work. (1): HS is the 
main binding component in Rama 27 fibroblast pericellular matrix for FGF1, FGF2 
and FGF6, whereas FGF10 can also bind substantially to CS/DS chains and FGF20 
does not bind to glycosaminoglycans produced by these cells. (2): The binding sites 
for each FGF were heterogeneously distributed in the matrix, which is consistent 
with the previous study with gold nanoparticle-FGF2 (Duchesne et al., 2012) and 
suggests that this may be a more general property of pericellular matrix. (3): The 
number of binding sites in the matrix is different for each FGF. This suggests that the 
HS chains in the pericellular matrix have strong selectivity to these FGFs rather than 
binding to every paracrine FGF. (4): The FRAP measurements indicate that different 
FGFs move in the matrix with different speeds, which allows the formation of 
different paracrine protein gradients. (5): The competition experiments support the 
idea generated from the binding and the FRAP experiments, that the pericellular 
matrix possesses a degree of supramolecular organisation. The competition data also 
hint at this supramolecular structure being altered when an exogenous protein binds, 
exemplified by the strong competition by FGF2 for FGF1 (Section 5.3.3).  
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Chapter 6 General discussion 
6.1 Using E. coli to make proteins 
The development of recombinant protein expression has transformed our 
understanding of biomolecular systems and the ability to manipulate these for 
clinical purposes. In the past decades, many proteins have been produced in E. coli, 
because yields are higher and costs lower than in other hosts. This has allowed the 
investigation of protein structure, interactions with biological molecules and 
synthetic ligands, and the elucidation of their biological activities from the level of 
cells to that of tissues and the organism. Many of these protein studies were designed 
to explore the structures underpinning activities and interactions, which have then led 
to the screening and identification of small molecule inhibitors. For example, many 
small molecule kinase inhibitors (e.g., imatinib and dasatinib, which interact with the 
kinase domain of Abelson murine leukemia viral oncogene homolog (ABL)) are 
used to treat cancers (Zhang et al., 2009). Moreover, the proteins themselves may 
have activities that are medically useful, exemplified by the use of FGFs in treating 
wounds and various ulcerative conditions (Nunes et al., 2015). So, it is very 
important to efficiently produce soluble and stable proteins with corresponding 
biological activities.  
Central to this thesis was the production of a series of FGFs with well characterised 
HS binding properties to investigate the functional significance of their interactions 
with the HS co-receptor. In Chapter 3, HaloTag was successfully used as a 
solubilisation partner to express FGFs. HaloTag enabled a number of FGFs that were 
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expressed as insoluble proteins to be soluble; moreover, the yield of proteins was 
often increased. Some FGFs were still hardly expressed as soluble proteins (e.g., 
Halo-FGF16) even with the HaloTag fusion. The yield of a protein is also an 
important issue, since a high yield of soluble protein makes purification simpler and 
also reduces the expense of protein production, which are important for both 
laboratory and large scale production of proteins. Thus, there is still considerable 
optimisation required for the expression of some of these FGFs. Another important 
aspect is the biological activities of the recombinant protein. The biological activities 
of produced FGFs were mainly tested by measuring the stimulation of MAPK 
phosphorylation. The cell signalling study indicates that the N-terminal HaloTag did 
not change the stimulation of phosphorylation of p44/42MAPK by the FGFs, which 
suggests HaloTag has little effect on their biological activities. This is consistent 
with the fact that different FGFs possess N-terminal extensions that vary greatly in 
length (Fig. 1.6 and (Xu et al., 2012)) and with the observation that FGF2 with a gold 
nanoparticle of ~9 nm diameter conjugated to the N-terminus stimulated MAPK 
phosphorylation identically to native FGF2 (Duchesne et al., 2012). Since some 
proteins (Halo-FGF16, FGF17 and Halo-FGF17) did not cause obvious 
phosphorylation of p44/42MAPK, a cell growth assay was used to test their biological 
activity. Cell growth is regulated by both cell division and cell survival, which is a 
more conventional and straightforward way to test the bioactivities of FGFs. The 
positive effect on cell growth indicates that these three proteins are also correctly 
folded, but in these cells they may mediate their effects by signalling pathways other 
than phosphorylation of p44/42MAPK. These FGFs all bind to heparin, a property that 
depends on the correct folding of the protein, since the canonical heparin binding site 
is formed from amino acids that are distant in sequence. Indeed, a peptide 
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corresponding to the part of the canonical binding site of FGF2 that is contiguous in 
sequence has an affinity 1000-fold lower for heparin than FGF2 (Kinsella et al., 
1998). Taken together with the biological activity of the FGFs measured here, these 
data indicate that the purified Halo-FGFs are correctly folded proteins. Whether 
HaloTag has any subtle effects on MAPK or other signalling pathways activated by 
FGFRs (Section 1.7) could be explored in the future by removal of the HaloTag with 
TEV protease. 
For some Halo-FGFs, e.g., Halo-FGF6, Halo-FGF8 and Halo-FGF22, HaloTag 
cannot be removed, since the released FGF always aggregates when TEV protease 
was used to cleave FGF from HaloTag. Thus, the work presented in Chapter 3 
represents a partial solution to the challenge of producing high quality soluble 
recombinant FGFs. 
A common strategy to produce soluble recombinant FGFs is to truncate the N- and 
sometimes the C-termini, leaving the core β trefoil core.  However, these parts of the 
FGFs are likely to have important functions for two reasons. Firstly, there is 
considerable variability in these regions of FGFs, which is most pronounced between 
FGF subfamilies, whereas within a subfamily these regions are of more similar 
length (Fig. 1.6 and (Xu et al., 2012)), suggesting they have undergone the same 
natural selection processes that led to the diversification of the FGF family and its 
functions. Secondly, the fact that they are largely unstructured itself also supports 
this contention (Beenken et al., 2012, Moy et al., 1996, Olsen et al., 2006). The 
unstructured regions of proteins are usually involved in molecular interactions, and 
are involved in the molecular regulation of signalling processes (Wright and Dyson, 
2015); in the case of the FGFs, there is evidence that this includes binding to the 
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FGFR and to HS via HBS3 for that part of the N-terminal unstructured region closest 
to strand 1 (Olsen et al., 2006, Beenken et al., 2012, Uniewicz et al., 2010, Xu et 
al., 2012). Thus, it will be important to develop means to produce full length soluble 
FGFs, including the more difficult cases. In some instances, although yields are far 
lower, mammalian expression systems may have to be employed. 
Since some FGF2 medicines have already been used to accelerate wound healing, the 
applications of FGF medicines are constantly being extended. As increasing numbers 
of studies are focused on the biological functions of different FGFs from embryonic 
development to tissue repair and some diseases, successful production of FGFs will 
be of great importance, which may lead us to new FGF medicines in the future. 
6.2 Binding selectivity of FGFs to heparin/HS   
The analysis of the HS binding specificity of five FGFs from four subfamilies 
suggested that this had been subjected to the same natural selection pressure that 
drove the diversification of the 18 paracrine and endocrine FGFs, the specificity of 
their functions, and their binding to FGFR isoforms (Xu et al., 2012, Xu et al., 2013). 
The previous work had suggested that the binding specificity of FGFs for their sugar 
ligands (Table 6.1, red coloured FGFs), including heparin, heparin derivatives and 
short heparin oligosaccharides arose as part of the natural selection process that led 
to the expansion and diversification of the FGF family (Uniewicz et al., 2010, Xu et 
al., 2012). However, only two members from one subfamily (FGF1 and FGF2) were 
part of the analysis. 
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In the current work, this analysis was extended to include further members of the 
FGF7 and FGF9 subfamilies, FGF10 and FGF20 (Section 4.3). FGF9 and FGF20 are 
from same subfamily (FGF9 subfamily) and were found to possess very similar 
binding selectivity for structures in the library of polysaccharides (Table 6.1, green 
coloured FGFs). Both of these proteins need a longer heparin oligosaccharide (dp4 
for FGF9 and dp12 for FGF20) for binding, which is one aspect that distinguishes 
them from FGFs in other subfamilies. FGF7 and FGF10 (from the FGF7 subfamily) 
bind to very similar heparin structures (Table 6.1, green coloured FGFs). They can 
also bind to DS and to CS, which is a unique property that distinguishes them from 
the other subfamilies; why this is the case is not known. Thus, the idea that the 
structures recognised by FGFs in the polysaccharide are more closely related for 
FGFs from the same subfamily, than for those from different subfamilies, a 
conclusion of the initial analysis (Xu et al., 2012) is supported by the present work. 
Table 6.1 Binding selectivity of FGFs to heparin, heparin derivatives and 
heparin oligosaccharides (Uniewicz et al., 2010, Xu et al., 2012, Li et al., 2015). 
Red coloured FGFs are from previous publications; green FGFs are from Chapter 4 
and blue FGFs were analysed by Yong Li (University of Liverpool) (Li, 2015). 
Subfamily  Name Heparin effect Sulfation preference dp length 
FGF1 FGF1 > 22oC NS ≈ 2S ≈ 6S dp2 ~ dp10 
 FGF2 > 22oC NS, 2S > 6S dp4 ~ dp10 
FGF4 FGF4 ~ 12oC NS ≈ 2S > 6S dp4 ~ dp10 
 FGF6 > 10oC 2S > 6S, NS dp6 ~ dp10 
FGF7 FGF3 ~ 15oC NS ≈ 6S > 2S dp4 ~ dp10 
 FGF7 ~ 7oC NS ≈ 2S ≈ 6S dp4 ~ dp8 
 FGF10 ~ 15oC NS ≈ 2S ≈ 6S dp4 ~ dp8 
FGF8 FGF17 ~ 15oC NS ≈ 2S ≈ 6S dp4 ~ dp10 
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 FGF18 > 15oC NS ≈ 6S > 2S dp6 ~ dp10 
FGF9 FGF9 ~ 20oC NS ≈ 6S > 2S dp4 ~ dp10 
 FGF20 ~ 12oC 6S ≈ 2S > NS dp10 ~ dp12 
Together with work performed in a parallel thesis (Li, 2015), there is now an almost 
fully comprehensive dataset on the interactions of FGFs with GAGs (Table 6.1). The 
hypothesis that the polysaccharide structures recognised by FGFs are more similar 
for FGFs in the same subfamily than for FGFs in different subfamilies is supported 
by these data (Table 6.1). This strongly suggests that the diversification of the FGF 
family and its functions in the course of evolution involved the diversification of the 
binding specificities of the FGFs for GAG co-receptor and FGFRs (Table 3.2 and 
(Zhang et al., 2006b, Ornitz et al., 1996)).  
The binding experiments with Halo-FGF1 and Halo-FGF2 (Chapter 5) indicate that 
the differences in binding specificity between members of the same subfamily can 
have a major impact on their interaction with HS in pericellular matrix. Thus, not 
only are there more binding sites in pericellular matrix HS of Rama 27 cells for 
Halo-FGF1, which is consistent with its greater promiscuity, but it also moves more 
slowly than FGF2, which will affect its range and potential gradients. The 
similarities in binding and diffusion of Halo-FGF2 and Halo-FGF6 may also reflect 
their differences in binding specificities: FGF2 preferentially binds structures 
containing N- and 2-O- sulfate groups from dp4; FGF6 prefers structures containing 
2-O- with either N- or 6-O- sulfate groups, but these need to be dp6 or longer. Thus, 
though FGF6 is more promiscuous in terms of sulfation pattern, it requires longer 
structures, which are rarer. In the case of Rama 27 cell pericellular matrix, these 
differences may compensate for each other, within the limits of detection and spatial 
resolution of the fluorescence measurements. The binding preferences for FGF10 
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and FGF20 are clearly more pronounced and this is too reflected in their binding and 
diffusion in Rama 27 pericellular matrix. Thus, at least for the FGFs investigated in 
Chapter 5, there is evidence that the divergence of the specificities of these FGFs for 
binding to GAG co-receptor may have significance at the level of controlling FGF 
movement between cells and this may have been one driver in the expansion of the 
FGF family.  
Taken collectively the available data suggest that the interactions of FGFs with HS 
are both specific and selective, but there is no simple one-to-one correspondence 
between a particular FGF and a single sequence of saccharides. This is not 
surprising. The interactions of FGFs with isoforms of the FGFR is also not one-to-
one, with the exception of that of FGF7 with FGFR2b (Zhang et al., 2006b). In more 
general terms, interactions of proteins with other polymers (DNA, RNA) generally 
demonstrates a graded specificity and selectivity: there is a consensus structure 
recognised by the protein, but more often than not the in vivo regulatory element 
recognised by the protein is some way off this consensus. This allows other 
interactions to participate in regulation and such “nonoptimal” (from an in vitro 
perspective) binding structures lie at the heart of the molecular regulation of many 
complex biological systems. 
For HS there is a misconception, that proteins recognise a sequence of saccharides. 
This in part stems from the unusual pentasaccharide sequence that binds 
antithrombin III and so regulates coagulation. The polysaccharide is not linear in 
solution (no polymer is), but possesses a range of conformations. Substitution of a 
single sulfate group alters the conformation of the polysaccharide, and it is the three 
dimensional disposition of specific groups (sulfate, carboxyl and hydroxyl) that 
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enables protein binding. Clear evidence is provided by the identification of 
antithrombin III binding structures that are distinct from the pentasaccharide (Petitou 
et al., 1999b, Petitou et al., 1999a), and by the generation of FGF binding structures, 
able to support FGFR activation, from completely unrelated (from a saccharide 
backbone perspective) sulfated plant polysaccharides (Rudd et al., 2010). Thus, the 
key finding is that the molecular specificity of the interactions of FGFs with HS has 
followed the diversification of this growth factor family, which in turn reflects 
natural selection pressures that led to the formation of more complex animal body 
plans. This leads to the conclusion that the interactions of FGFs with HS are specific, 
selective and functionally important. 
6.3 Binding and movement of FGFs in pericellular matrix 
Given the above, it is clear that in vitro experiments that aim to elucidate the 
specificity and selectivity of FGFs for HS can only achieve this in part. The 
polysaccharide in vivo is far more complex than the purified structures used in vitro. 
For example, HS in vivo will have bound endogenous heparin binding proteins and 
coordinated cations, both of which may change the conformation of the HS chain.  In 
addition, there are data that demonstrate clearly that HS in different tissue 
compartments has different protein binding properties (Rudland et al., 1993, Allen et 
al., 2001, Thompson et al., 2011). Though most of this work is at cellular resolution 
in tissues, at least for FGF2 it is also true at molecular length scales, since its binding 
sites are clustered in Rama 27 pericellular matrix (Duchesne et al., 2012). The 
binding and FRAP experiments (Chapter 5), therefore, probe far more than the 
number of saccharide binding sequences in HS and the diffusion of FGFs in 
pericellular matrix. If the FGF is considered as a (complex) reporter of HS structure, 
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it informs on how the binding structures on HS for that FGF are displayed, which in 
turn provides an indirect insight into the structure of the pericellular matrix. By using 
fixed Rama 27 fibroblasts, the selectivity of the pericellular matrix to different HS 
binding FGFs was studied with Halo-FGF1, Halo-FGF2, Halo-FGF6, Halo-FGF10 
and Halo-FGF20 in the absence of confounding effects of cellular biochemistry.  
 
Figure 6.1 Model of binding and movement of FGFs in the pericellular matrix. 
(A): Model for mobile FGFs (e.g., FGF1, FGF2 and FGF6). (B): Model for 
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immobile FGFs (e.g., FGF10). The cell membrane contains two types of constitutive 
proteoglycans: glypican and syndecan. The pericellular matrix contains HS chains, 
plasma membrane proteins (e.g., FGFR) endogenous matrix proteins (e.g., collagens) 
and HS binding signalling proteins (e.g., FGFs). The organisation of binding sites for 
FGFs is regulated by three key factors: organisation of membrane proteins (e.g., lipid 
rafts, links of plasma membrane proteins to cytoskeleton), the sulfation structure of 
HS (blue chains) and cross-linking of HS chains by interaction with endogenous 
ECM proteins. ①, diffusive movement of FGFs; ②, confined movement of FGFs 
and/or clustered binding; ③, cross-linking of HS chains by FGFs; ④, cross-linking 
of HS chains by endogenous ECM proteins (e.g., collagen); ⑤, transport of FGF to 
FGFR; ⑥, release of FGFs by digestion of HS chains by heparanase; ⑦, digestion 
of HS chains without release of FGFs, because the HS chain is linked to a 
endogenous ECM protein. 
The distribution of the Halo-FGFs in Rama 27 fibroblast pericellular matrix was 
heterogeneous, which indicates that their binding sites are not evenly distributed. 
This would arise from HS chains with different binding sites being spatially 
segregated, and to some of these binding sites being occupied by endogenous 
proteins, e.g., (Fig 6.1A ① to ④). CS and DS were also found to be involved in 
FGF binding and in organisation of pericellular matrix in two different ways. CS and 
DS had a direct role for FGF10, whereas they had an indirect role, for FGF1 and 
FGF6, since digestion of CS/DS chains was found to increase their binding (Section 
5.2).  
The data, therefore, show that the pericellular matrix can selectively bind different 
FGFs. Previous data led to the same conclusion (Rudland et al., 1993, Allen et al., 
2001, Thompson et al., 2011), but the resolution was much coarser. Here the 
conclusion applies to a single cell. This provides strong support for the idea that 
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pericellular matrix is a highly organised structure, which allows the cells to control 
the number and spatial distribution of FGF binding sites (Fig. 6.1).  
The data in this thesis also demonstrate that the control of binding and movement of 
FGFs in the pericellular matrix is not simply down to the cell synthesising HS chains 
with a particular sequence of saccharides and then localising the proteoglycan core 
protein to a particular place. For example, the differential effect of digestion of 
CS/DS with chondroitinase ABC on binding of FGF2 (no change), FGF1 and FGF6 
(both increase in binding) seems likely to be due to a reorganisation of protein-
polysaccharide interactions, which in some, but not all, cases frees up binding sites 
previously occupied or inaccessible. Similarly, the unexpected more effective 
competition by FGF2 for Halo-FGF1 binding, compared to competition by FGF1 
cannot be explained by simple mass action driven competition, but seems likely to 
need changes in the organisation of HS chains driven by FGF binding. Therefore, the 
structure of pericellular matrix of Rama 27 fibroblasts is regulated by cross-linking 
of GAGs chains, especially those of HS, by endogenous proteins and the 
exogenously added FGF (Fig. 6.1 A, ③ and ④). 
Different FGFs were found to move in the pericellular matrix with different speeds. 
FGFs that bind weakly or not at all to a particular configuration of HS, as in the case 
of FGF20 here, would be expected to undergo free diffusion in that locality, while 
FGFs, that do bind the HS chains may form gradients of different shapes (e.g., long-
slim gradient or short-fat gradients, Section 1.2) and also be stored in the matrix. 
Only a proportion of the FGFs (52% for FGF1, 81% for FGF2, 82% for FGF6 and 
none for FGF10) diffuses fast on the timescale of the FRAP experiments, and the rest 
seems to be strongly trapped (Figs 6.1 A and B, ②, ⑥ and ⑦). Although there are 
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no direct data, it seems reasonable to suppose that the immobile fraction in FRAP 
experiments is related to the confined motion (Fig. 6.1A, ②) observed by Duchesne 
et al. (Duchesne et al., 2012). Thus, the different classes of movement identified in 
the latter study, which additionally include diffusive motion and directed/restricted 
motion may be common to many FGFs and indeed to many HS-binding signalling 
proteins. What may differ is the proportion of each protein that is confined 
(“immobile” in the present work, Figs 6.1 A and B, ②, ⑥ and ⑦) or moving (Fig. 
6.1 A, ①) and the relative proportion of the types of movement a protein can 
undergo.   
In summary, how a matrix may selectively bind and transport individual HS-binding 
proteins will depend on different factors (Figs 6.1 A and B). In the fixed cell system, 
the structure of the pericellular matrix is organised by three main factors. Firstly, the 
location of the proteoglycan core protein, its association with cytoskeletal elements 
through its cytoplasmic domain (in the case of syndecans) and membrane 
microdomains, e.g., rafts (glypicans), will also be important (Fig. 6.1 A, lipid raft) 
(Pike, 2004, Lingwood and Simons, 2010, Simons and Gerl, 2010). Secondly, the 
sequence of saccharides of the HS chain will play an important role, but it is clearly 
not the sole regulator (Figs 6.1, A and B, different binding sites for different FGFs). 
Thirdly, the interactions of the HS chains with endogenous cellular HS-binding 
proteins (Fig. 6.1 A, ④), some of which will be membrane bound and others not, 
and further interactions of these proteins with other elements, such as CS, DS and 
HA, will influence the conformation of the HS chains, which in turn may alter their 
binding properties. The actions of heparanase on HS chains and the degree to which 
the latter are cross-linked by endogenous proteins will also contribute to the control 
of movement of FGFs (Fig. 6.1 B). Thus, the evidence presented in this thesis 
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indicates that pericellular matrix has a supramoleclar structure, which selectively and 
heterogeneously binds to proteins and regulates the movement of these proteins to 
their target cells with different speeds. The live cell would be more complicated, 
since many cell activities (the dynamics of cell membrane and membrane proteins 
and cell endocytosis) will add a further layer of regulation and complexity 
(Belenkaya et al., 2004, Yu et al., 2009).                                                          
6.4 Suggestions on future work 
Future work falls into two categories, that which is reasonably straightforward and 
can be explored in the immediate future and that which is more speculative. So far 
the interactions of only a limited number of FGFs with Rama 27 pericellular matrix 
have been explored. Thus, a HaloTag could be added to the N-terminus of FGFs that 
are currently untagged FGFs (FGF4, FGF5, FGF9 and FGF18). This may increase 
the soluble expression of these proteins and enable imaging and some biosensor 
studies that would expand on existing work on crosslinking of HS brushes 
(Migliorini et al., 2015) and mobility of the FGF in these models, very simplified 
extracellular matrices. For Halo-FGFs with low yield after heparin-affinity 
chromatography, re-engineering will be required, likely involving some degree of 
trimming of the N- and C-termini.  It may also be necessary in some cases to produce 
the protein in mammalian systems or to engage in refolding of insoluble protein. 
Since FGFs have different preferences for HS structure, an extended series of Halo-
FGFs would be a very useful tool for the analysis of HS chains in matrix. In addition, 
it would be important to extend the present work in several directions. So far only the 
pericellular matrix of one cell line has been investigated. Working with an epithelial 
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cell line would likely be very informative, since the pericellular matrix will be 
different. Moreover, the height of the cells is sufficient to enable the lateral and basal 
pericellular matrices to be imaged independently of the apical one. More challenging 
would be to work in a 3-dimensional culture system. The microscopy technology 
now exists at the Liverpool Centre for Cell Imaging, which received one of the first 
Zeiss light sheet microscopes in the UK. However, how to make measurement is less 
clear. A FRAP type of experiment might be possible: bleaching a series of adjacent 
lines (the light sheets) by increasing the power of the laser, but the time resolution is 
lower than in confocal microscopy, so information will be more limited. An 
interesting alternative would be to pump the Halo-FGF into the bottom of the sample 
and thus provide the sphere of cells with a “source” of FGF and to measure the 
diffusion of the FGF into and through the cell spheroid. Again this is not trivial, 
since there may be ‘leakage’ of the FGF through the agarose gel in which the 
spheroid is embedded and this may confound measurements. Such experiments could 
also take on a pulse-chase format, using for example, first a red FGF then a green 
one. 
The above analyses are limited by optical resolution and to understand the large scale 
organisation of matrix, molecular scale resolution would be an essential addition. 
Since the movement of FGFs is generally too fast for superresolution microscopy, 
the simplest solution would be to use electron microscopy. For this, a suitable 
chloromethyl terminated ligand for gold nanoparticles could be developed, which 
would allow the Halo-FGFs to be linked to gold nanoparticles. Alongside, antibody 
or the smaller nanobodies from camelids could be used to probe the location of 
various protein components, ranging from matrix proteins such as collagens, to the 
core proteins of proteoglycans. 
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Changing the structure of the HS on the cells would also be useful to understand how 
the sulfation modifications impact on HS chain and matrix structure. This would be 
best achieved by siRNA knockdown of HS biosynthetic enzymes, since it is rapid 
and so less likely to suffer from homeostatic mechanisms that compensate for the 
perturbation, as seen, for example, with the 2-O sulfotransferase knockout mouse 
(Bullock et al., 1998).  However, siRNA is never completely effective and a more 
useful tool would be small molecule inhibitors of the sulfotransferases, though these 
do not exist yet. 
Finally, there is now a considerable body of data on the binding and movement of 
FGFs in pericellular matrix.  It should be possible, therefore, to generate some simple 
models to allow simulations. Some informal work with the Department of 
Mathematics has been undertaken and this is likely to yield in the future a reasonable 
working model. Such simulations would be an effective means to generate 
hypotheses, which could then be tested. 
The Halo-FGFs would also be useful to probe the assembly of the ligand-receptor 
complex, since their colour can be altered by simply changing the fluorescent Halo-
ligand they react with.  By using a high concentration of competing oligosaccharide 
(as done in Duchesne et al., 2012, (Duchesne et al., 2012)), chlorate treatment 
(prevents all sulfation reaction) or siRNA for the EXTs (prevents HS biosynthesis), 
the exogenous oligosaccharide would be incorporated into the FGFR complex and 
would prevent binding of the FGF to any HS in the matrix. This would allow the 
assembly of the FGF onto the FGFR to be probed in the absence of the much greater 
signal (>99%) arising from the FGF binding HS. HaloTag may also be incorporated 
into the extracellular domain of the FGFR and this would enable ligand and FGFR to 
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be analysed independently, but simultaneously. Gene editing technology such as 
crisper would allow analysis of cells expressing normal levels of FGFR, which is 
likely to be important, since overexpression may lead to artificial associations of the 
FGFR. The use of gold nanoparticles with Halo ligands would then allow electron 
microscopy analysis, which would provide molecular scale validation of the optical 
measurements for FGF-FGFR assembly. 
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